Design and Synthesis of Bicyclic Ligands for the FK506-Binding Proteins 51 and 52

Yansong Wang

aus
Nanchong, China
2012
Erklärung


Eidesstattliche Versicherung
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet.

München, den 29.06.2012

............................................................
Yansong Wang

Dissertation eingereicht am 29.06.2012

1. Gutachter: Prof. Dr. Christoph W. Turck
2. Gutachter: Prof. Dr. Roland Beckmann

Mündliche Prüfung am 18.07.2012
Acknowledgements

This dissertation would not have been possible without the guidance and the help of several individuals who in one way or another contributed and extended their valuable assistance in the preparation and completion of this study.

First and foremost, I would like to express my deep and sincere gratitude to my supervisor Dr. Felix Hausch for the opportunity to carry out my PhD study in his group. His expertise, understanding, and patience added considerably to my graduate experience. I appreciate his vast knowledge, skills and his assistance in completing this study. I would also like to thank Prof. Turck, the thesis committee for reviewing this thesis and Prof. Holsboer for the financial support.

I wish to thank all my colleagues in the Hausch group for their support and the wonderful atmosphere. Especially, I must acknowledge Dr. Christian Kozany and Bastiaan Hoogeland for the fluorescence polarization assays. Appreciation also goes out to Anne-Katrin Fabian for the ITC measurement and Alexander Kirschner for the GR hormone binding assay. Thanks also go out to Ranganath Gopalakrishnan and Steffen Gaali for the scientific inputs and discussions.

I am also indebted to Dr. Andreas Bracher (MPI Biochemistry) for solving the co-crystal structures and Dr. Uwe Koch for modelling. Furthermore, I would also like to thank Ms. Dubler and Dr. Stephenson for NMR measurement, Ms. Elisabeth Weyher and Dr. Lars Allmendinger for high resolution Mass measurement.

Last but not the least, I would like to especially thank Yiye Zhang and my parents for their support, encouragement, quiet patience and unwavering love.
# Contents

1. Abstract .................................................................................................................. 1  
2. Introduction.............................................................................................................. 3  
   2.1 The FK506 binding protein (FKBPs) family ....................................................... 3  
   2.2 FKBPs 51 and 52 Structures ............................................................................... 3  
   2.3 Cellular and Physiological Functions of FKBPs 51 and FKBPs 52 ......................... 5  
      2.3.1 The role of FKBPs 51 and FKBPs 52 in steroid receptor signaling ............... 5  
      2.3.2 Biological implications of FKBPs 51 and FKBPs 52 in diseases ............... 7  
         2.3.2.1 Stress related diseases ..................................................................... 7  
         2.3.2.2 Cell proliferation and cancer.............................................................. 8  
         2.3.2.3 Immune system ............................................................................. 9  
         2.3.2.4 Reproductive development and reproductive success ..................... 10  
         2.3.2.5 Neurodegenerative diseases ........................................................... 10  
   2.4 Chemical biology of FKBPs ligands ................................................................. 11  
      2.4.1 Immunosuppressive FKBPs ligands ......................................................... 11  
      2.4.2 Non-immunosuppressive FKBPs ligands.................................................. 12  
      2.4.3 FKBPs 51 and FKBPs 52 ligands................................................................ 15  
   2.5 Interactions of FKBPs (SLF) and polycyclic ligand 3a with FKBPs 51 ......................... 16  
   2.6 Reported compounds with similar scaffolds as 4 and 5 ................................... 20  
   2.7 Intramolecular N-acyliminium cyclization ......................................................... 20  
3. Aim of this project ..................................................................................................25  
4. Results and discussion............................................................................................26  
   4.1 Design of conformationally defined FKBPs ligands ........................................... 26  
   4.2 Computer modelling........................................................................................... 27  
   4.3 Synthesis .........................................................................................................29  
      4.3.1 Synthesis of the bicyclic [3.3.1] aza-amide derivatives 4 and the bicyclic  
         [4.3.1] aza-amide derivatives 5 ................................................................. 29  
      4.3.1.1 Retrosynthetic analysis and strategy of the bicyclic [3.3.1] aza-amide  
         derivatives 4 ............................................................................................ 29  
      4.3.1.2 Synthesis of the bicyclic [3.3.1] aza-amide nucleus 17 ...................... 30  
      4.3.1.3 Retrosynthetic analysis and strategy of the bicyclic [4.3.1] aza-amide  
         derivatives 5 ............................................................................................ 32  
      4.3.1.4 Synthesis of the bicyclic [4.3.1] aza-amide nucleus 27 ..................... 32  


4.3.1.5 Synthesis of the bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic[4.3.1] aza-amide derivatives 5 ................................................................. 35
4.3.1.6 Synthesis of the monocyclic derivatives 6 ........................................... 36
4.4 Competition binding fluorescence polarization assay .................................. 37
  4.4.1 Binding affinity of the bicyclic aza-amide series ........................................ 37
  4.4.2 Binding affinity of the bicyclic aza-sulfonamide series ............................. 39
4.5 Cocrystal structure of 4g, 5f and 5g with FKBP51 FK1 .............................. 41
4.6 GR hormone radioactive binding assay ...................................................... 45
4.7 Thermodynamic analysis ........................................................................... 46
4.8 Synthesis of the C8-derivatized bicyclic [4.3.1] aza-amides 57 .................... 47
  4.8.1 Retrosynthetic analysis and strategy ......................................................... 49
  4.8.2 Synthesis of the bicyclic [4.3.1] aza-amide nucleus 57 ........................ 49
  4.8.3 Systematic study of the cyclization reaction ........................................... 51
  4.8.4 Functionalization of bicyclic [4.3.1] aza-amides nucleus 57 ..................... 55
4.9 Competition binding fluorescence polarization assay .................................. 57
4.10 Cocrystal structure of 71 and FKBP51 ..................................................... 58
4.11 Hypothetical binding mode of 73a and 73b .............................................. 60
5. Conclusion ...................................................................................................... 63
6. Materials and Methods .................................................................................. 65
  6.1 Biological analytical methods ...................................................................... 65
    6.1.1 Molecular modelling ............................................................................. 65
    6.1.2 Molecular modelling of FKBP51 with bicyclic derivatives 7, 8, 42 .......... 65
    6.1.3 Competition Binding Fluorescence Polarization Assay ......................... 65
    6.1.4 Isothermal Titration Calorimetry experiments ...................................... 67
    6.1.5 GR hormone binding assay. ................................................................. 67
    6.1.6 Crystallography .................................................................................. 67
    6.1.7 Reference compounds 5, 6b, 6c and 6h ................................................. 67
7. Experimental Section ....................................................................................... 68
  7.1 General chemical methods ........................................................................ 68
    7.1.1 Nuclear Magnetic Resonance (NMR) ................................................ 68
    7.1.2 Mass Spectrometry .............................................................................. 68
    7.1.3 Flash Chromatography ...................................................................... 69
    7.1.4 Thin Layer Chromatography .............................................................. 69
    7.1.5 High performance liquid chromatography (HPLC) .............................. 70
7.1.6 Preparatory Thin Layer Chromatography .................................................70
7.1.7 Preparative HPLC .....................................................................................71
7.1.8 Chiral HPLC ..............................................................................................71
7.1.9 Chemicals ....................................................................................................72
7.1.10 Solvents ....................................................................................................74
7.2 Chemical Synthesis ..........................................................................................75
7.2.1 Synthesis of 6-(cyanomethyl) picolinic acid 22 ........................................75
7.2.2 Synthesis of methyl 6-(cyanomethyl) picolinate 20 ....................................75
7.2.3 Synthesis of ethyl 6-cyanopicolinate 11 .......... ........................................76
7.2.4 Synthesis of ethyl 6-((tert-butoxycarbonylamino)methyl)picolinate 13 ......76
7.2.5 Synthesis of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) picolinate 23.77
7.2.6 Synthesis of ethyl 6-((tert-butoxycarbonylamino) methyl)piperidine-2- carboxylate 14 ..........................................................................................77
7.2.7 Synthesis of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) piperidine-2- carboxylate 24 diastereomeric mixture ................................................................78
7.2.8 Synthesis of 1-benzyl 2-ethyl 6-((tert-butoxycarbonylamino) methyl) piperidine-1,2-dicarboxylate 15 ...........................................................................79
7.2.9 Synthesis of 1-benzyl 2-methyl 6-2-(tert-butoxycarbonylamino) ethyl) piperidine-1, 2-dicarboxylate 25 ...........................................................................79
7.2.10 Synthesis of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 ........................................................................................................80
7.2.11 Synthesis of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27 ........................................................................................................80
7.2.12 Synthesis of 4-(2-bromoethoxy)-1, 2-dimethoxybenzene 28a ..................81
7.2.13 Synthesis of benzyl 3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 29a ..........................................................81
7.2.14 Synthesis of benzyl 3-ethyl-2-oxo-3,9-diazabicyclo [3.3.1]nonane-9-carboxylate 29b .........................................................................................................82
7.2.15 Synthesis of 3-ethyl-3,9-diazabicyclo[3.3.1]nonan-2-one 31b ....................83
7.2.16 Synthesis of 1-(3-ethyl-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione 4c .........................................................83
7.2.17 Synthesis of benzyl 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-2-oxo-3, 10- diazabicyclo [4.3.1] decane-10-carboxylate 30a ..................................................84
7.2.18 Synthesis of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decane-10-carboxylate 30b.................................................................85
7.2.19 Synthesis of 3- (2-(3, 4- dimethoxyphenoxy) ethyl) -3, 9- diazabicyclo[3.3.1]nonan-2-one 31a..........................................................................85
7.2.20 Synthesis of 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-3, 10-diazabicyclo[4.3.1] decan-2-one 32a.........................................................................................86
7.2.21 Synthesis of 3-(3,4-dimethoxyphenethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32b.................................................................................................86
7.2.22 Synthesis of 2-oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a ........87
7.2.23 Synthesis of 3,3-dimethyl-2-oxopentanoic acid 33b ............................87
7.2.24 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)eth.yl)-2-oxo-3,9- diazabicyclo [3.3.1]nonan-9-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2- dione 4a ...................................................................................................88
7.2.25 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9- diazabicyclo[3.3.1]nonan-9-yl)-3,3-dimethylpentane-1,2-dione 4b........89
7.2.26 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10- diazabicyclo [4.3.1]decan-10-yl)-3,3-dimethylpentane-1,2-dione 5b ......89
7.2.27 Synthesis of 1-(3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-diazabicyclo [4.3.1]decan-10-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione 5d ....90
7.2.28 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10- diazabicyclo [4.3.1]decan-10-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2- dione 5a ..........................................................................................................91
7.2.29 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10- diazabicyclo [4.3.1]decan-10-yl)-2-((1S)-2-ethyl-1-hydroxycyclohexyl)ethane-1,2-dione 5c.................................................................92
7.2.30 Synthesis of 1-tert-butyl 2-(2-(3,4-dimethoxyphenoxy)ethyl) piperidine-1, 2-dicarboxylate 38.................................................................93
7.2.31 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 .........................................................................................................................93
7.2.32 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(2-oxo-2-(3,4,5- trimethoxyphenyl)acetyl)piperidine-2-carboxylate 6a...............................93
7.2.33 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(3,5- dichlorophenylsulfonyl)piperidine-2-carboxylate 6e.......................................94
7.2.34 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(benzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate 6f .............................................................95
7.2.35 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(2-oxo-2,3-dihydrobenzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate 6g ..........96
7.2.36 Synthesis of 9-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 4e ........96
7.2.37 Synthesis of 9-(benzo[d]thiazol-6-ylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 4f ..........97
7.2.38 Synthesis of 10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5e ....98
7.2.39 Synthesis of 10-(benzo[d]thiazol-6-ylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5f ....98
7.2.40 Synthesis of 6-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-ylsulfonyl)benzo[d]thiazol-2(3H)-one 4g ....99
7.2.41 Synthesis of 6-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decan-10-ylsulfonyl)benzo[d]thiazol-2(3H)-one 5g ..100
7.2.42 Synthesis of 3,9-diazabicyclo[3.3.1]nonan-2-one 35 .................................101
7.2.43 Synthesis of 3,10-diazabicyclo[4.3.1]decan-2-one 36 ..........................101
7.2.44 Synthesis of 6-(2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-ylsulfonyl)benzo[d]thiazol-2(3H)-one 4h ..........................101
7.2.45 Synthesis of 6-(2-oxo-3,10-diazabicyclo[4.3.1]decan-10-ylsulfonyl)benzo[d]thiazol-2(3H)-one 5h ..........................102
7.2.46 Synthesis of 10-(3,5-dichloro-4-hydroxyphenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5i ....103
7.2.47 Synthesis of tert-butyl allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamate 48 .................................................................103
7.2.48 Synthesis of tert-butyl 2-(3,4-dimethoxyphenoxy)ethyl(4-(trimethylsilyl)but-2-eny1)carbamate 50 ........................................104
7.2.49 Synthesis of N-(2-(3,4-dimethoxyphenoxy)ethyl)-4-(trimethylsilyl)but-2-en-1-amine 51 .........................................................104
7.2.50 Synthesis of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-(trimethylsilyl)but-2-eny1)piperidine-2-carboxamide 53 ........105
7.2.51 Synthesis of (S)-tert-butyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-(trimethylsilyl)but-2-eny1)carbamoyl)-6-oxopiperidine-1-carboxylate 54 .105
7.2.52 Synthesis of (1S,5S,6R)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 57 ..............................................................................................................106
7.2.53 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71 ..............................................................................................................................................................................107
7.2.54 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one diastereomeric mixture ..............................................................................................................107
7.2.55 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one diastereomeric mixture ..............................................................................................................108
7.2.56 Synthesis of (1R,5S,6S)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)-3,10-diazabicyclo[4.3.1]decan-2-one 74 diastereomeric mixture ..............................................................................................................109
7.2.57 Synthesis of (2S)-1-benzyl 2-methyl 6-hydroxypiperidine-1,2-dicarboxylate 66 and (S)-methyl 2-(benzyloxycarbonylamino)-6-hydroxyhexanoate 67 ..............................................................................................................109
7.2.58 Synthesis of N-(2-(3,4-dimethoxyphenoxy)ethyl)prop-2-en-1-amine 58 ..............................................................................................................110
7.2.59 Synthesis of (S)-N-allyl-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxopiperidine-2-carboxamide 59 ..............................................................................................................110
7.2.60 Synthesis of (S)-benzyl 2-(allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamoyl)-6-oxopiperidine-1-carboxylate 60 ..............................................................................................................111
7.2.61 Synthesis of (S)-benzyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-(trimethylsilyl) but-2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 62 111
8. Abbreviations ........................................................................................................113
9. References ..........................................................................................................114
10. Curriculum Vitae ...............................................................................................127
The FK506-Binding Proteins 51 and 52 (FKBP51/52) belong to the immunophilin superfamily. Both proteins are highly homologous. They are composed of three domains and adopted similar conformations. They have cochaperone activity by participating in the Hsp90-steroid receptor complex to regulate the glucocorticoid receptor (GR) signal transduction. FKBP51 has been shown to be a negative regulator whereas FKBP52 is a positive regulator of the glucocorticoid receptor. FKBP51 is involved in the etiology of stress-related psychiatric disorders and has potential as a novel therapeutic target for psychiatric disorders. Few synthetic ligands for FKBP51 and FKBP52 were described and all of them display unfavorable pharmacokinetic profiles which make them unsuitable to study the biological roles of FKBP51 and FKBP52. In this project, the aim was to limit the ligand flexibility by ligand preorganization to mimic the FKBPs ligands active conformation and to focus on the improvement of their ligand efficiencies.

The bicyclic [3.3.1] aza-amide and bicyclic [4.3.1] aza-amide core structures were designed as rigid replacements for the pipecolyl-monocyclic scaffold. Their potential binding modes were first analyzed in silico. A synthetic route was then established to prepare a series of bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-amide derivatives 5. Their activities were tested in a competition binding fluorescence polarization assay, by isothermal titration calorimetry and in a GR hormone radioactive binding assay. Ligand 5h was identified as the most efficient FKBP ligand known today. It is the first lead-like ligand (MW = 367Da, LE= 0.29, clogP= 0.95) for the clinically relevant FKBP51 and offers three rigidly defined attachment points (R1, R2 and C8) for further lead optimization. The comparison of the three series compounds indicated that the bicyclic [4.3.1] aza-amide scaffold has a better degree of preorganization than the bicyclic [3.3.1] aza-amide scaffold which in turn is preferred over the monocyclic scaffold. The cocrystal structures of 4g, 5g and 5f with FKBP51 FK1 domain showed their binding modes are similar to those observed for compound 2 in complex with FKBP51 FK1.

Based on the cocrystal structures of 5g and 5f, the C8 substituted bicyclic [4.3.1] aza-amide scaffold was designed to increase the contact surface between ligand and protein to further enhance the binding affinity. A new stereoselective synthetic route
was established and optimised in which a stereoselective carbon-carbon bond formation by intramolecular N-acyliminium cyclization was the key step. The cocrystal structure of 71 with FKBP51 FK1 confirmed the desired conformation obtained from the stereoselective synthesis. A further racemic dihydroxylation of the C⁸ vinyl group substantially improved the affinity for all FKBPs yielding ligands with low nanomolar potencies that rivalled those of the natural product FK506. The higher binding affinity was proposed to be obtained from a putative hydrogen bond between the C¹¹-OH of 73a and Tyr⁵⁷ which was to be confirmed in the future by the corresponding cocrystal structure.

These results provided valuable information for the further optimization of FKBP51 ligands.
2. Introduction

2.1 The FK506 binding protein (FKBPs) family

The FK506 binding proteins (FKBPs) belong to the immunophilin family with high binding affinity to the immunosuppressive drugs FK506 and Rapamycin. It is a highly conserved class of proteins found in all organisms with peptidyl prolyl isomerase (PPIase) activity. The PPIase activity catalyzes cis–trans isomerization reactions of peptide bonds involving the amino acid proline (Figure 1) which is regarded to be necessary for the proper folding of several proteins.

\[ \text{cis} \quad \xrightarrow{\text{PPIases}} \quad \text{trans} \]

Figure 1: Peptidyl prolyl cis/trans-isomerization by PPIases.

In the nucleus, FKBPs regulate transcription, histone chaperon activity and chromatin modification, cancer progress and chemoresistance. In the cytoplasm, FKBPs play important roles in protein stability, protein trafficking, receptor signaling, kinase activity, intracellular Ca\(^{2+}\) homeostasis via interaction with calcium channels like the ryanodine receptor, regulation of inositol 1,4,5-triphosphate receptor and cation channel like TRPC. The human FKB family consists of FKB12, FKB12.6, FKB 13, FKB15, FKB22, FKB24, FKB25, FKB36, FKB38, FKB51, FKB52, FKB60, FKB65 and FKB133 with their homologs usually also be found in other mammalian FKB families among which the FKB12, FKB12.6, FKB38, FKB51 and FKB52 are the most studied and explored paralogs.

2.2 FKBP51 and 52 Structures
The amino acid sequences, domain organization and three-dimensional crystal structures of the full-length human FKBP51 and the overlapping fragments of human FKBP52 have been reported\textsuperscript{28, 29}. They are homologous proteins with 60\% identity and 75\% similarity in their amino acid sequences. Both proteins are composed of three domains and adopt similar conformations (Figure 2).

The N-terminal FK1 domain has the PPIase and FK506 binding activity and it is the primary regulatory domain for steroid hormone receptors\textsuperscript{20, 30}. Both the Hsp90 binding and the PPIase pocket are necessary for the modulation of the SHRs\textsuperscript{31}, the PPIase activity per se is not necessary. The 40s and the 80s loop (residues 71-76 and 118-122 for FKBP51, respectively) represent the largest structural divergence in the FK1 domain between FKBP51 and 52. In the 40s loop, the Asn\textsuperscript{74}, Glu\textsuperscript{75} and Pro\textsuperscript{76} in FKBP51 is replaced by Lys\textsuperscript{74}, Asp\textsuperscript{75} and Lys\textsuperscript{76} in FKBP52. The proline rich loop (80 loop) which sits on top of the binding pocket with Leu\textsuperscript{119} in FKBP51 and Pro\textsuperscript{119} in FKBP52 was found to be a major cause for the different functions of FKBP51 and FKBP52 on the steroid hormone receptors. The mutations of A116V and L119P in FKBP51 was found to switch the activity to full FKBP52-like characteristics towards AR activation.\textsuperscript{31}

The PPIase-like FK2 domain is structurally similar to the FK1 domain but exhibits no PPIase activity or FK506 binding activity. Like the FK1 domain, FK2 also has the typical FKBP fold - an antiparallel six stranded β sheet around a central α helix. The function of the FK2 domain is still not clear. A mutant of FKBP51 containing a three amino acids deletion (D195, H196 and D197) deletion in the FK2 domain still binds to Hsp90 but the integration into progesterone receptor complexes is abnormal which might be due to the decreased interaction with the receptor complex.\textsuperscript{29}

The C-terminal TPR domain is made up of three tetratricopeptide repeat (TPR) domain of a consensus 34-amino acid motif and is responsible for binding to Hsp90 through interaction with the EEVD motif in the C terminus of Hsp90.\textsuperscript{28, 29, 32} The residues at the TPR/Hsp90 binding interface are highly conserved in both FKBP51 and FKBP52 with the exception of Q333, F335, A365 in FKBP52 and R331,Y333,L363 in FKBP51. These variations may account for the different binding activity of them to Hsp90.
FKBP51                                                      FKBP52

Figure 2 The crystal structure of FKBP51 (PDB number 1KT0) and a composite of two partial structures for human FKBP52 (PDB numbers 1Q1C and 1P5Q) are shown in ribbon format colored based on secondary structure. The C-terminal TPR domains are shown in blue, the FK2 domains are in organe, the FK1 domains are in red. The figure, including the overlay of the two partial FKBP52 structures, was created using pymol.

2.3 Cellular and Physiological Functions of FKBP51 and FKBP52

Although FKBP51 and FKBP52 share high sequence and structural similarity, their cellular and physiological functions are different.

2.3.1 The role of FKBP51 and FKBP52 in steroid receptor signaling

FKBP51 and FKBP52 were first identified in complex with the steroid hormone receptors\(^{33, 34}\) and are best known as heat shock protein 90 (Hsp90) associated co-chaperone to regulate steroid hormone receptors (SHRs)\(^{30}\). They function antagonistically to each other. In most cell types, FKBP51 decreases the signal transduction of the SHRs\(^{35}\) whereas FKBP52 increases it for androgen receptor (AR)\(^{36}\), glucocorticoid receptor (GR)\(^{20}\) and progesterone receptor (PR)\(^{37}\). As an exception FKBP51 was found to increase rather than decrease the signalling of the AR in prostate cancer cell lines\(^{38, 39}\). Most SHRs, especially the glucocorticoid receptor (GR), primarily stay in the cytoplasm in the ligand free state and migrate to
the nucleus upon ligand binding after a Hsp90-assisted maturation process \(^{40, 41}\) (Figure 3).

**Figure 3**: Model of FKBP51 and 52 on steroid hormone maturation, ligand binding and nuclear translocation.

The latest model of FKBP regulation of SHRs maturation, hormone binding and nuclear translocation was postulated as follows \(^{42, 43}\): The FKBP binds to the C-terminus of Hsp90 via the TPR domain to enter the Hsp90-dimer-SHR complex, which is stabilized by the p23 cochaperone \(^{41}\). It brings the FKBP FK1 domain into contact with the receptor ligand binding domain to directly influence hormone binding affinity. As a result of the differences in the FK1 domain especially the proline rich loop of FKBP51 and FKBP52, hormone binding is repressed in the presence of FKBP51 and potentiated in the presence of FKBP52. Upon steroid binding, the SHR heterocomplex exchanges FKBP51 for FKBP52, which is able to interact with dynein. The whole SHR–chaperone complex translocates through the nuclear pore complex.
followed by receptor transformation, binding of the steroid-activated receptor to
hormone response elements and gene transcription regulation. The Hsp90–FKBP52
complex further assists the cytoplasmic retrotransport of a number of Hsp90-
associated factors. In intact cells, FKBP51 was shown to slow down the nuclear
translocation of the GR, possibly by blocking FKBP52 mediated recruitment of the
dynactin motor complex. Through the active involvement of FKBP51 and FKBP52 in
steroid receptor signaling, they play important roles in a variety of diseases which
depend on these hormone signaling pathways.

2.3.2 Biological implications of FKBP51 and FKBP52 in diseases

2.3.2.1 Stress related diseases

The hypothalamus-pituitary-adrenal (HPA) axis is a stress hormone system triggering
the physiological and behavioral response to chronic and acute stress in humans.
Upon stress the hypothalamus secretes corticotropin releasing hormone (CRH) which
triggers the synthesis and release of adrenocorticotropic hormone (ACTH) in the
pituitary gland and results in secretion of cortisol in the adrenal gland into the blood
to act on various tissues. The HPA axis is controlled by a negative feedback exerted
by cortisol via the GR to inhibit the further release of CRH and ACTH thereby
maintaining homeostasis of the HPA axis (Figure 4). The imbalance in the HPA axis
was correlated with the risk for and course of diseases such as major depression,
bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia and anxiety
disorders. One of the reasons for the inappropriate reaction of the HPA axis to
stress was claimed to be the malfunction of GR. FKBP51 and FKBP52 were shown
to have opposing functions on GR and FKBP51 has been shown to be an negative modulator of GR activity and
important in stress coping behavior and adaptation to stress. The induced fkbp5 mRNA levels and the FKBP51 expression pattern in the brain after a stress or glucocorticoid challenge was shown to be region specific and correlates to the fkbp5 baseline level. All these findings strongly indicated the important role of FKBP51 in the etiology of stress-related psychiatric disorders and the potential as a novel therapeutic target for psychiatric disorders.

Figure 4: The Hypothalamic–Pituitary–Cortisol System

2.3.2.2 Cell proliferation and cancer

FKBP51 is a protein with a progressively emerging role in cancer biology. The active role of FKBP51 in cell proliferation and cancer was shown by the increased level of FKBP51 in physiological conditions of cell growth and differentiation with preferential
expression in mitotically active cells\textsuperscript{65-68} and in gliomas\textsuperscript{69}, retinal tumor cells\textsuperscript{70}, melanoma\textsuperscript{71, 72}, prostate cancer\textsuperscript{73, 74} and prostatic hyperplasia\textsuperscript{75}. In prostate cancer cells, FKBP51 was indentified as a positive regulator of AR and androgen-dependent cell growth, which is distinctly different from the effect observed on GR and PR, where FKBP51 is a negative modulator\textsuperscript{39, 76-79}. FKBP51 was described to enhance NF-κB mediated transcription to protect from apoptosis upon a number of stimuli and to enhance cell viability or proliferation in leukemia\textsuperscript{71} and melanocyte malignancy\textsuperscript{80}. Via the action on GR, FKBP51 suppressed proliferation in colorectal adenocarcinoma\textsuperscript{81} and the dexamethasone-induced expression of FKBP51 by the GR in myeloma cells has been interpreted as an adaptive process before cell death\textsuperscript{82}. The decreased FKBP51 expression in several cancer cell lines and in pancreatic cancer tissue was correlated with increased AKT phosphorylation and a reduced cell sensitivity to chemotherapeutic agents\textsuperscript{13, 14}. FKBP51 was proposed to negatively regulate the activity of the cell growth regulator AKT and serve as a scaffolding protein to recruit the phosphatase PHLPP\textsuperscript{13}. Taken all together, the involvement of FKBP51 in a wide variety of cancers indicated FKBP51 as an important molecular player with divergent functions and represented a promising cancer therapy target\textsuperscript{39, 69, 71, 72, 83}.

By contrast, less is known about the role of FKBP52 in cancer. The recently observed increased expression of FKBP52 in prostate needle biopsies from human patients\textsuperscript{84}, prostate cancer cells\textsuperscript{85} and breast cancer cells\textsuperscript{86} together with the androgen, progesterone and glucocorticoid insensitivity phenotypes observed in FKBP52 knockout mice\textsuperscript{36, 37, 87-89} indicated FKBP52 as a potential therapeutic target in a variety of diseases dependent on these hormone signaling pathways.

### 2.3.2.3 Immune system

FKBP51 also plays a role in immune-related diseases and inflammation mainly through regulation of GR activity and modulation of NF-κB-dependent gene expression by FKBP51\textsuperscript{69, 90-93}. It was shown that FKBP51 modulates the stability of IκB, the phosphorylation of NF-κB and enhances DNA binding of NF-κB. Enhanced FKBP51 expression in bone marrow cells was observed in rheumatoid arthritis\textsuperscript{90} and in the treatment of chronic obstructive pulmonary disease\textsuperscript{94}. The inhibiting of endogenous MHC class II-restricted antigen presentation by FK506 was also shown
to be mediated by FKBP51\textsuperscript{95}. Additionally, like other smaller FKBPs, FKBP51 can bind to FK506 to mediate inhibition of the calcineurin which activates nuclear factor of activated T cells\textsuperscript{96, 97}.

### 2.3.2.4 Reproductive development and reproductive success

The important role of FKBP51 and FKBP52 in mammalian reproductive development and reproductive success was shown by the studies of FKBP51 knockout and FKBP52 knockout mouse lines. Male FKBP52 knockout mice display phenotypes consistent with partial androgen insensitivity where the secondary sex organs are mainly affected with dysgenic prostate, smaller seminal vesicles, ambiguous external genitalia and retention of nipples into adulthood while the primary sex organs like testes remain unaffected.\textsuperscript{36, 89} Female FKBP52 knockout mice seem to be morphologically normal but sterile.\textsuperscript{37} A failure of embryonic implantation and decidualization was found to be the reason for the infertility which indicated the crucial role for FKBP52 in female reproduction and uterine signaling\textsuperscript{88}. FKBP51 knockout mice display no obvious morphologically phenotypes and reproduce normally compared to FKBP52 knockout mice. The double knockout of both FKBP51 and FKBP52 genes is embryonic lethal in mice\textsuperscript{98} indicating that FKBP51 and FKBP52 have some crucial but redundant roles in embryonic development.

### 2.3.2.5 Neurodegenerative diseases

With their high expression in the central and peripheral nervous system, FKBP12, FKBP38, FKBP51, FKBP52 and FKBP65 also play important role in neurodegenerative disorders with neurotropic, neuroprotective and neurotransmitter releasing effects\textsuperscript{15, 99-101}. In Parkinson’s Disease (PD), FKBP52 was found to be associated with RET51, which is a tyrosine kinase receptor important in the development and maintenance of the nervous system in a phosphorylation dependent manner. This was independent of Hsp90 or other chaperones\textsuperscript{102}. In studies of PD and Alzheimer’s Disease (AD), FKBP51 and FKBP52 showed
contrasting effect on tau stability. FKBP51 preserves tau levels but reduces its phosphorylation and enhances the tau mediated MT polymerization\textsuperscript{15} whereas increased levels of FKBP52 is correlated with decreased tau stability\textsuperscript{101, 103}. The PPIase activity of FKBP51 and FKBP52 are regarded critical for the regulation of tau\textsuperscript{104, 105}. FKBP52 was also shown to interact with Atox\textsuperscript{106, 107} to modulate Aβ pathogenesis by modulating Aβ generation and toxicity via copper homeostasis in AD\textsuperscript{108, 109}. A transgenic mouse model of amyotrophic lateral sclerosis indicated the correlation of decreased expression of FKBP52 with degeneration of anterior lateral horn neurons and deregulation of axonal transport\textsuperscript{110}.

### 2.4 Chemical biology of FKBPs ligands

#### 2.4.1 Immunosuppressive FKBPs ligands

Best known as immunosuppressive ligands used in the clinic as transplantation medicine, FK506 and rapamycin (Sirolimus) bind to FKBPs with very high affinity. Isolated from \textit{Streptomyces tsukubaensis}, FK506 consists of a FKBPs binding domain and an effector domain with which the FKBPs-FK506 complex binds and allosterically inhibits the secondary target calcineurin to induce the immunosuppressive effect\textsuperscript{111}. FKBP12, FKBP12.6 and FKBP51 are thought to be the primary FKBPs to mediate the immunosuppressive action of FK506\textsuperscript{97, 112}.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{immunosuppressive_ligands.png}
\caption{Clinically used immunosuppressive FKBPs ligands derived from FK506 and rapamycin.\textsuperscript{113} The modified substructures were shaded in yellow.}
\end{figure}
Isolated from *Streptomyces hygroscopicus*, rapamycin binds to FKBP51 and FKBP52 and exhibits the immunosuppressive activity via a different ternary partner, the serine-threonine protein kinase mammalian target of rapamycin (mTOR). Many immunosuppressive FK506 and rapamycin analogs (Figure 5) were designed and used in various phases of clinical trials or in the clinic against various disorders like breast cancer, melanoma and advanced renal cell carcinoma, metastatic soft-tissue sarcomas etc. with improvement in terms of side effects, solubility and efficacy\(^{113}\).

### 2.4.2 Non-immunosuppressive FKBP51 ligands

Besides the immunosuppressive effects, FK506 and Rapamycin were also shown to have neuroprotective and neurotropic effects\(^{114, 115}\). The non-immunosuppressive FKBP51 ligands were developed to reduce the suppression of immune responses of FK506 and Rapamycin but preserve or improve the neuroprotective and neurite outgrowth promotive activities in a variety of neuronal cell systems. These ligands were active in animal models of cerebral ischemia\(^ {116, 117}\), traumatic brain injury\(^ {118}\), diabetic neuropathy\(^ {119}\), Parkinson’s disease\(^ {120-122}\), and other types of physical neuronal injury\(^ {123-126}\).

Semi- or biosynthetic analogs of FK506 or Rapamycin are one type of the non-immunosuppressive FKBP51 ligands. Their bindings to calcineurin/ mTOR were abolished by modification of the effector domain (e.g., FK1706, meridamycin, normeridamycin, ILS920, Way-124466, Wye-592, L685-818) (Figure 6).

The second type of non-immunosuppressive FKBP51 ligands consists of small synthetic FKBP51 ligands. They were designed to mimic the dicarbonyl pipecolyl moiety of the FK506 and rapamycin but lack the effector domain (Figure 7). VX-10,367 is the most potent synthetic FKBP12 ligands known to date\(^ {127}\) while its analogue biricodar (VX-710) was reported to retain high potency for FKBP12. It was investigated in several clinical trials as chemosensitizing agents but it displayed only modest affinity for FKBP51 and FKBP52\(^ {128}\). GPI1046 and its analogs (GPI1485, JNJ460/GM284\(^ {129}\)) were reported to have neurotrophic and neuroprotective activities and high FKBP12 binding affinity although contrary results were also reported\(^ {116, 130-133}\). GPI1046 was inactive for FKBP51 and FKBP52\(^ {134}\). GPI1485 was claimed as the active form of its prodrug GPI1046 produced after in vivo ester hydrolysis\(^ {135}\).
Figure 6: Representative biosynthetic or semi-synthetic analogs of FK506 or rapamycin as non-immunosuppressive FKBP ligands.
2. Introduction

GPI1485 failed to show activity in two phase II clinical trials\textsuperscript{136} and was inactive in a PPIase assay of FKBP12\textsuperscript{137}. Various FK506 analogs (VX-853, V-13,661 and V-13,670) were claimed not to bind FKBP12 but to other unidentified protein targets to produce at least some of the effects of FK506\textsuperscript{126,138}. VX-853 (Timcodar) was shown to be active in two animals mode of peripheral nerve diseases and advanced to a phase II clinical study for diabetic neuropathy\textsuperscript{113}. It showed no affinity for FKBP51 and FKBP52\textsuperscript{134}, the selectivity profile of these ligands for other FKBP family members are unknown. The cycloheximide analog DM-CHX was developed as a selective FKBP ligand for FKBP38 vs. other FKBP homologs and it was active in an animal model of focal cerebral ischemia\textsuperscript{117}. Hudack et al. designed a tetrahydroisoquinoline moiety \textbf{A} via acyl iminium chemistry followed by systematic structure activity relationship study to give \textbf{A1} and \textbf{A2} with low nanomolar affinity for FKBP12\textsuperscript{139}.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{synthetic_ligands.png}
\caption{Synthetic neuroimmunophilin ligands. The core of FK506 or rapamycin or equivalent groups are shown in yellow\textsuperscript{140}.}
\end{figure}
2. Introduction

2.4.3 FKBP51 and FKBP52 ligands

Compared to the active research on the biology of FKBP51 and FKBP52, few efforts for the discovery of novel synthetic FKBP51 and FKBP52 ligands were described. The first described synthetic ligand for FKBP51 and FKBP52 with low micromolar affinity was SLF\(^{141}\), a simplified analogue of FK506 and rapamycin that was originally developed for FKBP12 with low nanomolar affinity\(^{142}\). Ranganath Gopalakrishnan et al. elaborated the first detailed structure–activity relationship study for FKBP51 and FKBP52 ligands based on SLF\(^{134}\). Compared to FK506, SLF has the piperidine core derived from the diketoamide pipecolinic core of FK506 and rapamycin but it lacks the effector domain. Based on the co-crystal structure of SLF and FKBP51, a series of synthetic FK506 analogues for FKBP51 and 52 based on the pipecolate scaffold \(\text{C}\) were prepared. In particular, a cyclohexyl ring system which more closely resembles the pyranose ring in the high-affinity ligands rapamycin and FK506 was implemented instead of the tert-pentyl group to target the proline rich loop.

The best compounds of this series are \(\text{C1}\) and \(\text{C2}\) (Figure 8) with binding affinities of 1 µM to 4 µM. Furthermore, a focused sulfonamide library for FKBP51 and 52 were prepared using a solid phase strategy\(^{143}\). With the same pipecolate scaffold \(\text{C}\), sulfonamids were attached at the \(R_2\) position as bioisosteric replacement of the metabolic labile diketo amide moiety. Compound \(\text{C3}\) was claimed to be the best known ligand for the large FKBP5s to date, albeit without selectivity while \(\text{C4}\) has exceptionally high affinity for FKBP12, rivaling those of the natural products FK506 and rapamycin. However, \(\text{C4}\) displayed but only low micromolar affinity for FKBP51 and FKBP52.

Unfortunately all of the described FKBP51 and 52 ligands are very large, show only modest binding affinity and suffer from low drug-like Properties.

As SLF and FK506 were the only two public known FKBP51 and FKBP52 ligands\(^{141}\) at the start of this thesis, they were used as prototypes for our structure based rational ligand design.
2.5 Interactions of 2 (SLF) and polycyclic ligand 3a with FKBP51

FK506 (1) (Figure 9a) binds to the peptidyl prolyl isomerase (PPIase) domain of FKBP51/52 and inhibits their PPIase activity. SAR studies with synthetic FKBP ligands indicated the dicarbonyl pipecolyl-scaffold (shadowed in Figure 9) of FK506 as the most important group for their binding to FKBP s. The α-keto amide has been suggested as an analogue of the twisted amide in the transition state of the peptidyl-prolyl isomerisation catalyzed by FKBP's \(^{144, 145}\).

SLF (2) (Figure 9b) is a simplified synthetic analogue of FK506 with micromolar affinity for FKBP51/52. Its cocrystal structure with the FK506-binding domain of FKBP51 and a first SAR study were recently reported\(^{134}\). Upon binding of compound 2, FKBP51 adopts a very similar conformation as found in the FK506 complex. Most active site residues are virtually superimposable in the two co-crystal structures (Figure 9c). A comparison with the cocrystal structure of FK506\(^{146}\) showed that most of the key interactions are conserved. The conserved interactions include hydrophobic contacts between the piperidine ring and the indole of Trp\(^{90}\), hydrogen
bonds between the C$_8$-amide carbonyl and Tyr$_{113}$-OH and between the C$_1$-amide carbonyl and Ile$_{87}$-NH, a dipolar interaction between C$_1$ and Tyr$_{113}$-OH (142°, 3.2Å) and aromatic hydrogen contacts of Tyr$_5$, Phe$_{67}$ and Phe$_{130}$ with the C$_9$-carbonyl. Part of the lower binding affinity of 2 may be due to its higher flexibility compared to FK506. Compound 2 and all other known FKBP51/52 ligands, including the natural products FK506 and rapamycin display unfavorable pharmacokinetic profiles and suffer from a very low ligand efficiency (<0.18). This is below the widely accepted lower limit of 0.3$^{147}$ (Figure 9a and 9b).

<table>
<thead>
<tr>
<th>Protein</th>
<th>FKBP51</th>
<th>FKBP52</th>
<th>FKBP12</th>
<th>FKBP51</th>
<th>FKBP52</th>
<th>FKBP12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki(µM)</td>
<td>0.028±0.009$^{141}$ (0.18)</td>
<td>0.08±0.01$^{141}$ (0.17)</td>
<td>0.01±0.003$^{141}$ (0.24)</td>
<td>2.1±0.3$^{141}$ (0.19)</td>
<td>2.7±0.2$^{141}$ (0.18)</td>
<td>0.01±0.003$^{141}$ (0.26)</td>
</tr>
</tbody>
</table>

Figure 9: (a) Immunosuppressive drug FK506 (1). (b) A synthetic analog thereof SLF (2). The pipecolate and α-keto amide core structure as the key FKBP recognition motif is shaded gray with binding affinities for FKBP51, FKBP52 and FKBP12. The ligand efficiency (LE) is defined as the ratio of Gibbs free energy (ΔG) to the number of non-hydrogen atoms (N) of the compound: LE = (ΔG)/N, where ΔG = -RTlnK, with RT equal to 0.6 kcal/mol. The unit of LE is kcal/mol/non-hydrogen atom$^{148}$. (c) Surface representation of FKBP51 in complex with 2 (4DRK) (magenta). FK506 bound to FKBP51 (3O5R) is superimposed in cyan.
Studies with the smaller homolog FKBP12 showed that binding affinity and ligand efficiency might be improved by macrocyclization\(^{149}\) or by rigid polycyclic scaffolds\(^ {139}\). Flexible ligands are thought to suffer an entropic penalty upon binding due to the freezing of rotatable bonds\(^ {150}\). In turn, reducing ligand flexibility, e.g., by macrocyclization, is an appealing concept to improve potency. It is also well known that flexible ligands often adopt higher energy conformations upon binding to fine-tune ligand-protein interactions\(^ {151-154}\). Thus, in principle, additional binding energy could be gained by preorganizing or stabilizing these high-energy active conformations. Thus representative examples of the polycyclic scaffold 3\(^ {a-3e}\) were synthesized (Table 1). Unfortunately, these did not enhance binding affinity and ligand efficiency for FKBP51/52.

To get an insight into the molecular binding mode, the polycyclic ligand 3\(^ {a}\) was cocrystallized with the FK506-binding domain of FKBP51 (Figure 10). Compound 3\(^ {a}\) bound to the FKBP51 FK1 domain in a similar way as the core of FK506 or the synthetic analog 2 with most of the key interactions conserved. The picolyl ring of the ligand sits atop the indole of Trp\(^ {90}\) of FKBP51 which forms the floor of the hydrophobic binding pocket. Two hydrogen bonds between the C\(^ {16}\)-amide carbonyl and Tyr\(^ {113}\)-OH and between the C\(^ {1}\)-amide carbonyl and Ile\(^ {87}\)-NH are observed. These
two hydrogen bonds are a hallmark of FKBP ligands. Tyr$^{113}$-OH also approaches the C$^1$ carbonyl almost perpendicular ($88.3\,^\circ$) at 3.4Å. This putative dipolar interaction has been observed previously in FKBP-ligand structures but might be less strong in case of 3a$^{155}$. The C$^{17}$-carbonyl engages the three $\varepsilon$-hydrogens of the aromatic residues Tyr$^{57}$, Phe$^{67}$ and Phe$^{130}$ which form the apparent carbonyl binding pocket of FKBPs. The C$^8$ of the bicyclic bridge system forms van-der-Waals contacts with the tip of Phe$^{77}$. Ring B and ring C stack on top of each other via $\pi-\pi$ interactions. The preorganization by the rigid ring B might lock ring C into a conformation favourable for binding. The stacking of these two rings could represent a productive ligand hydrophobic collapse$^{156}$. Favourable van-der-Waals interactions between Tyr$^{57}$ and C$^{15}$-OMe, between Asp$^{68}$ and C$^{19}$-OMe, and between Tyr$^{113}$, Ser$^{118}$ and C$^{20}$-OMe also contribute to the binding of the ligand. This is supported by the inactive ring C analogs 3b-3e where the aromatic ring C is replaced by an aliphatic moiety or sulfonamides aromatic ring (Table 1).

<table>
<thead>
<tr>
<th>Compound</th>
<th>R$_2$</th>
<th>FKBP51 IC50(µM) (LE)</th>
<th>FKBP52 IC50(µM) (LE)</th>
<th>FKBP12 IC50(µM) (LE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a</td>
<td>OMe</td>
<td>18.1±1.2 (0.17)</td>
<td>19±1.5 (0.17)</td>
<td>0.5±0.1 (0.23)</td>
</tr>
<tr>
<td>3b</td>
<td>HO</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>2.8±4.5 (0.23)</td>
</tr>
<tr>
<td>3c</td>
<td>OMe</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>27.7±11.4 (0.20)</td>
</tr>
<tr>
<td>3d</td>
<td>Cl</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.87±2.5 (0.25)</td>
</tr>
<tr>
<td>3e</td>
<td>OH</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>2.1±0.3 (0.23)</td>
</tr>
</tbody>
</table>

Table 1: Binding affinities and ligand efficiencies of polycyclic ligands 3a-3e for FKBP51, 52 and 12.

Cyclohexyl rings that mimic the pyranose of FK506 or rapamycin were recently shown to be preferred substructures compared to the trimethoxyphenyl moieties in a monocyclic scaffold$^{134}$. In contrast, in the polycyclic context a dramatic decrease of the binding affinity was observed when ring C was changed to the cyclohexyl $\alpha$-keto amide substructure in 3b. The lower affinity of 3b might be due to less favourable
intramolecular interactions leading to the loss of the preorganized conformation. Likewise, derivative 3c bearing the tert-penyl group present in 2 was also inactive. Although sulfonamides were suitable surrogates for the α-keto amide substructure in monocyclic FKBP51/52 ligands, polycyclic aza-sulfonamide compounds 3d and 3e were both inactive. This might be because these sulfonamide aromatic rings were locked at different angles compared to the constrained sulfonamides due to π-π interactions with ring B.

2.6 Reported compounds with similar scaffolds as 4 and 5

The proposed [3.3.1] aza-amide scaffold and [4.3.1] aza-amide scaffold were not found in nature. The closest natural products are exemplified by the [4.2.1] alkaloids such as anatoxin A and [3.2.1] aza-amide scaffolds in the tropane alkaloids (Figure 11). The closest synthetic analogues of the [3.3.1] aza-amide scaffold were reported as part of the polycyclic scaffold 3.

![Chemical structures](image)

Figure 11: The chemical structure of (a) Anatoxin A, (b) Tropane

In the synthesis of anatoxin A, tropane alkaloids and the polycyclic scaffold 3, the intramolecular N-acyliminium cyclization was employed as a key step.

2.7 Intramolecular N-acyliminium cyclization

The N-acyliminium or N-acyliminium ion chemistry has been extensively employed for the synthesis of N-heterocyclic ring systems related to alkaloids. It has been systematically studied especially by Speckamp et al. based on the succinimide
2. Introduction

Under acidic condition, the hemiaminal D1 is converted to the N-acyliminium ion intermediate D2 (Scheme 1). Compared to the iminium ion which has been widely employed in the Mannich reaction, the Bischler-Napieralski reaction and the Pictet-Spengler reaction, the carbonyl group adjacent to the nitrogen atom greatly increased the electrophilic reactivity of the N-acyliminium ion which broadens the range of nucleophiles that can be used in carbon-carbon bond formation reactions. Because of its high activity, the N-acyliminium ion intermediate is seldom if ever isolated\textsuperscript{162, 163} and usually is generated \textit{in situ}. Intermediate D2 was found to be reactive towards a wide variety of \(\pi\)-nucleophiles including alkenes, allenes, alkynes and aromatic and heteroaromatic systems\textsuperscript{162}.

![Scheme 1](image)

\textbf{Scheme 1}: Mechanism of N-acyliminium chemistry.

The intramolecular N-acyliminium cyclization is widely employed especially in the synthesis of bicyclic and polycyclic N-heterocyclic ring systems. Some examples even showed high stereocontrol during the C-nucleophilic additions to N-acyliminium species\textsuperscript{164, 165} which makes the intramolecular N-acyliminium cyclization even more attractive for the synthesis of alkaloidal ring systems.

Generally, the N-acyliminium ion can be generated from three sources. \(\alpha\)-Oxygenated amides is the most common source of N-acyliminium ions while the use of other \(\alpha\)-substituted amides such as bisamides, \(\alpha\)-chloroalkyl amides and \(\alpha\)-thioalkyl amides were also reported\textsuperscript{162}. The \(\alpha\)-oxygenated amides can be prepare by addition of an amide to an aldehyde or ketone under acid condition (reaction 1 in Scheme 2)\textsuperscript{164}, electrochemical oxidation of amides or carbamates (reaction 1 in Scheme 2)\textsuperscript{166}, reduction of cyclic imides in the presence of an alcohol (reaction 3 in Scheme 2)\textsuperscript{167}, and addition of Grignard reagents to cyclic imides (reaction 4 in Scheme 2)\textsuperscript{168}. Acylation of imines with an acid chloride or acid anhydride to afford acyliminium species was also reported (reaction 5 in Scheme 2)\textsuperscript{169}. Although the protonation of N-acylimines is possible in principle, very few examples have been
described (reaction 6 in Scheme 2)\textsuperscript{170}. The limitation is mainly due to the tautomerization of the N-acylimines to enamides when $\alpha$-hydrogen atoms are present.

\textbf{Scheme 2}: Summary of the N-acyliminium ion generation.

The intramolecular N-acyliminium cyclization has been used to construct pyrrolidines, piperidines and related rings\textsuperscript{171-174}, pyrrolizidines\textsuperscript{175}, indolizidines\textsuperscript{176, 177}, spirocyclic systems\textsuperscript{178}, ring systems containing a seven-membered or eight-membered ring\textsuperscript{179}, polycyclic and bridged systems\textsuperscript{180}. Some of its applications in preparation of bicyclic or polycyclic N- heterocyclic ring systems of natural products are shown in Scheme 3.
Scheme 3: Some examples of intramolecular N-acyliminium cyclization in preparation of bicyclic and polycyclic N- heterocyclic ring system of natural products.

A silicon-directed N-acyliminium ion cyclization was employed to prepare the fused bicyclic structures of Isoretronecanol\(^\text{(1)}\) and Epilupinine (reaction 1 and 2 in Scheme 3)\(^\text{(2)}\). For the spirocyclic systems of Perhydrohistrionicotoxin, the furan ring was found to be a good \(\pi\)-nucleophile for the intramolecular N-acyliminium ion cyclization (reaction 3 in Scheme 3)\(^\text{(3)}\). The bridge bicyclic system in Quinocarcin was prepared through acylated amide reduction followed by cyclization (reaction 4 in Scheme 3)\(^\text{(4)}\). The Lewis acid induced cyclization of enolic \(\pi\)-nucleophiles could easily afford the tropane-like system (reaction 5 in Scheme 3)\(^\text{(5)}\). An 8-Azabicyclo[4.2.1] system like in
Anatoxin-a was shown to be obtained by lewis acid-induced cyclization of an unfunctionalised alkene π-nucleophiles\textsuperscript{159} (reaction 6 in Scheme 3). The intramolecular N-acyliminium cyclization was also crucial in the synthesis of other natural products like Gephyrotoxin\textsuperscript{183}, Laudanosine\textsuperscript{180}, Yohimbine\textsuperscript{184}, Ajmalicine\textsuperscript{185}, Vindorosine\textsuperscript{186}, Gelsemine\textsuperscript{187}, Sarains\textsuperscript{188} and so on.
FKBP51 and FKBP52 have important implications in diseases like cancer and depression. However, all known FKBP51 and FKBP52 ligands display unfavorable pharmacokinetic profiles which make them unsuitable to study the biological roles of FKBP51 and FKBP52.

In this project, the aim was to limit the ligand flexibility by ligand preorganization to mimic the FKBPs ligands active conformation and to focus on improvement of their ligand affinities and efficiencies. Two new classes of conformationally defined pipecolyl analogs based on aza-amide bicycles as rigid replacements for the pipecolyl-monocyclic scaffold were designed. First, efficient synthetic procedures for the bicyclic [3.3.1] aza-amide and [4.3.1] aza-amide core structures had to be developed. Second, the bicyclic [3.3.1] and [4.3.1] aza-amide scaffold had to be derivatized to identify the best substituents and to probe the energetic contribution of the individual subgroups. Third, a detailed biological and biophysical characterization of selected analogs was intended to elucidate the molecular underpinnings of binding of the constrained FKBP ligands in detail.

The final goal was to provide efficient and well understood scaffold for the further optimization of FKBP51 ligands.
4. Results and discussion

4.1 Design of conformationally defined FKBP ligands

The multiple interactions of $3a$ with the protein made the direct assessment of the contribution of the C$^1$-C$^6$ cyclization difficult. We therefore decided to synthesize bicyclic [3.3.1] aza-amides derivatives $4$ (Figure 12). This rigidified aza-amid nucleus is a simplified mimic of the $3a$ core with the idea of limiting the flexibility of these monocyclic ligands which may decrease the entropic costs upon binding meanwhile increasing the flexibility of the $R_1$ and $R_2$ substituents to allow them to increase the interactions with the protein. The unrestricted substituents could be better suited to mimic the active conformation of monocyclic piperolate-based FKBP ligands like $2$. In such a constrained bicycle, the C$^1$-carbonyl oxygen is preoriented for interaction with Ile$^{87}$. A hydrogen bond with the backbone amide of this residue is a hallmark of most FKBP ligands known so far. In addition, the important hydrophobic interaction between the piperidine ring and the indole of Trp$^{90}$ together with the hydrogen bond between the C$^8$-amide carbonyl and Tyr$^{113}$-OH would be highly conserved. Further optimization of $R_1$ could more closely resemble those present in the monocyclic ligands like $1$ to help to improve the binding affinity. The bicyclic [4.3.1] aza-amide derivatives $5$ (Figure 12) with a similar structure as $4$ and a two-atom linker between C$^1$- C$^6$ was also proposed. It could adopt to a similar conformation as $4$ and with the possibility of further modification at C$^8$ and C$^9$ position.
4. Results and discussion

![Proposed bicyclic [3.3.1] aza-amide derivatives 4, bicyclic [4.3.1] aza-amide derivatives 5 and the corresponding monocyclic derivatives 6 derived from 1 (FK506), prototypic synthetic FKBP ligand 2 (SLF) and polycyclic ligand 3a.](image)

**Figure 12:** Proposed bicyclic [3.3.1] aza-amide derivatives 4, bicyclic [4.3.1] aza-amide derivatives 5 and the corresponding monocyclic derivatives 6 derived from 1 (FK506), prototypic synthetic FKBP ligand 2 (SLF) and polycyclic ligand 3a.

### 4.2 Computer modelling

Computer modelling of the bicyclic [3.3.1] aza-amide nucleus 7 and the bicyclic [4.3.1] aza-amide nucleus 8 into the binding pocket of FKBP51 indicated no obvious steric hindrance between the protein and the bicyclic aza-amide nucleus 7 and 8 (Figure 13). The C\(^1\)-C\(^6\), N\(^7\), O\(^1\) and O\(^{10}\) of the bicyclic [3.3.1] aza-amide nucleus 7 and C\(^1\)-C\(^6\), N\(^7\), O\(^1\) and O\(^{11}\) of the bicyclic [4.3.1] aza-amide nucleus 8 were overlaid with the corresponding atoms of 2 (SLF) in the cocrystal structure of 2 and FKBP51 FK1 domain. The binding mode of the bicyclic [3.3.1] aza-amide nucleus 7 and the bicyclic [4.3.1] aza-amide nucleus 8 was nearly superimposable with the common elements of the pipecolate and \(\alpha\)-keto amide region (Figure 1 and 4). Small deviations were observed which may be due to the bicyclic ring strains in 7 and 8. The geometry of the important hydrogen bond acceptor C\(^1\)=O was quantified by the O\(^1\)-C\(^1\)-C\(^2\)-N\(^7\) dihedral angle which varied from 153° to 193° among known cocrystallized FKBP51 ligands (Table 2) while the O\(^1\)-C\(^1\)-C\(^2\)-N\(^7\) dihedral angle in 7 is locked to 157° and 175° for 8.
4. Results and discussion

Figure 13: (a) The structure of the bicyclic [3.3.1] aza-amide nucleus \( \mathbf{7} \) (b) The bicyclic [4.3.1] aza-amide nucleus \( \mathbf{8} \) used for computer modeling. (c) Superimposition of \( \mathbf{7} \) (orange) with \( \mathbf{2} \) (magenta) modelled into the FKBP51 FK1 domain. (d) Superimposition of \( \mathbf{8} \) (yellow) with \( \mathbf{2} \) (magenta) modelled into the FKBP51 FK1 domain. (e) A space filling mode of \( \mathbf{7} \) positioned into the pocket of FKBP51 FK1 domain. f) A space filling mode of \( \mathbf{8} \) positioned into the pocket of FKBP51 FK1 domain.
4. Results and discussion

Based on this parameter, the geometry of the bicyclic [4.3.1] aza-amide nucleus 8 along the C1-C2 bond is predicted to be preorganized nearly identical as the experimentally observed conformation in the unconstrained FKBP ligands, while the predicted dihedral angle in the bicyclic [3.3.1] aza-amide nucleus 7 deviates more. The similar geometry shared by the bicyclic [3.3.1] aza-amide nucleus 7 and the bicyclic [4.3.1] aza-amide nucleus 8 with the most unconstrained FKBP ligands might enhance the affinity of the bicyclic [3.3.1] aza-amide and bicyclic [4.3.1] aza-amide derivatives for the FK1 domain of FKBP51 and 52. We therefore decided to prepare the corresponding bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-amide derivatives 5 to address the contribution of the bicyclization.

<table>
<thead>
<tr>
<th>Compound (PDB number)</th>
<th>3a</th>
<th>FK506 (1) (3O5R)</th>
<th>C2a</th>
<th>C2b</th>
<th>C3</th>
<th>SLF(2)</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>O1-C1-C2-N7 dihedral angle</td>
<td>153°</td>
<td>179°</td>
<td>193°</td>
<td>191°</td>
<td>185°</td>
<td>185°</td>
<td>157°</td>
<td>175°</td>
</tr>
</tbody>
</table>

Table 2: The O1-C1-C2-N7 dihedral angle for all known cocrystallized FKBP51 ligands and the computer modelling bicyclic [3.3.1] aza-amide nucleus 7 and the bicyclic [4.3.1] aza-amide nucleus 8.

4.3 Synthesis

4.3.1 Synthesis of the bicyclic [3.3.1] aza-amide derivatives 4 and the bicyclic [4.3.1] aza-amide derivatives 5

4.3.1.1 Retrosynthetic analysis and strategy of the bicyclic [3.3.1] aza-amide derivatives 4

The retrosynthesis of the bicyclic [3.3.1] aza-amide derivatives 4 is outlined in Scheme 4. The R1 substructure in 4 was envisioned to be incorporated through alkylation from 9 followed by sequential deprotection and introduction of the α-ketone amide moiety or sulfonamide moiety as R2. The bicyclic nucleus 9 was expected to be most expediently generated by cyclization of a cis-2,6-disubstituted piperidine precursor 10. The piperidine ring in 10 was thought to be obtained from 11 with reduction of a 2, 6-disubstituted pyridine and the amine group could be obtained from reduction of a cyano group. 11 could be easily prepared from 12 via aromatic nucleophilic substitution.
4. Results and discussion

**Scheme 4:** Retrosynthesis of the bicyclic [3.3.1] aza-amide derivatives

4.3.1.2 Synthesis of the bicyclic [3.3.1] aza-amide nucleus 17

The bicyclic [3.3.1] aza-amide nucleus 17 was prepared in a 6-step synthetic route as shown in Scheme 5. Aromatic nucleophilic substitution of commercially available ethyl 6-bromopicolinate 12 with copper(Ⅰ) cyanide in presence of pyridine via a Rosenmund-von Braun reaction afforded the corresponding cyanylated compound 11. Selective hydrogenation of the cyano group with Raney-Ni with concomitant in situ protection of the produced primary amine group with the tert-butyloxycarbonyl (Boc) group was accomplished in a one-pot reaction to give the product 13. Compound 13 was further reduced by platinum oxide in acetic acid at 50 bar H₂ from which the cis enantiomers 14 were separated and used for the next step. Incorporation of the carboxybenzyl (Cbz) group to protect the secondary amine group in 14 gave the product 15. The Boc protection group was efficiently removed by 1:1 TFA in DCM to give the primary amine product 16. Without isolation and purification, the crude product 16 was further subjected to ring closure in refluxing pyridine to yield the [3.3.1] core 17 in gram scale.
4. Results and discussion

Scheme 5: Synthesis of bicyclic [3.3.1] aza-amide nucleus 17: (a) CuCN, pyridine, reflux, 60%. (b) Raney-Ni, Boc$_2$O, H$_2$ 1 bar, RT, overnight, 68%. (c) Pto$_2$, AcOH, H$_2$ 50 bar, RT, 2 days, 49%. (d) Cbz-Cl, N,N-diisopropylethylamine RT, 6h, 96%. (e) 50% TFA in DCM, RT, 1h. (f) pyridine, reflux, 2h, 76% (2 steps).

Two products were observed by TLC and LCMS for the reduction of 13. Theoretically, reducing the compound 13 could give four stereoisomers: two cis enantiomers 14a and 14b together with two trans enantiomers 14c and 14d. Only the cis enantiomers 14a and 14b (Scheme 6) could cyclize to afford compound 17. The compound 17 and products thereof will be enantiomeric mixture, but only the final product from 14a was expected to bind to the FKBPs due to the steric hindrance. 14a and 14b were separated as racemic mixture and used for further reaction without stereochemical resolution. Compound 17 was characterized by HPLC, NMR and Mass spectroscopy, no diastereomers were observed.

Scheme 6: The four stereoisomeric products 14a, 14b, 14c, 14d from the reduction of 13
4. Results and discussion

Because of the high similarity between the bicyclic [3.3.1] aza-amide derivatives 4 and the bicyclic [4.3.1] aza-amide derivatives 5, the following syntheses of 17 to afford 4 will be discussed later together with the synthesis of the bicyclic [4.3.1] aza-amide derivatives 5.

4.3.1.3 Retrosynthetic analysis and strategy of the bicyclic [4.3.1] aza-amide derivatives 5

The retrosynthesis of the bicyclic [4.3.1] aza-amide derivatives 5 is outlined in Scheme 7. The analysis was based on the synthetic route of bicyclic [3.3.1] aza-amide derivatives described above. The R₁ substructure in 5 was envisioned to be incorporated through alkylation from 18 followed by sequential deprotection and introduction of the α-ketone amide moiety or the sulfonamide moiety as R₂. The bicyclic nucleus 18 was expected to be most expeditiously generated by cyclization of a cis-2,6-disubstituted piperidine precursor 19. The piperidine ring in 19 was thought to be obtained from 20 by reduction of a 2,6-disubstituted pyridine and the amine group could be obtained from reduction of a cyanomethyl group. 20 could be easily prepared from 21.

4.3.1.4 Synthesis of the bicyclic [4.3.1] aza-amide nucleus 27

The novel bicyclic [4.3.1] aza-amide nucleus 27 was prepared in a 7-step synthetic route as shown in Scheme 8. Aromatic nucleophilic substitution of commercially available 6-bromopicolinic acid 21 with acetonitrile in presence of n-butyl lithium.
afforded the corresponding cyanomethylated product $22^{191}$. The carboxylic acid group in $22$ was further subjected to methylation under mild condition with trimethylsilyldiazomethane in MeOH at room temperature to give the product $20^{192}$. Selective hydrogenation of the cyanomethyl group with Raney-Ni with concomitant *in situ* protection of the produced primary amine group with the tert-butyloxycarbonyl (Boc) group was accomplished in a one-pot reaction to give the product $23$. Compound $23$ was further reduced by platinum oxide in acetic acid at 50 bar $\text{H}_2$ to afford a mixture of diastereomers which were used for the next step. $^{190}$ Incorporation of the carboxybenzyl (Cbz) group to protect the secondary amine group in $24$ gave the product $25$. The Boc protection group was efficiently removed by 1:1 TFA in DCM to give the primary amine product $26$. Without isolation and purification, the crude product $29$ was further subjected to ring closure to yield $27$ in refluxing pyridine.

\[\text{Scheme 8: Synthesis of the bicyclic [4.3.1] aza-amide nucleus } 27: \text{ (a) Acetonitrile, BuLi, -78°C, 3h, 87%}. \text{ (b) Trimethylsilyldiazomethane, MeOH, RT, overnight, 46%}. \text{ (c) Raney-Ni, Boc}_2\text{O, H}_2 1 \text{ bar, RT, overnight, 76%}. \text{ (d) PtO}_2, \text{ AcOH, H}_2 50 \text{ bar, RT, 2 days, 98%}. \text{ (e) Cbz-Cl, N,N-diisopropylethylamine RT, 6h, 86%}. \text{ (f) 50% TFA in DCM, RT, 1h}. \text{ (g) Pyridine, reflux, 2h, 34% (2 steps)}.\]

Attempts to use $12$ as starting material failed as $28$ was found to be the main product under the condition of 1.1eq BuLi and 1.5eq acetonitrile at -78 °C. (Scheme 9)
4. Results and discussion

Scheme 9: Side reaction of cyanomethylation based on 12 (a) 1.5eq Acetonitrile, 1.1eq BuLi, -78°C, 3h, 75%.

Similar to the intermediate 14 described above, two products were observed for 24 by TLC and LCMS. Theoretically, reducing compound 23 would also give four stereoisomers: two cis-enantiomers and two trans-enantiomers. Only the cis-enantiomers 24a and 24b (Scheme 10) could cyclize to afford compound 27. The compound 27 and product thereof will be two enantiomeric mixture, but only the final product from 24b was expected to bind to the FKBPs due to the correct positioning of the C1-carbonyl group. The diastereomeric mixture of compounds 24a, 24b, 24c and 24d were used for further reaction without diastereomeric separation.

Scheme 10: The four stereoisomeric products 24a, 24b, 24c, 24d from the reduction of 23

Most of the synthetic steps carried out in Scheme 5 had good yield except the last two steps. The cyclization reaction in refluxing pyridine for two days to give the product 27 was accompanied by hydrolysis of ester in 26 and decomposition of 26. The total yield for the final two steps was as low as 34%. One reason is that only two diastereomers of the four diastereomeric mixtures in 26 could cyclize to afford enantiomeric mixture of compound 27. Furthermore, it might be due to the increased ring size that it becomes more difficult to construct the lactam ring through cyclization. Reactivity in cyclization reaction is influenced by the activation energy in the transition state. The activation energy is thought to reflect the strain energy of the ring to be formed and is markedly dependent on ring size. The higher strain energy makes the cyclization of 27 to form the 7-membered ring more difficult. Compound 27 was characterized by HPLC, NMR and Mass spectroscopy, no diastereomers were observed.
4. Results and discussion

4.3.1.5 Synthesis of the bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic[4.3.1] aza-amide derivatives 5

Because of the high similarity between the bicyclic [3.3.1] aza-amide derivatives 4 and the bicyclic [4.3.1] aza-amide derivatives 5, their following syntheses were carried out in the same way. The successful synthesis of bicyclic [4.3.1] aza-amide compound 17/27 makes further incorporation of different R₁ and R₂ substitutions into the scaffold 17/27 possible (Scheme 11).

Scheme 11: Synthesis of bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-amide derivatives 5: (a) 28a-28c (R₁-Br), NaH, THF, RT, 3 days (25% -95%). (b) Pd/C H₂ 1 bar, RT, 1h (71% -100%). (c) 33a or 33b (R₂-OH) EDC-HCl, HOBT, TEA, RT, 6h (23% -76%). (d) 34a-34d (R₃-Cl), DIPEA, DCM, RT, overnight (13% -53%).

The R₁ and R₂ substituents were selected based on previous preliminary structure-activity relationships for FKBP51. R₁ was intended to mimic the 3-{3',4'-dimethoxyphenyl)propyl branch of the ester “top” group in the monocyclic ligand 2 or possibly the ring C of 3a. The R₂ groups were chosen to resemble the α-keto amide and the pyranose moieties in FK506. Sulfonamides as R₃ were shown to be suitable surrogates for the α-keto amide substructure in monocyclic FKBP51/52 ligands.

The series of bicyclic [3.3.1] aza-amide ketoamide derivatives 4a-4c and bicyclic [4.3.1] aza-amide ketoamide derivatives 5a-5d were synthesized from 17/27 through a 3-step synthetic route as shown in scheme 8. 17/27 in dry THF was deprotonated...
followed by addition of \( \text{28} \) to give the substituted products \( \text{29/30} \). The Cbz-protected amine group was deprotected by catalytic hydrogenation using Pd/C in MeOH to give the free amine product \( \text{31/32} \). The secondary amine group in \( \text{31/32} \) was coupled with \( \alpha \)-keto acid \( \text{33} \) to give the final product \( \text{4a-4c and 5a-5d} \). The series of bicyclic [3.3.1] aza-sulfonamide derivatives \( \text{4e-4g} \) and bicyclic [4.3.1] aza-sulfonamide derivatives \( \text{5e-5g and 5i} \) were prepared by coupling the secondary amine group in \( \text{31/32} \) with commercial sulfonyl chloride \( \text{34a-d} \). To further clarify the contribution of the R\(_1\) group to the overall ligand efficiency, the bicyclic ligands \( \text{4h and 5h} \) without R\(_1\) were prepared by hydrogenation cleavage of the Cbz group in \( \text{17 and 27} \) followed by coupling of the secondary amines of \( \text{35 and 36} \) with 2-oxo-2,3-dihydro-benzothiazole-6-sulfonyl chloride \( \text{34c} \). (Scheme 12).

All of these two series of ligands were obtained as an enantiomers mixture, but only one of the enantiomers was expected to bind to the FKBPs due to the steric hindrance. Ligands were characterized by HPLC, NMR and Mass spectrosopy, no diastereomers were observed.

**4.3.1.6 Synthesis of the monocyclic derivatives \( \text{6} \)**

To assess the role of the cyclization, the corresponding mononcyclic derivatives \( \text{6} \) as reference compounds bearing the same substituents as in \( \text{4 and 5} \) were prepared (Scheme 13). Nucleophilic substitution of commercially available Boc-pipecolic acid \( \text{37} \) with \( \text{28a} \) followed by cleavage of the Boc group afford \( \text{39} \). This was then converted to corresponding \( \alpha \)-keto amide \( \text{6a} \) and sulfonamides \( \text{6e-6g} \). (scheme 10)
4. Results and discussion

Scheme 13: Synthesis of monocyclic ligands 6a and 6e-6g: (a) K₂CO₃, acetone, reflux, overnight (100%) (b) 20% TFA in DCM, RT, 2h (100%) (c) 33a (R₂-OH), TEA, HATU, DCM, RT, overnight (42% for 6a) (d) 34a-34c (R₃-Cl), DIPEA, DCM, RT, overnight (20%-48% for 6e to 6g)

4.4 Competition binding fluorescence polarization assay

4.4.1 Binding affinity of the bicyclic aza-amide series.

A competition binding fluorescence polarization assay was used to evaluate the binding of potential ligands to the FKBP12 and to the FK1 domain of FKBP51 and FKBP52. SLF linked to a fluorophore was used as a tracer. The affinity of any new synthesized ligand was assessed by its ability of competition with fluo-2 for the FKBPs.

Among the α-keto amide series (Table 3), the tert-pentyl series compounds 4b, 5b and 6b were all inactive for FKBP51/52. The higher affinities of 4a compared to 4b and 5a compared to 5b for FKBP51/52/12 indicated that the trimethoxyphenyl moiety is a better R2 substructure than tert-pentyl for the bicyclic scaffolds. The activity of 5c for FKBP51/52/12 suggested the cyclohexyl analog which more closely mimics the pyranose group of the high affinity natural product ligands like FK506 is also effective.
in the bicyclic context. The higher affinity of 5a compared to 5d for FKBP51/52/12 suggests that a three-atom spacer compared to a two-atom spacer is preferred for optimal positioning of the dimethoxyphenyl group in R1. This is consistent with the SAR observed for monocyclic FKBP51/52 ligands.134

Table 3: Binding affinities of monocyclic or bicyclic ketoamide ligands for FKBP51, FKBP52 and FKBP12 determined by fluorescence polarization assay141. LE is indicated in parentheses. *Mixture of diasteromers.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R1</th>
<th>R2</th>
<th>FKBP52</th>
<th>FKBP51</th>
<th>FKBP12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td></td>
<td>Ki (µM)</td>
<td>LE</td>
<td>Ki (µM)</td>
</tr>
<tr>
<td>4a</td>
<td>1</td>
<td></td>
<td>79.4±20 (0.15)</td>
<td>51.1±7.6 (0.15)</td>
<td>0.2±0.01 (0.24)</td>
</tr>
<tr>
<td>5a</td>
<td>2</td>
<td></td>
<td>45.2±13.5 (0.15)</td>
<td>23.7±3.1 (0.16)</td>
<td>0.3±0.007 (0.23)</td>
</tr>
<tr>
<td>6a</td>
<td>-</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.3±0.03 (0.22)</td>
</tr>
<tr>
<td>4b</td>
<td>1</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>3.5±0.1 (0.24)</td>
</tr>
<tr>
<td>5b</td>
<td>2</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>1.5±0.1 (0.24)</td>
</tr>
<tr>
<td>6b</td>
<td>-</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.9±0.1 (0.27)</td>
</tr>
<tr>
<td>4c</td>
<td>1</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>6.3±0.02 (0.26)</td>
</tr>
<tr>
<td>5c*</td>
<td>2</td>
<td></td>
<td>27.2±0.2 (0.17)</td>
<td>19.7±0.5 (0.18)</td>
<td>0.6±0.1 (0.23)</td>
</tr>
<tr>
<td>6c*</td>
<td>-</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>2.78 (0.22)</td>
</tr>
<tr>
<td>5d</td>
<td>2</td>
<td></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>1.5±0.04 (0.21)</td>
</tr>
</tbody>
</table>

With simplified R1 in 4c, the affinity for FKBP51/52/12 was abolished regardless of R2 indicating the importance of binding contributions by suitable R1 groups. The comparison of 4a, 5a and 6a for FKBP51/52 indicates that the bicyclic [4.3.1] aza-
amide scaffold has a better degree of preorganization than the bicyclic [3.3.1] aza-amide scaffold which in turn is preferred over the monocyclic scaffold. The same trend was observed for FKBP51/52/12 in the cyclohexyl analog series (5c > 6c). In terms of ligand efficiency, where the free energy is divided by the number of non-hydrogen atoms\(^{147}\), the bicyclic [4.3.1] aza-amide scaffold and bicyclic [3.3.1] aza-amide scaffold both represented a clear improvement over the monocyclic scaffold.

### 4.4.2 Binding affinity of the bicyclic aza-sulfonamide series.

A library of sulfonamide ligands was first described for FKBP12\(^{195}\). Recently, sulfonamides were identified as suitable surrogates for the α-keto amide substructure in monocyclic FKBP51 ligands\(^{143}\). To test whether this SAR would be extended to the constrained bicyclic scaffolds, selected phenyl sulfonamides were introduced at the N\(^7\) position of the bicycles. All the bicyclic [3.3.1] aza-sulfonamides and bicyclic [4.3.1] aza-sulfonamides have low micromolar binding affinities for FKBP51/52. 5g even displayed submicromolar affinity for FKBP51 while all bicyclic sulfonamides have submicromolar or even low nanomolar level binding affinities for FKBP12. All sulfonamides had better binding affinities than the corresponding α-keto-amide series compounds for FKBP51/52/12. For the sulfonamide series, the bicyclic [4.3.1] scaffold provides better binding affinity than the bicyclic [3.3.1] scaffold than the monocyclic scaffold. The same trend was also observed for the α-keto amide series before (Table 4).

For the first three sulfonyl aza-sulfonamide series (Table 4), the preferred 2-(3′,4′-dimethoxyphenyl)oxy ethyl substituent identified above was kept constant as R\(_1\) group. With the m,m-dichlorophenyl substructure as R\(_2\), for FKBP51/52/12 both the [3.3.1] aza-sulfonamide 4e and the bicyclic [4.3.1] aza-sulfonamide 5e have better binding affinity than monocyclic sulfonamide 6e while 5e is slightly worse than 4e. With the benzothiazole substructure as R\(_2\), for FKBP51/52 both the [3.3.1] aza-sulfonamide 4f and the bicyclic [4.3.1] aza-sulfonamide 5f have better binding affinity than monocyclic sulfonamide 6f. For FKBP12, 5f is better than 6f than 4f.
### Table 4: Binding affinities of monocyclic or bicyclic sulfonamide ligands for FKBP51, FKBP52 and FKBP12 determined by fluorescence polarization assay.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R&lt;sub&gt;1&lt;/sub&gt;</th>
<th>R&lt;sub&gt;2&lt;/sub&gt;</th>
<th>FKBP52</th>
<th>FKBP51</th>
<th>FKBP12</th>
</tr>
</thead>
<tbody>
<tr>
<td>K&lt;sub&gt;i&lt;/sub&gt;[µM] (LE)</td>
<td>K&lt;sub&gt;i&lt;/sub&gt;[µM] (LE)</td>
<td>K&lt;sub&gt;i&lt;/sub&gt;[µM] (LE)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4e 1</td>
<td><img src="image" alt="Structure 4e" /></td>
<td><img src="image" alt="Structure 4e" /></td>
<td>12.2±3.7 (0.20)</td>
<td>8.8±1.1 (0.21)</td>
<td>0.14±0.01 (0.28)</td>
</tr>
<tr>
<td>5e 2</td>
<td><img src="image" alt="Structure 5e" /></td>
<td><img src="image" alt="Structure 5e" /></td>
<td>1.6±0.3 (0.23)</td>
<td>1.2±0.2 (0.23)</td>
<td>0.01±0.002 (0.32)</td>
</tr>
<tr>
<td>5i 2</td>
<td><img src="image" alt="Structure 5i" /></td>
<td><img src="image" alt="Structure 5i" /></td>
<td>3.5±0.4 (0.21)</td>
<td>1±0.1 (0.23)</td>
<td>0.4±0.04 (0.24)</td>
</tr>
<tr>
<td>6e -</td>
<td><img src="image" alt="Structure 6e" /></td>
<td><img src="image" alt="Structure 6e" /></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.4±0.006 (0.27)</td>
</tr>
<tr>
<td>4f 1</td>
<td><img src="image" alt="Structure 4f" /></td>
<td><img src="image" alt="Structure 4f" /></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.9±0.2 (0.24)</td>
</tr>
<tr>
<td>5f 2</td>
<td><img src="image" alt="Structure 5f" /></td>
<td><img src="image" alt="Structure 5f" /></td>
<td>3.6±0.5 (0.21)</td>
<td>2.1±0.2 (0.22)</td>
<td>0.03±0.007 (0.29)</td>
</tr>
<tr>
<td>6f -</td>
<td><img src="image" alt="Structure 6f" /></td>
<td><img src="image" alt="Structure 6f" /></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.1±0.00003 (0.28)</td>
</tr>
<tr>
<td>4g 1</td>
<td><img src="image" alt="Structure 4g" /></td>
<td><img src="image" alt="Structure 4g" /></td>
<td>&gt;100</td>
<td>13.9±0.9 (0.19)</td>
<td>0.07±0.0004 (0.28)</td>
</tr>
<tr>
<td>5g 2</td>
<td><img src="image" alt="Structure 5g" /></td>
<td><img src="image" alt="Structure 5g" /></td>
<td>1.2±0.2 (0.22)</td>
<td>0.3±0.02 (0.24)</td>
<td>0.001±0.0003 (0.34)</td>
</tr>
<tr>
<td>6g -</td>
<td><img src="image" alt="Structure 6g" /></td>
<td><img src="image" alt="Structure 6g" /></td>
<td>12.4±1.3 (0.19)</td>
<td>7.6±0.5 (0.20)</td>
<td>0.002±0.0001 (0.35)</td>
</tr>
<tr>
<td>4h 1</td>
<td><img src="image" alt="Structure 4h" /></td>
<td><img src="image" alt="Structure 4h" /></td>
<td>46.4±3.8 (0.26)</td>
<td>27±1.7 (0.27)</td>
<td>0.1±0.0005 (0.42)</td>
</tr>
<tr>
<td>5h 2</td>
<td><img src="image" alt="Structure 5h" /></td>
<td><img src="image" alt="Structure 5h" /></td>
<td>22.6±1 (0.27)</td>
<td>9.8±0.5 (0.29)</td>
<td>0.06±0.002 (0.41)</td>
</tr>
<tr>
<td>6h -</td>
<td><img src="image" alt="Structure 6h" /></td>
<td><img src="image" alt="Structure 6h" /></td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.2±0.004 (0.38)</td>
</tr>
</tbody>
</table>

With the benzothiazolone substructure as R<sub>2</sub>, for FKBP51/52/12 the bicyclic [4.3.1] aza-sulfonamide 5g has better binding affinity than monocyclic sulfonamide 6g, but the [3.3.1] aza-sulfonamide 4g is worse than 6g. The p-hydroxyl m,m-dichlorophenyl substructure as R<sub>2</sub>, the bicyclic [4.3.1] aza-sulfonamide 5i showed higher binding
affinity compared to the similar analog 5e for FKBP51/52 but not for FKBP12. When R_A substituent was minimized or deleted, (the series of 4h, 5h and 6h), as expected this reduced the affinity to FKBP51/52/12 but only to a rather small extent, at least in the context of the high-affinity benzothiazolone substituent as R_2. As observed before, the cyclization improved affinity (5h > 4h > 6h) and the same trend was observed for the smaller homolog FKBP12. For these sulfonamide series, the bicyclic [4.3.1] aza-amide scaffold and the bicyclic [3.3.1] aza-amide scaffold also showed a clear improvement over the monocyclic scaffold with the constantly highest ligand efficiency value of the bicyclic [4.3.1] aza-amide scaffold. Importantly, however, removal of the R_A substituent increased ligand efficiency in all cases. Ligand 5h is much more efficient than the natural products FK506 or rapamycin and represents the most efficient FKBP ligand known today. It is the first lead-like ligand (MW= 367Da, LE= 0.29, clogP= 0.95) for the clinically relevant FKBP51 and offers three rigidly defined attachment points (R_1, R_2 and C_8) for further lead optimization.

The assay results of the α-keto amide series and the sulfonamide series strongly suggests that the higher affinities of the [4.3.1] aza-amide series are indeed an inherent property of the seven-membered bicycle. Importantly, for all four sulfonyl [4.3.1] aza-amides 5 prepared low micromolar affinities were obtained which is almost a factor of ten better than the corresponding sulfonamide analogs of 2, i.e., in an optimized monocyclic scaffold^{143}.

4.5 Cocrystal structure of 4g, 5f and 5g with FKBP51 FK1

To better understand the enhanced binding of the [4.3.1] aza-amide bicycles, the ligands 4g, 5f and 5g were cocrystallized with the FK506-binding domain of FKBP51 with resolution of 1.08Å, 1.1Å and 1.15Å respectively (Figure 14). The overall binding modes of 4g, 5f and 5g were similar to those observed for compound 2^{134} or for a sulfonamide-based analog^{143} in complex with FKBP51. Importantly, the positioning of the C_1-carbonyl oxygen of 5f and 5g and the geometry of the hydrogen bond to Ile^{87}-NH was more similar to those observed for FK506 or to 2 than those of the [3.3.1] bicycles 4g or 3a compared to the latter two.

The dihedral angle formed by O_1-C_1-C_2-N_7 of 5f and 5g were between 173° and 175°. This is very similar to unconstrained FKBP ligands when bound to FKBP51.
4. Results and discussion

(167°-179°, Table 5). In contrast, the O^1-C^1-C^2-N^7 dihedral angle of the [3.3.1] bicycle 4g was substantially smaller (148°). This translated into an altered orientation of the C^1-carbonyl group towards the Ile^97-NH donor (quantified by the C^1-O^1-Ile^87N-Val^86C dihedral angle and the O^1-C^1-Tyr^{113}O angle). The C^1-O^1-Ile^87N-Val^86C dihedral angle was substantially smaller for the [3.3.1] bicycles (122° for 4g, 97° for 3a) compared to the [4.3.1] bicycles (147°-167°, Table 5), which resembled much closer the unconstrained FKBP ligands (144°-196°, Table 5). Likewise, the O^1-C^1-Tyr^{113}O angle, which defines the C^1-Tyr^{113}O diolplar contact, is much more similar between the [4.3.1] bicycles (100°-102°) those and the unconstrained FKBP ligands (99°-114°) than those observed for the [3.3.1] bicycles (90° for 4g, 86° for 3a).

Similar to 3a the C^8-methylene of the bicyclic linker in 4g, 5f and 5g form van-der-Waals contacts with Phe^77 while the C^9-methylene of 5f and 5g do not seem to engage in any contacts with the protein nor intramolecularly with other parts of the ligand. The benzothiazole substituent and benzothiazolone substituent as R^2 sit in a pocket below the 80s loop (Ser^{118}-Ile^{122}) which is known to be functionally relevant for the modulation of the steroid hormone receptors by the large FKBP 31. Here, two orientations for the benzothiazole/benzothiazolone substituents seem to be possible, each rotated vs. each other by 180°. In one conformation of the thiazolones, the sulfur is within hydrogen bond distance to Ser^{118}. The C^{15}-H of 5f engages the backbone carbonyl of Leu^{119} below van-der-Waals distance (2.9Å).

<table>
<thead>
<tr>
<th>Compound (PDB number)</th>
<th>C^1-Tyr-O dipolar distance (Å)</th>
<th>angle O^1-C^1-O^2-Tyr^{113}O (°)</th>
<th>O^1-Ile^{87}N bond distance (Å)</th>
<th>dihedral angle O^1-C^1-C^2-N^7 (°)</th>
<th>dihedral angle Val^86N-Val^86C (°)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a</td>
<td>3.4</td>
<td>86°</td>
<td>2.8</td>
<td>153°</td>
<td>96°</td>
</tr>
<tr>
<td>FK506 (1) (3O5R)</td>
<td>3.2</td>
<td>101°</td>
<td>2.9</td>
<td>179°</td>
<td>144°</td>
</tr>
<tr>
<td>C2a (4DRN)</td>
<td>3.5</td>
<td>114°</td>
<td>2.9</td>
<td>193°</td>
<td>197°</td>
</tr>
<tr>
<td>C2b (4DRP)</td>
<td>3.5</td>
<td>111°</td>
<td>2.8</td>
<td>191°</td>
<td>164°</td>
</tr>
<tr>
<td>C3 (4DRQ)</td>
<td>3.1</td>
<td>99°</td>
<td>3.0</td>
<td>185°</td>
<td>158°</td>
</tr>
<tr>
<td>SLF(2) (4DRK)</td>
<td>3.2</td>
<td>107°</td>
<td>2.9</td>
<td>185°</td>
<td>144°</td>
</tr>
<tr>
<td>5f in conformation1</td>
<td>3.0</td>
<td>102°</td>
<td>2.8</td>
<td>173°</td>
<td>142°</td>
</tr>
<tr>
<td>5f in conformation2</td>
<td>3.0</td>
<td>102°</td>
<td>2.9</td>
<td>172°</td>
<td>144°</td>
</tr>
<tr>
<td>5g in conformation1</td>
<td>3.0</td>
<td>100°</td>
<td>2.8</td>
<td>175°</td>
<td>152°</td>
</tr>
<tr>
<td>5g in conformation2</td>
<td>3.0</td>
<td>102°</td>
<td>2.8</td>
<td>175°</td>
<td>158°</td>
</tr>
<tr>
<td>4g in conformation1</td>
<td>3.1</td>
<td>90°</td>
<td>2.8</td>
<td>147°</td>
<td>128°</td>
</tr>
<tr>
<td>4g in conformation2</td>
<td>3.1</td>
<td>90°</td>
<td>2.8</td>
<td>148°</td>
<td>122°</td>
</tr>
</tbody>
</table>

Table 5 Quantification of structural parameters for known cocrystallized FKBP51 ligands and the cocrystallized FKBP51 ligands 4g, 5f and 5g.
4. Results and discussion

Figure 14: The bicyclic sulfonyl [3.3.1] aza-amide derivative 4g, the bicyclic sulfonyl [4.3.1] aza-amide derivative 5f and 5g and their cocrystal structures with the FK506-binding domain of FKBP51, resolved to a resolution of 1.08Å, 1.1Å and 1.15Å respectively. Color code is as in Figure 2, putative hydrogen bonds are dashed in orange, aromatic hydrogen bonds are dashed in cyan. Lys$^{121}$ is removed for clarity.
4. Results and discussion

In the homologous cocrystal structure of 5g, Leu\textsuperscript{119} moves outward and the O\textsuperscript{14}-thiazolone engages the carbonyl of L\textsuperscript{119} in a dipolar interaction. Almost identical contacts are observed for the thiazolone in the corresponding [3.3.1] analog 4g. For both conformations of 4g, 5f and 5g, the ortho-hydrogens of the aryl sulfonamide form aromatic hydrogen bonds with Tyr\textsuperscript{113} and Asp\textsuperscript{68}, respectively, similar to those previously observed for monocyclic pipecolate sulfonamide ligands\textsuperscript{143}. Importantly, only minimal interactions of the benzothiazole or the benzothiazolone ring are present for 5f, 5g and 4g. Indirectly the C\textsuperscript{9} stabilized the observed conformation. The 2-(3',4'-dimethoxyphenyl)oxy ethyl substituent R\textsubscript{1} overlays almost perfectly with the 3-(3',4'-dimethoxyphenyl)propyl moiety in the complex of 2, sitting in a cradle formed by Gly\textsuperscript{84}-Ile\textsuperscript{87} and Tyr\textsuperscript{113}.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Scaffold</th>
<th>N'-Tyr\textsuperscript{113}-O distance (Å)</th>
<th>O'-Tyr\textsuperscript{113}-O distance (Å)</th>
<th>pyramidalization\textsuperscript{(a)}</th>
</tr>
</thead>
<tbody>
<tr>
<td>FK506</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C2a (comp 3f-1\textsuperscript{196})</td>
<td></td>
<td>3.6</td>
<td>2.6</td>
<td>176°</td>
</tr>
<tr>
<td>C2b (comp 3f-2\textsuperscript{196})</td>
<td></td>
<td>3.7</td>
<td>2.6</td>
<td>-178°</td>
</tr>
<tr>
<td>SLF (2) (comp 2a\textsuperscript{186})</td>
<td></td>
<td>3.6</td>
<td>2.6</td>
<td>-179°</td>
</tr>
<tr>
<td>C3 (comp 20\textsuperscript{197})</td>
<td></td>
<td>3.8</td>
<td>3.4</td>
<td>146°</td>
</tr>
<tr>
<td>3a</td>
<td></td>
<td>3.5</td>
<td>2.6</td>
<td>-178°</td>
</tr>
<tr>
<td>4g (conformation1)</td>
<td></td>
<td>3.3</td>
<td>3.6</td>
<td>139°</td>
</tr>
<tr>
<td>4g (conformation2)</td>
<td></td>
<td>3.2</td>
<td>3.6</td>
<td>140°</td>
</tr>
<tr>
<td>5f (conformation1)</td>
<td></td>
<td>3.1</td>
<td>2.8</td>
<td>136°</td>
</tr>
<tr>
<td>5f (conformation2)</td>
<td></td>
<td>3.0</td>
<td>2.7</td>
<td>132°</td>
</tr>
<tr>
<td>5g (conformation1)</td>
<td></td>
<td>3.3</td>
<td>3.2</td>
<td>136°</td>
</tr>
<tr>
<td>5g (conformation2)</td>
<td></td>
<td>3.3</td>
<td>3.2</td>
<td>139°</td>
</tr>
</tbody>
</table>

Table 6: Quantification of the N\textsuperscript{7} and S=O\textsuperscript{a} interactions with Tyr\textsuperscript{113} of FKBP51 for the known cocrystallized FKBP51 ligands and for bicycles of this work. (a) The pyramidal is quantified by the angle of S-N\textsuperscript{7} vs the C\textsuperscript{2}-N\textsuperscript{7}-C\textsuperscript{6} plane.

A strong tendency for pyramidalization of N\textsuperscript{7} of the sulfonamides was also observed which indicated a substantial degree of sp\textsuperscript{3} hybridization (Table 6). For all bicyclic sulfonamides a distance below 3.3 Å was observed between Tyr\textsuperscript{113}-OH and N\textsuperscript{7} accompanied by an increased distance between Tyr\textsuperscript{113}-OH…O\textsuperscript{A}=S. The Tyr\textsuperscript{113}-OH…O\textsuperscript{A}=S contact in 5f, 5g and 4g is substantially longer than the corresponding bond distance in α-keto amide ligands like 5a and 2 (Table 6). In the cocrystal structure of 5f, Tyr\textsuperscript{113}-OH clearly approaches the O\textsuperscript{A}=S and N\textsuperscript{7} within a distance of a
4. Results and discussion

bifurcated hydrogen bond. Both sulfonamide oxygens in \textit{5f}, \textit{5g} and \textit{4g} are involved in several close edge-on aromatic CH⋯O contacts. The strong tendency for pyramidalization and the shifting from a hydrogen bond to a bifurcated hydrogen bond (to $O^A=S$ and $N^7$) together with the higher binding affinity of the bicyclic aza-sulfonamides than the corresponding $\alpha$-keto amides indicated that the bicyclic aza-sulfonamide might better represent the active conformation for FKBP51.

4.6 GR hormone radioactive binding assay

The main physiological role of FKBP51 is believed to be the inhibition of glucocorticoid receptor signalling, especially in stressful situations\textsuperscript{113}. The FKBP51-GR interplay has been difficult to assess pharmacologically, however, largely due to lack of appropriate chemical probes. With the optimized FKBP51 ligands in hand we therefore set out to investigate the functional consequences of FKBP51 inhibition in a GR hormone radioactive binding assay, a defined reconstituted biochemical model of GR activity that obviates many of the pitfalls of the assays used earlier\textsuperscript{113, 198}. The functional effects of the ligands were assessed by their ability to block the inhibitory effect of FKBP51 on GR activity. Gratifyingly, we observed a clear dose-dependent recovery of GR binding by \textit{4g}, \textit{5g} and \textit{6g} (Figure 15), which showed functional activity on an important downstream FKBP51 target and mirrored their affinities to FKBP51 in the fluorescence polarization assay results (Table 4).

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{figure15.png}
\caption{Relieve of FKBP51-mediated suppression of the glucocorticoid receptor hormone binding affinity by \textit{4g}, \textit{5g} and \textit{6g}.}
\end{figure}
4. Results and discussion

4.7 Thermodynamic analysis

The [4.3.1] bicyclization contributed \( \Delta \Delta G > 2 \text{kcal/mol} \) to the binding energy compared to the monocycles. This is more than could have been achieved by van-der-Waals contacts of the bridging \( C^8 \)-methylene \(^{199}\). Towards elucidating the origin of the additional binding energy in more detail, the thermodynamic parameters for complex formation of the most advanced compounds \( 4g, 5g \) and \( 6g \) with FK506-binding domain of FKBP51 were determined by isothermal titration calorimetry (ITC) (Figure 16). The binding affinities (\( K_d \)) of \( 4g, 5g \) and \( 6g \) were obtained by ITC were 10.5\( \mu \text{M} \), 0.36\( \mu \text{M} \) and 3.3\( \mu \text{M} \) respectively which is in excellent agreement with the fluorescence polarization assay results (Table 4).

The binding of \( 6g \) and \( 4g \) was driven both enthalpically and entropically. Surprisingly, however, we observed a strong increase in binding enthalpy \( \Delta H \) for the [4.3.1] bicycle \( 5g \) compared to \( 6g \) and \( 4g \) (-13.5\( \text{kcal/mol} \) vs -3.0 and -4.5\( \text{kcal/mol} \), respectively) which was largely compensated by a substantial entropic offset. Similar, on first sight counter-intuitive negative changes of binding entropy upon ligand rigidification have recently been observed by several groups\(^{200-203}\). In one case the counterproductive entropic change was shown to be caused by a stronger ordering of the protein by the more rigid ligands\(^{203}\). The large increase in binding enthalpy of \( 5g \) vs \( 6g \) is probably due to (i) the better hydrogen bond acceptor properties of the \( C^1 \)-amide compared to the \( C^1 \)-ester, (ii) stabilization of the conformation of \( O^1-C^1-C^2-N^7 \), (iii) additional van-der-Waals contacts by the \( C^8 \)-methylene, (iv) stabilization of the \( N^7 \) pyramidalization.

The direct comparison of \( 5g \) and \( 4g \) reveals the strong orientation dependence of the hydrogen bond and dipolar contact network around the \( C^1=O \) carbonyl which could account for a substantial amount of the additional binding entropy of \( 5g \). Importantly, amide vs ester replacements had previously been shown to be inactive in the monocyclic scaffolds\(^{134, 143}\).
4. Results and discussion

<table>
<thead>
<tr>
<th>Compound</th>
<th>ΔH (KCal/mol)</th>
<th>ΔS (KCal/mole/K)</th>
<th>TΔS (KCal/mol)</th>
<th>ΔG (KCal/mol)</th>
<th>Kd (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6g</td>
<td>-4,47800</td>
<td>0,00983</td>
<td>2,88166</td>
<td>-7,35966</td>
<td>3,25733</td>
</tr>
<tr>
<td>4g</td>
<td>-2,98600</td>
<td>0,01260</td>
<td>3,69369</td>
<td>-6,67969</td>
<td>10,49318</td>
</tr>
<tr>
<td>5g</td>
<td>-13,57000</td>
<td>-0,01680</td>
<td>-4,92492</td>
<td>-8,64508</td>
<td>0,35842</td>
</tr>
</tbody>
</table>

(b)

Figure 16: (a). Thermodynamic parameters for binding of 4g, 5g and 6g to FK506 binding domain of FKBP51. (b) Thermodynamic signatures of 4g, 5g and 6g upon binding to the FK506-binding domain of FKBP51.

4.8 Synthesis of the C⁸-derivatized bicyclic [4.3.1] aza-amides 57

From the above results, the bicyclic [4.3.1] aza-amide scaffold was identified as a privileged substructure for FK506-binding proteins (FKBPs). The cocrystal structures of the bicyclic [4.3.1] aza-amide derivatives 5f and 5g in complex with FKBP51 FK1 revealed the possibility to further introduce additional substituents into
4. Results and discussion

the bicyclic [4.3.1] aza-amide nucleus at C8 which would increase the contact surface with the FKBP51/52 and may help to increase the binding affinity. Therefore we designed and synthesized a new series of C8-derivative bicyclic [4.3.1] aza-amide derivatives 41 (Figure 17).

![Diagram](image)

**Figure 17:** (a) Proposed C8-derivatized bicyclic [4.3.1] aza-amide derivatives 41 based on the bicyclic [4.3.1] aza-amide derivatives 5 and the C8-substituted bicyclic [4.3.1] aza-amide nucleus 42 used for the computer modelling study. (b) The superimposition of the energy-minimized C8-derivative bicyclic [4.3.1] aza-amide nucleus 42 (yellow) with compound 2 (blue) bound to the FKBP51 FK1 domain. (c) Space filling model of the energy-minimized C8-derivative bicyclic [4.3.1] aza-amide nucleus 42 positioned into the FKBP51 FK1 domain as in b.

The C8-derivatized bicyclic [4.3.1] aza-amide nucleus 42 was modelled into the binding pocket of FKBP51 (Figure 17b, 17c). The C1-C6, N7, O1 and O11 of the 42 were overlaid with the corresponding atoms of 2 (SLF) in the cocrystal structure of 2 and FKBP51 FK1 domain. A conserved binding mode of C8-derivative bicyclic [4.3.1] aza-amide nucleus 42 was enforced with the common elements of the pipecolate and α-keto amide region (Figure 9) being nearly superimposable in the two structures. It indicated no obvious sterically hindrance between the protein and the bicyclic aza-amide nucleus 42.
4. Results and discussion

4.8.1 Retrosynthetic analysis and strategy

To control the stereochemistry at C², C⁶ and C⁸ a new synthetic strategy was devised as outlined in Scheme 14. The bicyclic nucleus 43 was envisioned to be prepared from 44 through carbon-carbon bond formation between C⁶ and C⁸ by N-acyliminium cyclization. The stereochemistry of C⁶ would be dictated by the stereochemistry at C² whereas the stereochemistry at C⁸ was envisioned to be substrate-controlled by steric interference with C⁴ of the piperidine ring. An electron-donating group at the vinyl group of C⁸ was thought to facilitate the intramolecular cyclization as well as to subsequently provide a functional group for further diversification. The amide moiety in 44 could be incorporated by coupling between 45 and 46.

Scheme 14: Retrosynthesis of the C⁸-substituted bicyclic [4.3.1] aza-amide nucleus 43.

4.8.2 Synthesis of the bicyclic [4.3.1] aza-amide nucleus 57

The commercially available 44 was alkylated with 45 to afford compound 28a, which was reacted with commercially available 47 to yield compound 48. The allyltrimethylsilyl group was introduced by a metathesis reaction with Grubbs catalyst I in DCM as a cis/trans isomeric mixture 50 (1:1 based on NMR) followed by deprotection of the Boc-protection group with silica to give the N¹⁰-building block 51. The secondary amine group in 51 was coupled with commercial (S)-6-oxopiperidine-2-carboxylic acid 52 in presence of HOAt, EDC-HCl and DIPEA in DCM at room temperature to give 53 followed by Boc-protection of the N⁷-position in 53 to give the compound 54. 54 was regioselectively reduced with DIBAL-H followed by cyclization within 30% TFA in DCM and cleavage of Boc protection group to afford 57 in a one-
pot reaction with 76% yield and excellent diastereoselectivity (dr>99:1 determined by NMR) (Scheme 15).

Scheme 15: Synthesis of 57 (a) K$_2$CO$_3$ in acetone, reflux, overnight, 46% (b) NaH in DMF, 0°C, 2h, 69% (c) Grubbs catalyst I in DCM, reflux, 67% (d) SiO$_2$, 150°C, vacuo, 85% (e) HOAt, EDC, DIPEA in DCM, RT, 24h, 90% (f) BuLi, (Boc)$_2$O in THF, -78°C, overnight, 72% (g) 3eq DIBAL-H, THF, -78°C (h) 30% TFA in DCM at 0°C (76% for two steps)

The C$^2$ position is particularly prone to racemization. To support the absence of racemization, simplified model reactions were carried out (Scheme 16). The Boc-protection group in 48 was cleaved with 50% TFA in DCM at room temperature followed by coupling with commercial (S)-6-oxopiperidine-2-carboxylic acid 52 to afford 59. The N$^7$-position in 59 was protected with Cbz group to give the compound 60 which had excellent enantiomeric excess (ee >99:1) based on chiral HPLC analysis.
4. Results and discussion

a)

Scheme 16: a). Synthesis of a model compound 60 to check the racemization at C² position. (a) 50% TFA in DCM, RT, 2h (b) HBTU, DIPEA in DCM, RT, 24h, 95% (c) BuLi, Cbz-Cl in THF, -78°C, 5h, 60%. b) Chiral HPLC spectroscopic data of 60.

4.8.3 Systematic study of the cyclization reaction.

A mechanism study showed that when 55 was treated with 10% TFA in DCM at -78°C and stirred at -20°C for 2h, 55 was converted to 61 as the only product.
4. Results and discussion

observed in LCMS. With further addition of TFA to 50% at 0°C, 61 was converted to 57 as the only product which supported that the cyclization was through intramolecular N-acyliminium cyclization but not intramolecular iminium cyclization (Scheme 17).

Scheme 17: Mechanism study for the cyclization step based on 55. (a) 10% TFA in DCM, -78°C, 2h (b) 50% TFA in DCM, 0°C, 2h, (76% for two steps)

Before the establishment of the crucial intramolecular N-acyliminium cyclization, different cyclization conditions were tested. As the N-acyliminium cyclization was planned to be carried out under acid condition, the N7-position in 53 was first protected with Cbz-protection group instead of the acid sensitive Boc-protection group to afford 62. Different reduction conditions were then carried out to selectively reduce 62 (Scheme 18).

Under condition b only trace amounts of 63 were produced but the cleavage of Cbz group to afford 53 (based on NMR and Mass spectroscopy) as the main product. Condition c could afford the production of 63 but with low conversion rate while excessive amounts of NaBH4 in MeOH afford 63 with 64 as a side product. The side reaction could be reduced to a smaller extent by using excessive amounts of NaBH4 under mild acidic condition (pH= 6) in MeOH (condition d). No reaction was observed when THF or DMF was used as solvent instead of MeOH. Condition e was found to be the best to convert 62 to 63 without any side reaction. Unfortunatly, 63 is very labile and attempts to purify 58 by chromatography were unsuccessful and the production of 63 was deduced from LCMS results.
4. Results and discussion

Scheme 18: Different reduction conditions and possible products from the reduction of 62. a) BuLi, Cbz-Cl in THF, -78 °C, overnight, 60%

To better understand this reduction reaction, a model reaction was carried out to check the reduction condition and stability of the hemiaminal product. When 65 was treated with NaBH₄ in MeOH at 0 °C, 66 and 67 were produced. Both of them were purified with chromatography and characterized with NMR (Scheme 19). The low yields might be due to other side reactions such as Cbz group cleavage of 65, but further efforts to elucidate the side reactions were not put forth.

Scheme 19: A simplified model study of the selective reduction step based on 65. (a) 2.2 eq NaBH₄ in MeOH, RT, 2h, (26% for 64, 21% for 65)

The lability of 63 might be due to the coexistence of the electron-rich substructure and hemiaminal in one molecule. Thus, 63 was used for the next step without purification.
Scheme 20: Three conditions for the synthesis of 62 based on 57.

Condition 1: (a) excessive NaBH4, MeOH, 0°C, (b) 20% TFA in DCM at 0°C, (c) 60% TFA in DCM at 0°C, (34% for three steps)

Condition 2: (a) excessive NaBH4, MeOH, 0°C (d) 10% TFA in DCM at 0°C, (51% for two steps)

Condition 3: (a) 3eq DIBAL-H, THF, -78°C (d) 20% TFA in DCM at 0°C, (83% for two steps)

(e) 33% HBr in acetic acid at 0°C, 69%

When NaBH4 was used as a reducing reagent, 20% TFA was added to the reaction mixture of 63 at 0°C to afford the methoxylated compound 68 in situ followed by cyclization in the presence of 60% TFA in DCM at 0°C to afford 70 with 34% yield in all three steps and excellent diastereoselectivity (dr>99:1 determined by HPLC) (Scheme 20 condition 1). Later it was found that the methoxylation step was not a prerequisite and that 63 could be converted to 70 directly by cyclization with 10% TFA in DCM at 0°C with 51% yield for all two steps and excellent diastereoselectivity (dr>99:1 determined by NMR) (Scheme 20 condition 2). Different acidic conditions like SnCl4, TiCl4 or formic acid instead of TFA were tried for the cyclization process. Rapidly decomposition of 63 was observed in the presence of the lewis acid SnCl4 or TiCl4 at -78°C while slow conversion and many side reactions were observed when formic acid was used at -20°C. When DIBAL-H was used as a reducing reagent, the reaction mixture of 63 was evaporated in vacuo followed by cyclization within 20% TFA in DCM at 0°C with 83% yield for two steps and excellent
4. Results and discussion

diastereoselectivity (dr>99:1 determined by NMR) (Scheme 20 condition 3). The Cbz group in \( \text{70} \) was then cleaved by 33% HBr in acetic acid at 0°C to afford \( \text{57} \) with 69% yield.

**4.8.4 Functionalization of bicyclic [4.3.1] aza-amides nucleus \( \text{57} \)**

At this point a m,m-dichlorophenylsulfonyl group as a preferred substructure for FKBPs was installed at the \( \text{N}^7 \) of \( \text{57} \) in presence of DIPEA to afford \( \text{71} \) with moderate yield and conversion ratio which might be due to the steric hindrance of the secondary amine. The terminal vinyl group at \( \text{C}^8 \) in \( \text{71} \) was further submitted to dihydroxylation. The attempts to stereoselective dihydroxylate the vinyl group in \( \text{71} \) was conducted with AD-Mix-Alpha or AD-Mix-Beta at room temperature. Unfortunately, the dihydroxylation with 7 eq AD-Mix-Alpha afforded \( \text{72} \) as a 6:1 diastereomeric mixture of \( \text{C}^{11} \) epimers with only 60% conversion, while with 2 eq AD-Mix-Beta, \( \text{73} \) was obtained with 100% conversion but still as a 2:1 diastereomeric mixture of \( \text{C}^{11} \) epimers (Scheme 21). Diastereomers were observed by NMR for both \( \text{72} \) and \( \text{73} \) which could not be separated by HPLC.

![Scheme 21: Synthesis of \( \text{71} \), \( \text{72} \) and \( \text{73} \) (a) 34a, DIPEA, DCM, RT, overnight, 48%, (b) 7 eq AD-Mix-Alpha, water, t-BuOH, RT,57%, (c) 2 eq AD-Mix-Beta, water, t-BuOH, RT,94%.](image-url)
4. Results and discussion

a)

\[
\begin{align*}
\text{73} & \quad + \\
& \quad \text{Scheme 22: a) Synthesis of 65} \\
& \quad (a) 6\text{eq tert-Butyldimethylsilyl} \\
& \quad \text{trifluoromethanesulfonate, 2,6-} \\
& \quad \text{lutidine, DCM, 0°C. b) HPLC} \\
& \quad \text{spectroscopic data of the} \\
& \quad \text{crude 74.}
\end{align*}
\]

In a small test reaction, the double silylation of 73 resulted in two separable peaks with the same mass identified by LCMS. These two peaks have a ratio of 2:1 by HPLC analysis (Scheme 22). Further purification of these two peaks was to be carried out in the future.

Although the attempt to stereoselective dihydroxylate the vinyl group in 71 was unsuccessful, the terminal vinyl group at C\textsuperscript{8} allows for a versatile and straightforward derivatization to further improve the interaction with FKBPs. An overview for future SAR study is outlined in Scheme 23.
4.9 Competition binding fluorescence polarization assay

The affinities of the C₈-derivatized ligands 71 and 73 for FKBPs were measured by a fluorescence polarization assay using purified human FKBP12 or the purified FK506-binding domain of FKBP51 and FKBP52 expressed in E.coli (Table 7)¹⁴¹. As SLF (2) has a comparable higher binding affinity than other simplified synthetic ligands, it was linked to a fluorophore to be used as a fluorescence-labelled ligand. The affinity of 71 and 73 were assessed by its ability of competition with the fluo-2 for the FK1 domain of FKBPs.
4. Results and discussion

Compound 71 retained slightly improved binding affinity and similar ligand efficiency compared to the corresponding C8-unmodified control 5e demonstrating that substituents can be accommodated in the C8-position. The approximately 5 times better binding affinity of 73 compared to 5e might result from the increased contact surface between ligand and protein. The introduction of additional hydroxyl groups at C11 and C12 substantially improved the ligand affinity and efficiency for all FKBPs yielding ligands with low nanomolar potencies. 73 is 175 times (for FKBP51) and 75 times (for FKBP52) better than 63 and rivalls the affinity of the natural product FK506.

<table>
<thead>
<tr>
<th>Compound</th>
<th>FKBP51</th>
<th>LE</th>
<th>FKBP52</th>
<th>LE</th>
<th>FKBP12</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>71</td>
<td>1.4 ±0.2</td>
<td>0.22</td>
<td>2.1 ±0.4</td>
<td>0.21</td>
<td>0.03±0.003</td>
<td>0.28</td>
</tr>
<tr>
<td>73</td>
<td>0.008 ± 0.02a</td>
<td>0.29</td>
<td>0.03 ± 0.08</td>
<td>0.27</td>
<td>&lt;0.001b</td>
<td></td>
</tr>
<tr>
<td>5e</td>
<td>8.8±1.0</td>
<td>0.21</td>
<td>12.3±3.7</td>
<td>0.2</td>
<td>0.14±0.01</td>
<td>0.28</td>
</tr>
<tr>
<td>FK506</td>
<td>0.09±0.02a</td>
<td>0.17</td>
<td>0.23±0.07</td>
<td>0.16</td>
<td>0.0006±0.0001</td>
<td>0.22</td>
</tr>
</tbody>
</table>

Table 7: Binding affinities 71, 73 and 5e for FKBP51, FKBP52 and FKBP12. (a) With sg586 as tracer. (b) This the detection limit of tracer fluo-2.

4.10 Cocrystal structure of 71 and FKBP51

The X-ray crystal structure of the FKBP51 FK1 domain complexed with ligand 71 was solved to 1.08 Å resolution. In this complex, FKBP51 adopts the same folding topology as observed in FKBP51 complexed with 5f and 5g. The ligand adopts a similar binding mode compared to that of 5f or 5g with the common piperolate ring being nearly superimposable (Figure 18). The piperolate ring of the ligand sits atop the indole of Trp90, which forms the floor of the FKBP binding pocket. Similar to FK506 the C1-carbonyl of the piperolate forms a hydrogen bond with the backbone amide of Ile87 with a distance of 2.8Å, almost the same as the [4.3.1] bicycles 5f and 5g (2.8-2.9 Å). The C1-O1-Ile87N-Val86C dihedral angle was 167° (Table 8). This is very similar to 5f and 5g (142°-158°, Table 5) and resembled the unconstrained FKBP ligands (144°-196°, Table 5). The dihedral angle formed by O1-C1-C2-N7 of 71 was 175° which is the same as in 5g, only marginally different from 5f, and very similar to
unconstrained FKBP ligands when bound to FKBP51 (167°-179°, Table 5). Likewise, the O¹-C¹-Tyr¹¹³O angle and C¹-Tyr¹¹³O dipolar distance which define the C¹-Tyr¹¹³O dioplar contact, are 101° and 3.1Å respectively. Both values are similar to the [4.3.1] bicycles 5f and 5g (100°-102°, 3.0 Å).

**Figure 18:** The C⁶-substituted bicyclic [4.3.1] aza-amide derivative 71 and cocrystal structures with the FK506-binding domain of FKBP51, resolved at a resolution of 1.08 Å. 71 bound to the FK1 domain of FKBP51. Key residues of FKBP51 are show in orange, the two hydrogen bonds between O¹ and HN-Ile⁸⁷ and between O¹³a and HO-Tyr¹¹³ are shown dashed red. The dipolar interaction between the C¹-carbonyl and HO-Tyr¹¹³ is dashed in green. Aromatic hydrogen bonds between C¹⁵-H and OH-Tyr¹¹³, C¹⁹-H and OH-Asp⁶⁸ are dashed in cyan. van-der-Waals interactions between Cl¹⁸ and C-Lys¹¹⁸ are dashed yellow. The halogen bond between Cl¹⁶ and O-Ser¹¹⁸ is dashed magneta.

One oxygen of the sulfonamide (S=Oₐ) forms a rather weak hydrogen bond with the hydroxyl group of Tyr¹¹³ with a distance of 3.2Å which is longer than the corresponding bond distance in α-keto amides like FK506, 5a and 2. FKBP51 and 71 engage in a number of aromatic CH···O-acceptor interactions, e.g., the oxygen of the sulfonamide (S=Oₐ) and the ε-hydrogens of Tyr⁵⁷, Phe⁶⁷ and Phe¹³⁰. As expected, the dichloro aryl ring sits below the 80s loop and packs on Ile¹²². The two ortho-hydrogens of the sulfonylphenyl ring form close contacts (2.9 Å) with the p-oxygen of Tyr¹¹³ and with carboxylate of Asp⁶⁸ (2.8 Å), respectively. These two contacts are much shorter than normal aromatic hydrogen bonds. One of the aromatic chlorines might form a van-der-Waals contact with Lys¹²¹ (3.3 Å). The other chlorine approaches Ser¹¹⁸ to form a halogen bond (2.5 Å) with the C¹⁶-Cl-Ser¹¹⁸-O angle of
4. Results and discussion

166°. The Ser\textsuperscript{118} Such short distance is rather uncommon for halogen bonds. Like 4g, 5f and 5g (Table 6), 71 also has a similar N\textsuperscript{7} pyramidalization (Table 8) and a short distance of 3.4 Å between N\textsuperscript{7} and Tyr\textsuperscript{113}-OH. The C\textsuperscript{11} approaches Tyr\textsuperscript{57} with a distance of 3.7 Å and the C\textsuperscript{12}- C\textsuperscript{11}- Tyr\textsuperscript{113}-O angle of 125°. The C\textsuperscript{8}-vinyl substitution points out of the pocket which clearly confirmed the desired conformation obtained from our stereoselective synthesis and also indicated the possibility of introducing more potential ligand-protein interaction with further allyl functionalization.

<table>
<thead>
<tr>
<th>Compound (PDB number)</th>
<th>C\textsuperscript{1}-Tyr\textsuperscript{113}-O dipolar distance (Å)</th>
<th>angle O\textsuperscript{1}-C\textsuperscript{1}-Tyr\textsuperscript{113}-O</th>
<th>O\textsuperscript{1}-Ile\textsuperscript{87}N distance (Å)</th>
<th>dihedral angle O\textsuperscript{1}-C\textsuperscript{1}-C\textsuperscript{2}-N\textsuperscript{7}</th>
<th>dihedral angle Val\textsuperscript{86}C\textsuperscript{1}-Ile\textsuperscript{87}N-O\textsuperscript{1}-C\textsuperscript{1}</th>
<th>O\textsuperscript{9}/S=O\textsuperscript{8} Tyr\textsuperscript{113}-O distance (Å)</th>
<th>Pyramid alization (\textsuperscript{a})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fk506 (1) (3O5R)</td>
<td>3.2</td>
<td>101°</td>
<td>2.9</td>
<td>179°</td>
<td>144°</td>
<td>2.6</td>
<td>3.6</td>
</tr>
<tr>
<td>71</td>
<td>3.1</td>
<td>101°</td>
<td>2.8</td>
<td>175°</td>
<td>167°</td>
<td>3.2</td>
<td>3.4</td>
</tr>
</tbody>
</table>

Table 8: Quantification of structural parameters for cocrystallized 71 with FKBP51 FK1 and compared with the cocrystal structure of FK506. (\textsuperscript{a}) The pyramidalization is quantified by the angle of S-N\textsuperscript{7} vs the C\textsuperscript{2}-N\textsuperscript{7}-C\textsuperscript{6} plane.

4.11 Hypothetical binding mode of 73a and 73b

The low nanomolar potency of 73 based on the dihydroxylation of 71 showed the importance of these two hydroxy groups. Due to the difficulties of stereoselective dihydroxylation and purification, their cocrystal structures with FKBP51 FK1 domain were not available. Based on the cocrystal structure of 71 with FKBP51 FK1 domain, the hypothetical binding mode of 73a and 73b were proposed by computer modelling which was carried out by Dr. Uwe Koch from Lead Discovery Center GmbH (Figure 19). 73a and 73b bind to the FKBP51 FK1 domain with the conserved binding mode as 71. The only difference between 73a and 73b is at the C\textsuperscript{11} position with a R-conformation for 73a and a S-conformation for 73b. In 73a, the C\textsuperscript{11}-OH approaches Tyr\textsuperscript{57} and Asp\textsuperscript{68} with a distance of 4.2Å and 3.8Å respectively which would be too far to form hydrogen bonds. In 73b, the C\textsuperscript{11}-OH approaches Asp\textsuperscript{68} with a distance of 3.8Å which is still above the threshold of hydrogen bond while it might engage in a hydrogen bond with Tyr\textsuperscript{57} with a proposed distance of 2.9 Å. This could
explain the higher binding affinity of the 71. The angle formed by C$^{11}$- O$^{11}$-Tyr$^{57}$- O of 73b was 133° and the dihedral angle C$^9$- C$^{11}$- O-Tyr$^{57}$ was 62°. While the angle formed by O$^{11}$- Tyr$^{57}$- O- Tyr$^{57}$- C$^4$ angle was 147° and the dihedral angle O$^{11}$- Tyr$^{57}$- O- Tyr$^{57}$- C$^4$- Tyr$^{57}$- C$^3$ was 117° (Table 9). This hypothesis has to be confirmed in the future by experimental cocrystal structures.

![Figure 19](image-url)

**Figure 19:** a, b) The structure of 73a and 73b used for computer modelling study. c) Computer modelling of 73a (blue) bound into the FKBP51 FK1 domain with the distances measured between C$^{11}$ hydroxy group and Tyr$^{57}$ and Asp$^{68}$. d) Computer modelling of 73b (blue) bound into the FKBP51 FK1 domain with the distances measured between C$^{11}$ hydroxy group and Tyr$^{57}$ and Asp$^{68}$. The distance measurement between C$^{11}$ hydroxy group and Tyr$^{57}$ and Asp$^{68}$ are dashed yellow.
Table 9: Quantification of structural parameters for the proposed hydrogen bond between Tyr$^{57}$–OH and C$^{11}$-OH.
In order to improve the ligand affinities and efficiencies of the FKBP ligands, new scaffolds were proposed to preorganize the ligands to limit the flexibility and mimic the active conformation. The bicyclic [3.3.1] aza-amide and bicyclic [4.3.1] aza-amide core structures were designed as rigid replacements for the pipecolyl-monocyclic scaffold and their potential binding modes were analyzed in silico. With the synthetic route established in this study, a series of bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-amide derivatives 5 were prepared. Their binding affinities for FKBP51, 52 and 12 were measured with a competition binding fluorescence polarization assay. Among the α-keto amide series, the trimethoxyphenyl moiety is shown to be a better R₂ substructure than tert-pentyl for the bicyclic scaffold, while the cyclohexyl analog which more closely mimic the pyranose group in the high affinity natural product ligands is also effective in the bicyclic context. A three-atom spacer compared to a two-atom spacer is preferred for optimal positioning of the dimethoxyphenyl group in R₁. For the sulfonyl aza-amides series, the benzothiazolone substituent was found to be the best R₂ to afford 5g with nanomolar affinities for FKBP51/52/12. When R₁ substituent was minimized or lacking, the affinities of the bicyclic compounds to FKBP51/52/12 were only reduced to a rather small extent with the benzothiazolone substituent as R₂. Ligand 5h is much more efficient that the natural products FK506 or rapamycin and represents the most efficient FKBP ligand known today. It is the first lead-like ligand (MW= 367Da, LE= 0.29, clogP= 0.95) for the clinically relevant FKBP51 and offers three rigidly defined attachment points (R₁, R₂ and C₈) for further lead optimization. Both compound series indicate that the bicyclic [4.3.1] aza-amide scaffold has a better degree of preorganization than the bicyclic [3.3.1] aza-amide scaffold which in turn is preferred over the monocyclic scaffold. The higher affinities of the [4.3.1] aza-amide series are an inherent property of the seven-membered bicycle. Such a trend was also observed in a GR hormone radioactive binding assay and isothermal titration calorimetry (ITC) measurements of 4g, 5g and 6g. The higher binding affinity of 5g compared to 4g and 6g was dissected to be a strong increase in binding enthalpy with a substantial entropic offset compensation. The cocrystal structures of 4d, 5c and 5d with the FKBP51 FK1 domain showed that their binding modes are similar to
those observed for compound 2 in complex with FKBP51 FK1. This confirmed the rational design of the ligands and also provided valuable information for future SAR studies.

Based on the cocrysal structure of 5c and 5d, a C₈ substitution was proposed to be introduced into the bicyclic [4.3.1] aza-amide scaffold which was identified as a privileged scaffold for FK506-binding proteins (FKBPs). The C₈ substitution was predicted to increase the contact surface between ligand and protein to further enhance the binding affinity for FKBP51 and 52. The idea was supported by computer modelling which showed the steric possibility for further incorporating substituents at the C₈ position. A new stereoselective synthetic route was established and optimised in which a stereoselective carbon-carbon bond formation by N-acyliminium cyclization was the key step with 76% yield and excellent diastereoselectivity (dr>99:1 determined by NMR). In the cocrysal structure of 63 with FKBP51 FK1, the retained binding mode of 63 compared to the corresponding C₈-unmodified control 5e demonstrates that substituents can be accommodated in the C₈-position. It confirmed the desired conformation obtained from the stereoselective synthesis and also indicated the possibility of introducing more potential ligand-protein interaction by further functionalization of the vinyl group. The racemic dihydroxylation of the C₈ vinyl group substantially improved the affinity for all FKBPs yielding ligands with low nanomolar potencies that rivalled those of the natural product FK506. The higher binding affinity was proposed to be obtained from a putative hydrogen bond between the C¹¹-OH of 64b and Tyr⁵⁷. This will be confirmed in the future by a corresponding cocrysal structure. A more detailed and systematic SAR study of the terminal vinyl group at C₈ will be carried out.
6. Materials and Methods

6.1 Biological analytical methods

6.1.1 Molecular modelling

The co-crystal structure of SLF, FKBP51 or Compound 3a with the FK1 domain of FKBP51 were obtained from Dr. Andreas Bracher in Prof. Ulich Hartl’s group at Max Planck Institute of Biochemistry. Two of these structures were later published (4DRK and 3O5R). All computer simulations were performed on Dell computer AMD athlon™64x2 dual core processor 3800+ 2.00GHz, 960MB RAM. Microsoft windows XP professional version 2002 service pack 2.

6.1.2 Molecular modelling of FKBP51 with bicyclic derivatives 7, 8, 42

The bicyclic [3.3.1] aza-amide nucleus 7, the bicyclic [4.3.1] aza-amide nucleus 8 and the C\textsuperscript{8}-derivative bicyclic [4.3.1] aza-amide derivatives 42 were constructed with Chemdraw 3D ultra 10.1. The structures were first drawn and cleaned up followed by energy calculation and minimization by MM2 computations with the minimum RMS gradient value at 0.1. Then, the C\textsuperscript{1}-C\textsuperscript{6}, N\textsuperscript{7}, O\textsuperscript{1} and O\textsuperscript{10} of the bicyclic [3.3.1] aza-amide nucleus or the C\textsuperscript{1}-C\textsuperscript{6}, N\textsuperscript{7}, O\textsuperscript{1} and O\textsuperscript{11} of the bicyclic [4.3.1] aza-amide nucleus was aligned and overlaid with corresponding atoms of 2 in the cocrystal structure of 2 and FKBP51. The resulting structures were saved as pdb files and visualized in PyMol.

6.1.3 Competition Binding Fluorescence Polarization Assay

The competition binding fluorescence polarization assay was performed as described under the guidance of Dr. Christian Kozany and Bastiaan Hoogeland. Fluorescence polarization (FP) assays are widely used in high throughput screening in drug discovery. The fluorophore-labeled ligand with size less than 5000 Da is
excited by polarized light and emit depolarized light due to the rapid molecular motion of the fluorophore during its fluorescence lifetime. This is usually in the nanosecond range and defined as the period between absorption of an excitation photon and the emission of a photon through fluorescence (Figure 14). If the fluorophore-labeled ligand binds to a receptor of significantly greater size, the rotation of fluorophore compared to the fluorescence lifetime is severely slowed down which causes less depolarization of the original plane of polarization. The extent of binding can be quantified by measuring the extent of depolarization.

Figure 14: (a) and (b) Scheme of FP assay mechanism. (c) Scheme of a competition binding FP assays.

In competition binding FP assays, an inhibitor competes with fluorophore-labeled ligand in binding for a receptor which results in the increase of free fluorophore-labeled ligand in solution. Thereby relatively less polarized light is emitted. Titration of the fluorophore-labeled ligand and receptor complex with the inhibitor gives the relative binding affinity ($IC_{50}$) of the inhibitor. The competition binding FP assay allows the determination of binding affinity of inhibitors from low nanomolar to high micromole range quickly and reproducibly.
6.1.4 Isothermal Titration Calorimetry experiments

The Isothermal Titration Calorimetry experiments were performed by Anne-Katrin Fabian.

Bacterially expressed, affinity purified human HisFKBP51FK1 (aa 1-140) was dialysed against ITC buffer (20mM HEPES pH=8, 150mM NaCl, 5% DMSO). The activity was confirmed by active site titration in an FP Assay as described before. The pH of protein was determined and ligand solutions were degassed and matched within 0.02 pH units.

ITC experiments were performed with a MicroCal iTC200 titration microcalorimeter (GE Healthcare). All experiments were conducted at 20°C. Compound 3d (1mM) was measured by injection into the measurement cell containing the protein (89µM). Due to the limiting solubility compounds 2d and 4d were measured in a reverse setup injecting the protein (0.5mM and 0.16mM, respectively) into a solution of the ligand (40µM for 2d, 15µM for 4d). Heats of dilution were measured in blank titrations and subtracted from the binding heat values. ORIGIN software (version 7.0 Microcal) was used for data collection and analysis.

6.1.5 GR hormone binding assay.

The GR hormone binding assay was performed by Alexander Kirschner.

6.1.6 Crystallography

The crystallography was performed by Dr. Andreas Bracher as described.

6.1.7 Reference compounds 5, 6b, 6c and 6h

The polycyclic compounds 5 and monocyclic compounds 6b, 6c and 6h were prepared by Christoph Kress and Ranganath Gopalakrishnan.
7. Experimental Section

7.1 General chemical methods

All reactions were performed in flame-dried glassware fitted with rubber septa under argon unless otherwise noted. Air- and moisture-sensitive liquids were transferred via syringe. Organic solvents were dried over MgSO\textsubscript{4} and concentrated by rotary evaporation.

7.1.1 Nuclear Magnetic Resonance (NMR)

The NMR measurements were performed by Claudia Dubler and Dr. David S. Stephenson.

The \textsuperscript{1}H, \textsuperscript{13}C-NMR-spectra, 2D HSQC, HMBC, COSY and NOESY were recorded on a Bruker AC 300, Bruker XL 400 or Bruker AMX 600 at room temperature at the NMR-facility, Department of Chemistry and Pharmacy, Ludwig-Maximilians-Universität München. Chemical shifts were reported in \(\delta\) values (ppm); the hydrogenated residues of deuterated solvent were used as internal standard (CDCl\textsubscript{3}: \(\delta = 7.26\) ppm in \textsuperscript{1}H NMR and \(\delta = 77\) ppm in \textsuperscript{13}C NMR). Signals were described as s, d, t, and m for singlet, doublet, triplet and multiplet respectively. All coupling constants (J) were given in Hz.

7.1.2 Mass Spectrometry

The Mass spectra (m/z) were obtained on a Thermo Finnigan LCQ DECA XP Plus mass spectrometer (ESI) at the Max Planck Institute of Psychiatry while the high resolution mass spectrometry was carried out by Elisabeth Weyher at MPI for Biochemistry (Microchemistry Core facility) on Varian Mat711 mass spectrometer (ESI) or on a JMS GCmate II JEOL mass spectrometer (EI) by Dr. Lars Allmendinger at the Department of Chemistry and Pharmacy, Ludwig-Maximilians-University Munich.
7. Experimental Section

7.1.3 Flash Chromatography

Flash chromatography was performed using thick-walled glass columns and silica gel 60 (0.04 – 0.063 mm) from Roth. The relative proportion of solvents in mixed chromatography solvents refers to the volume: volume ratio. Interchim Puriflash 430 with an UV detector was used as automated flash chromatography.

7.1.4 Thin Layer Chromatography

Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel (Merck silica gel 60 F254, layer thickness 0.25mm) using the indicated solvent ratio (volume: volume). UV-active compounds were detected by UV-light determination (λ = 254 nm and λ = 366 nm), non-UV-active compounds were detected with different TLC staining solutions:

Hanessian’s Staining Solution:

\[ 5 \text{ g CeSO}_4, \]
\[ 25 \text{ g NH}_4\text{MO}_7\text{O}_{24} \cdot 4 \text{H}_2\text{O}, \]
\[ 450 \text{ mL H}_2\text{O}, \]
\[ 50 \text{ mL, H}_2\text{SO}_4 \]

Ninhydrin Staining Solution:

\[ 0.5 \text{ g Ninhydrin}, \]
\[ 100 \text{ mL EtOH}, \]
\[ 5\text{mL AcOH} \]

Potassium Permanganate Staining Solution:

\[ 1.5 \text{ g KMnO}_4, \]
\[ 10 \text{ g K}_2\text{CO}_3, \]
\[ 1.25 \text{ mL 10\% NaOH} \]
The TLC plates were dipped in one of the reagents listed above and then heated to stain the spots.

**7.1.5 High performance liquid chromatography (HPLC)**

Analytical HPLC: Beckman System Gold 125S Solvent Module, System Gold Diode Array Detector Module 168

**Column:** Jupiter 4 µm Proteo 90 A, 250 x 4.6 mm, Phenomenex, Torrance, USA,

**Wavelength:** 224nm, 280nm, Diode Array

**Mobile phase:**

**Solvent A:**
- 95% H₂O
- 5% AcCN
- 0.1% TFA

**Solvent B:**
- 95% AcCN
- 5% H₂O
- 0.1% TFA

**Flow rate:** 1ml/min

**Standard Gradient:** 0-100% B in 20min, 1 ml/min

**7.1.6 Preparatory Thin Layer Chromatography**

The pre-coated preparative TLC plate SIL G-200 UV₂₅₄ was purchased from MACHEREY-NAGEL GmbH (layer: 2.0mm silica gel with fluorescent indicator UV₂₅₄).
7. Experimental Section

7.1.7 Preparative HPLC

The compounds were dissolved in 40% buffer B, and the purification was carried out with an injection loop volume of 2 mL.

Preparative HPLC: Beckman System Gold Programmable Solvent Module 126 NMP
Beckman Programmable Detector Module 166
Column: Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 21.2 mm 10 micron
Wavelength: 224 nm

Mobile phase:
Solvent A: 95% H$_2$O
5% MeOH
0.1% TFA

Solvent B: 95% MeOH
5% H$_2$O
0.1% TFA

Flow rate: 25ml/min

7.1.8 Chiral HPLC

Pump: Waters 515 HPLC Pump
Detector: LDC Analytical Spectromonitor 5000 Photodiode Array Detector
Column: DAICEL Chemical Industries LTD. Chiralcel OD-H

Solvent A: Hexane
Solvent B: i-propanol
wavelength: 220nm
Standard Gradient: 1:1 60 min, 0.5 ml/min
7. Experimental Section

7.1.9 Chemicals

Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Lancaster, Fluka, Merck, Roth and were used without purification.

<table>
<thead>
<tr>
<th>Substance name</th>
<th>CAS-Number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>(z)-1-Ethoxy-2-(tributylstannyl)ethene</td>
<td>e2342g1</td>
<td>Activate scientific GmbH</td>
</tr>
<tr>
<td>1-Hydroxybenzotriazol</td>
<td>123333-53-9</td>
<td>Aldrich</td>
</tr>
<tr>
<td>6-Bromopicolinic acid</td>
<td>21190-87-4</td>
<td>Activate scientific GmbH</td>
</tr>
<tr>
<td>anhydrous Acetonitril</td>
<td>75-05-8</td>
<td>Roth</td>
</tr>
<tr>
<td>Benzyl chloroformate</td>
<td>501-53-1</td>
<td>Aldrich</td>
</tr>
<tr>
<td>Di-tert-butyl-dicarbonat, 98%</td>
<td>24424-99-5</td>
<td>Fluka</td>
</tr>
<tr>
<td>EDC-HCl</td>
<td>25952-53-8</td>
<td>Aldrich</td>
</tr>
<tr>
<td>Ethyl-6-bromo-2-Pyridinecarboxylate</td>
<td>21190-88-5</td>
<td>Chempur</td>
</tr>
<tr>
<td>Hydrogen chloride</td>
<td>7647-01-0</td>
<td>Roth</td>
</tr>
<tr>
<td>30% Hydrogen peroxide</td>
<td>7722-84-1</td>
<td>Roth</td>
</tr>
<tr>
<td>Lithium chloride</td>
<td>7447-41-8</td>
<td>Merck</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>7487-88-9</td>
<td>Roth</td>
</tr>
<tr>
<td>N,N'-Diisopropylethylamine</td>
<td>7087-68-5</td>
<td>Aldrich</td>
</tr>
<tr>
<td>N-Bromosuccinimid, 99%</td>
<td>128-08-5</td>
<td>Aldrich</td>
</tr>
<tr>
<td>n-BuLi (2M in Cyclohexane)</td>
<td>109-72-8</td>
<td>Aldrich</td>
</tr>
<tr>
<td>Palladium on carbon</td>
<td>7440-05-3</td>
<td>Aldrich</td>
</tr>
<tr>
<td>Platinum dioxide</td>
<td>1314-15-4</td>
<td>Merck</td>
</tr>
<tr>
<td>Potassium carbonate</td>
<td>584-08-7</td>
<td>Roth</td>
</tr>
<tr>
<td>Pyridine</td>
<td>110-86-1</td>
<td>Roth</td>
</tr>
<tr>
<td>Raney nickel catalyst</td>
<td>7440-02-0</td>
<td>Merck</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>26628-22-8</td>
<td>Merck</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>144-55-8</td>
<td>Merck</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>Merck</td>
</tr>
</tbody>
</table>
### 7. Experimental Section

<table>
<thead>
<tr>
<th>Chemical</th>
<th>CAS Number</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium hydride 60% dispersion in mineral oil</td>
<td>7646-69-7</td>
<td>Aldrich</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>Merck</td>
</tr>
<tr>
<td>Sulfuric acid</td>
<td>7664-93-9</td>
<td>Roth</td>
</tr>
<tr>
<td>Thionyl chloride</td>
<td>7719-09-7</td>
<td>Merck</td>
</tr>
<tr>
<td>Triethylamine</td>
<td>121-44-8</td>
<td>Merck</td>
</tr>
<tr>
<td>Trifluoroacetic acid</td>
<td>76-05-1</td>
<td>Fluka</td>
</tr>
<tr>
<td>(Trimethylsilyl)diazomethane 2.0M in Et₂O</td>
<td>18107-18-1</td>
<td>Aldrich</td>
</tr>
<tr>
<td>9-BBN 0.5M in THF</td>
<td>280-64-8</td>
<td>Aldrich</td>
</tr>
<tr>
<td>1,2-Dibromoethane</td>
<td>106-93-4</td>
<td>Fluka</td>
</tr>
<tr>
<td>1,4-Dioxane</td>
<td>123-91-1</td>
<td>Roth</td>
</tr>
<tr>
<td>3,4-Dimethoxyphenol</td>
<td>2033-89-8</td>
<td>Fluka</td>
</tr>
<tr>
<td>Chloroform</td>
<td>67-66-3</td>
<td>Roth</td>
</tr>
<tr>
<td>Dichloromethane</td>
<td>75-09-2</td>
<td>Roth</td>
</tr>
<tr>
<td>Dichloromethane dry</td>
<td>75-09-2</td>
<td>Roth</td>
</tr>
<tr>
<td>Tetrahydrofuran</td>
<td>109-99-9</td>
<td>Roth</td>
</tr>
<tr>
<td>Acetone</td>
<td>67-64-1</td>
<td>Roth</td>
</tr>
<tr>
<td>Methanol</td>
<td>67-56-1</td>
<td>Roth</td>
</tr>
<tr>
<td>Methanol HPLC</td>
<td>67-56-1</td>
<td>Roth</td>
</tr>
<tr>
<td>Acetonitrile HPLC</td>
<td>75-05-8</td>
<td>Roth</td>
</tr>
<tr>
<td>Toluene</td>
<td>108-88-3</td>
<td>Roth</td>
</tr>
<tr>
<td>Diethylether</td>
<td>60-29-7</td>
<td>Roth</td>
</tr>
<tr>
<td>DMF</td>
<td>68-12-2</td>
<td>Roth</td>
</tr>
<tr>
<td>TFA</td>
<td>76-05-1</td>
<td>Roth</td>
</tr>
<tr>
<td>Formic acid</td>
<td>64-18-6</td>
<td>Roth</td>
</tr>
<tr>
<td>DIPEA</td>
<td>7087-68-5</td>
<td>Fluka</td>
</tr>
<tr>
<td>Triethylamine</td>
<td>121-44-8</td>
<td>Merck</td>
</tr>
<tr>
<td>MgSO₄</td>
<td>7487-88-9</td>
<td>Roth</td>
</tr>
<tr>
<td>KMnO₄</td>
<td>7722-64-7</td>
<td>Merck</td>
</tr>
<tr>
<td>NaCl</td>
<td>7647-14-5</td>
<td>VWR</td>
</tr>
<tr>
<td>LiOH</td>
<td>1310-65-2</td>
<td>Sigma</td>
</tr>
<tr>
<td>n-BuLi 2M in cyclohexane</td>
<td>109-72-8</td>
<td>Aldrich</td>
</tr>
<tr>
<td>NaN₃</td>
<td>26628-22-8</td>
<td>Aldrich</td>
</tr>
</tbody>
</table>
7. Experimental Section

<table>
<thead>
<tr>
<th>Chemical</th>
<th>CAS Number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>KOH</td>
<td>1310-58-3</td>
<td>Roth</td>
</tr>
<tr>
<td>K$_2$CO$_3$</td>
<td>584-08-7</td>
<td>Roth</td>
</tr>
<tr>
<td>DMAP</td>
<td>1122-58-3</td>
<td>Fluka</td>
</tr>
<tr>
<td>NaHMDS 1M in THF</td>
<td>1070-89-9</td>
<td>Aldrich</td>
</tr>
<tr>
<td>NaHCO$_3$</td>
<td>144-55-8</td>
<td>Roth</td>
</tr>
<tr>
<td>NH$_4$Cl</td>
<td>12125-02-9</td>
<td>Merck</td>
</tr>
<tr>
<td>HATU</td>
<td>148893-10-1</td>
<td>Nova Biochem</td>
</tr>
<tr>
<td>CDCl$_3$</td>
<td>865-49-6</td>
<td>Roth</td>
</tr>
</tbody>
</table>

7.1.10 Solvents

Solvents were purchased from commercial suppliers Roth and Aldrich with ROTISOLV®, ROTIPURAN®, ROTIDRY® and HPLC grade and were used without purification.

<table>
<thead>
<tr>
<th>Solvent</th>
<th>Quality</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetic acid</td>
<td>ROTISOLV $\geq$99,9%</td>
<td>Roth</td>
</tr>
<tr>
<td>Acetone</td>
<td>ROTISOLV $\geq$99,8%</td>
<td>Roth</td>
</tr>
<tr>
<td>Acetonitril</td>
<td>ROTISOLV $\geq$99,9%</td>
<td>Roth</td>
</tr>
<tr>
<td>Anhydrous Methanol</td>
<td>ROTISOLV $\geq$99,9%</td>
<td>Roth</td>
</tr>
<tr>
<td>Chloroform</td>
<td>99 % for Synthesis</td>
<td>Roth</td>
</tr>
<tr>
<td>Cyclohexane</td>
<td>ROTIPURAN $\geq$99,5%</td>
<td>Roth</td>
</tr>
<tr>
<td>Dichloromethane</td>
<td>ROTIDRY $\geq$99,8%</td>
<td>Roth</td>
</tr>
<tr>
<td>Diethyl ether</td>
<td>ROTISOLV $\geq$99,8%</td>
<td>Roth</td>
</tr>
<tr>
<td>Dimethylformamide</td>
<td>ROTISOLV $\geq$99,9%</td>
<td>Roth</td>
</tr>
<tr>
<td>Ethyl acetate</td>
<td>ROTISOLV $\geq$99%</td>
<td>Roth</td>
</tr>
<tr>
<td>Methanol</td>
<td>ROTISOLV $\geq$99,9%</td>
<td>Roth</td>
</tr>
<tr>
<td>n-Hexane</td>
<td>ROTISOLV $\geq$99%</td>
<td>Roth</td>
</tr>
<tr>
<td>Pentane</td>
<td>ROTIPURAN $\geq$99%</td>
<td>Roth</td>
</tr>
<tr>
<td>Tetrahydrofuran</td>
<td>anhydrous, $\geq$99.9%</td>
<td>Aldrich</td>
</tr>
</tbody>
</table>
7.2 Chemical Synthesis

7.2.1 Synthesis of 6-(cyanomethyl)picolinic acid 22

To 100 ml anhydrous THF under argon at -78°C was added butyl lithium (6.02 g, 94 mmol) followed by addition of acetonitrile (4.06 g, 99 mmol) and stirring for 30 min. Then 6-bromopicolinic acid 21 (2.5 g, 12.38 mmol) in 100 ml anhydrous THF cooled on ice was added dropwise. After 2 h at -78°C and 30 min at room temperature, the reaction mixture was concentrated in vacuo, dissolved in DCM (100 ml) and extracted with saturated NaHCO₃ solution (3 x 100 ml). The aqueous layers were acidified with 10% HCl, and extracted with DCM (6 x 100 ml). The collected organic layers were dried over MgSO₄ and concentrated in vacuo. This crude product was used for next reaction without further purification.

TLC [20% MeOH, 0.2% TFA in CHCl₃]: Rᵢ = 0.04
Yield: 1.76 g, 10.9 mmol (87.7%)

¹H NMR (300 MHz, CDCl₃): δ = 8.1 (d, 1H, J=7.75 Hz), 8.05 (t, 1H, J=7.77, 7.77 Hz), 7.75 (d, 1H, J=7.8 Hz), 4.08 (s, 2H)

¹³C NMR (75 MHz, CDCl₃): δ = 163.69, 150.06, 146.67, 140.26, 126.86, 123.68, 116.05, 26.47


7.2.2 Synthesis of methyl 6-(cyanomethyl) picolinate 20

13.35 ml 2M TMSCHN₂ in Et₂O (3.05 g, 26.7 mmol) was added dropwise to crude 6-(cyanomethyl) picolinic acid 22 (1.31 g, 8.1 mmol) in 27 ml anhydrous MeOH at 0°C. After stirring at room temperature for 5 h, the reaction was quenched with saturated NaHCO₃ solution (100 ml) and extracted with DCM (6 x 100 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The pure product was obtained by flash chromatography with hexane: EtOAc 1:1.

TLC [Hexane: EtOAc 1:1]: Rᵢ = 0.54
Yield: 750 mg, 4.3 mmol (52.7%)
7. Experimental Section

$^1$HNMR (300 MHz, CDCl$_3$): $\delta$ = 8.01-8.06 (m, 1H), 7.87 (t, 1H, J=7.79,7.79 Hz), 7.64 (d, 1H), 4.02 (s, 2H), 3.94 (s, 3H)

$^{13}$C NMR (300 MHz, CDCl$_3$): $\delta$ = 164.95, 151.05, 148.11, 138.61, 125.49, 124.41, 116.60, 53.04, 26.59


7.2.3 Synthesis of ethyl 6-cyanopicolinate 11

CuCN (31.1g, 348mmol) was added to a solution of ethyl 6-bromopicolinate 12 (16g, 69.5mmol) in 608 ml pyridine. The mixture was heated under reflux for 16 h, filtered through celite and concentrated in vacuo. Saturated NaHCO$_3$ solution (100 ml) was added and extracted with DCM (6 x 100 ml). The organic layers were dried over MgSO$_4$ and concentrated in vacuo. The mixture was purified by flash chromatography with hexane: EtOAc 1:1.

TLC [Hexane: EtOAc 1:1]: $R_f$ = 0.65

Yield: 7.3g, 41.4mmol (60%)

$^1$HNMR (600 MHz, CDCl$_3$): $\delta$ = 8.32 (dd, 1H, J=1.15, 7.97Hz), 8.04 (t, 1H, J=7.86, 7.86Hz), 7.88 (dd, 1H, J=1.13, 7.76Hz), 4.52 (q, 2H, J=7.13, 7.13, 7.12Hz), 1.40 (t, 3H, J=7.13, 7.13Hz)

$^{13}$C NMR (300 MHz, CDCl$_3$): $\delta$ = 163.76, 150.06, 138.70, 134.23, 131.40, 128.12, 116.62, 62.89, 14.44

HRMS: 177.0669[M + H], calculated 177.0664[M + H]$^+$

7.2.4 Synthesis of ethyl 6-((tert-butoxycarbonylamino)methyl)picolinate 13

To a solution of ethyl 6-cyanopicolinate 11 (7.87g, 44.7mmol) in 350 ml MeOH was added Boc$_2$O (19.5g, 89mmol) and catalytic amounts of Raney nickel. The reaction mixture was degased with argon and stirred under 1 atm H$_2$ at room temperature for 24 h, filtered through celite and concentrated in vacuo. The mixture was purified by flash chromatography with EtOAc: DCM 1:5.

TLC [EtOAc: DCM 1:5]: $R_f$ = 0.34
7. Experimental Section

Yield: 8.74g, 31.2mmol (68%)

$^1$HNMR (300 MHz, CDCl$_3$): $\delta$ = 7.98(d, 1H, J=7.73Hz), 7.79(t, 1H, J=7.76, 7.76Hz), 7.48 (d, 1H, J=7.78Hz), 5.51(s, 1H), 4.48-4.58(m,2H), 4.40-4.48(m,2H), 1.44(s, 9H), 1.34-1.42(m,3H)

$^{13}$C NMR (75 MHz, CDCl$_3$): $\delta$ = 165.01, 158.55, 155.95, 147.68, 137.62, 125.05, 123.65, 79.65, 61.88, 45.85, 28.35, 14.26

HRMS: 281.1505[M + H]$^+$, calculated 281.1501[M + H]$^+$

7.2.5 Synthesis of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) picolinate 23

To a solution of methyl 6-(cyanomethyl) picolinate 20 (0.75g, 4.3mmol) in 54 ml MeOH was added Boc$_2$O (1.858g, 8.5mmol) and catalytic amounts of Raney nickel. The reaction mixture was degased with argon and stirred under 1 atm H$_2$ at room temperature for 24 h, filtered through celite and concentrated in vacuo. The mixture was purified by flash chromatography with EtOAc: DCM 1:2.

TLC [EtOAc: DCM 1:2]: $R_f$ = 0.54

Yield: 860mg, 3.1mmol (76%)

$^1$HNMR (300 MHz, CDCl$_3$) $\delta$ = 7.90(dd, 1H, J=1.01,7.75Hz), 7.69(t, 1H, J=7.75, 7.75Hz), 7.31(d, 1H, J=7.73Hz), 3.92 (s, 3H), 3.48 (d, 2H, J=5.89Hz), 3.01(t, 2H, J=6.64, 6.64Hz), 1.34(s, 9H)

$^{13}$C NMR (300 MHz, CDCl$_3$) $\delta$ = 165.71, 159.92, 155.87, 147.51, 137.29, 126.70, 122.92, 78.97, 52.71, 39.90, 37.79, 28.31

HRMS: m/z: found 281.1457[M + H]$^+$, calculated 281.1501[M + H]$^+$

7.2.6 Synthesis of ethyl 6-((tert-butoxycarbonylamino) methyl)piperidine-2-carboxylate 14

To a solution of ethyl 6-((tert-butoxycarbonylamino) methyl)picolinate 13 (8.74g, 31.2mmol) in 150 ml AcOH was added catalytic amounts of PtO$_2$ and degassed with argon in a hydrogenation reactor (Roth). The reaction was stirred at room
temperature under H\textsubscript{2} (40bar) for 3 days. 13 was not fully converted. The reaction mixture was filtered through celite, concentrated in vacuo and purified by flash chromatography with EtOAc. The retrieval of 13 was used with the same procedure until 100% converted.

TLC [EtOAc]: \( R_f = 0.38 \)

Yield: 4.35g, 15.2mmol (49%)

\(^1\)HNMR (600 MHz, CDCl\textsubscript{3}) \( \delta = 5.07 \) (s, 1H), 4.14-4.2 (m, 2H), 3.33 (dd, 1H, J=2.83, 11.52 Hz), 3.23-3.35 (m, 1H), 2.90-3.05 (m, 1H), 2.66-2.70 (m, 1H), 1.97-2.05 (m, 3H), 1.86-1.92 (m, 1H), 1.59-1.65 (m, 1H), 1.4-1.48 (m, 10H), 1.32-1.4 (m, 1H), 1.03-1.12 (m, 1H).

\(^{13}\)C NMR (300 MHz, CDCl\textsubscript{3}) \( \delta = 175.0, 156.25, 79.3, (60.92, 60.97), (58.7, 58.75), 55.68, 46, (29.06,29.1), (28.96,29.01), (28.37,28.41), 23.92, (14.13,14.17) \)

MS (ESI) m/z: found 287.2 [M + H]\textsuperscript{+}, calculated 287.20 [M + H]\textsuperscript{+}

7.2.7 Synthesis of methyl 6-\((2\text{-}(\text{tert-butoxycarbonylamino}) \text{ethyl}) \).piperidine-2-carboxylate 24 diastereomeric mixture

To a solution of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) picolinate 23 (644mg, 2.3mmol) in 33 ml AcOH was added catalytic amounts of PtO\textsubscript{2} and degassed with argon in a hydrogenation reactor (Roth). The reaction was stirred at room temperature under H\textsubscript{2} (50bar) for 2 days, filtered through celite, concentrated in vacuo and purified by flash chromatography with EtOAc.

TLC [EtOAc]: \( R_f = 0.31 \)

Yield: 646mg, 2.3mmol (98 %)

\(^1\)HNMR (300 MHz, CDCl\textsubscript{3}) \( \delta = 4.81-4.95 \) (m, 1H), 3.66 (s, 3H), 3.25-3.42 (m, 1H), 3.05-3.25 (m, 2H), 2.85-3.00 (m, 1H), 2.48-2.60 (m, 1H), 1.95-2.05 (m, 1H), 1.85-1.95 (m, 1H), 1.45-1.65 (m, 3H), 1.38 (s, 9H), 1.15-1.38 (m, 2H), 0.95-1.1 (m, 1H)

\(^{13}\)C NMR (300 MHz, CDCl\textsubscript{3}) \( \delta = 173.46, 156.05, 78.98, 59.08, 54.12, 51.86, 37.48, 37.01, 31.73, 29.15, 28.34, 24.28 \)

HRMS : m/z: found 287.1876 [M + H]\textsuperscript{+}, calculated 287.1971 [M + H]\textsuperscript{+}
7. Experimental Section

7.2.8 Synthesis of 1-benzyl 2-ethyl 6-((tert-butoxycarbonylamino) methyl) piperidine-1,2-dicarboxylate 15

To a solution of ethyl 6-((tert-butoxycarbonylamino)methyl)piperidine-2-carboxylate 14 (4.35g, 15.2mmol) in 50 ml DCM at 0°C was added dropwisely benzyl chloroformate (3.89g, 22.8mmol) followed by addition of N,N-diisopropylethylamine (7.85g, 60.8mmol). After stirring at room temperature for 5 h, a saturated NH₄Cl solution (20 ml) was added. The mixture was extracted with DCM (4 x 20 ml). The organic layers were dried over MgSO₄, concentrated in vacuo and purified by flash chromatography with hexane: EtOAc 3:1

TLC [Hexane :EtOAc 3:1]: Rᵣ = 0.26

Yield: 6.14g, 14.6mmol (96%)

¹H NMR (300 MHz, CDCl₃) δ = 7.25-7.4(m, 5H), 5.2-5.4(m, 1H), 5.0-5.1(m, 1H), 4.7-5-0(m, 1H), 4.36-4.52(m, 1H), 4.06-4.3(m, 1H), 3.3-3.5(m, 1H), 2.9-3.14(m, 1H), 2.18-2.35(m, 1H), 1.5-1.8(m, 6H), 1.3-1.5(m, 10H), 1.1-1.3(m, 3H)

¹³C NMR (300 MHz, CDCl₃) δ = 173.4, 157.1, 156.4, 136.79, 128.68, 128.17, 127.96, 79.14, 67.8, 61.80, 53.4, 50.54, 42.58, 28.69, 26.26, 16.53, 14.33

MS (ESI) m/z: found 421.22[M + H]⁺, calculated 421.23[M + H]⁺

HRMS : m/z: found 421.2333 [M + H]⁺, calculated 421.2339 [M + H]⁺

7.2.9 Synthesis of 1-benzyl 2-methyl 6-(2-(tert-butoxycarbonylamino) ethyl) piperidine-1, 2-dicarboxylate 25

To a solution of methyl 6-(2-(tert-butoxycarbonylamino)ethyl)piperidine-2-carboxylate 24 (646mg, 2.3mmol) in 7 ml DCM at 0°C was added dropwisely benzyl chloroformate (578mg, 3.4mmol) followed by addition of N,N-diisopropylethylamine (1167mg, 9mmol). After stirring at room temperature for 6 h, a saturated NH₄Cl solution (20 ml) was added and extracted with DCM (4 x 20 ml). The organic layers were dried over MgSO₄, concentrated in vacuo and purified by flash chromatography with hexane: EtOAc 2:1

TLC [Hexane :EtOAc 2:1]: Rᵣ = 0.46

Yield: 812mg,1.9mmol (86%)
7. Experimental Section

$^1$HNMR (300 MHz, CDCl$_3$) $\delta$ = 7.28-7.42(m, 5H), 5.02-5.26(m, 2H), 4.78-5.01(m, 0.5H), 4.66-4.70(m, 0.5H), 4.20-4.44(m, 1H), 3.55-3.73(m, 3H), 2.85-3.45(m, 2H), 2.19-2.34(m, 1H), 1.45-1.75(m, 7H), 1.42(s, 9H)

$^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ = 172.89, 156.45, 156.05, 136.40, 128.50, 128.45, 128.10, 127.51, 126.92, 78.85, 67.55, 52.45, 52.08, 48.40, 37.50, 33.27, 28.70, 28.44, 25.84, 15.88

HRMS : m/z: found 421.2437 [M + H]$^+$, calculated 421.2339 [M + H]$^+$

7.2.10 Synthesis of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17

Step 1: 1-Benzyl 2-ethyl 6-((tert-butoxycarbonylamino)methyl)piperidine-1,2-dicarboxylate 15 (6.11g, 15mmol) in 50% TFA in DCM was stirred at room temperature for 1 h and then concentrated in vacuo. DCM was added and evaporated for 3 times to remove the TFA. The produced 16 was used for the next step without further purification.

Step 2: The crude product from step 1 in 300 ml pyridine was heated under reflux for 2 h. The mixture was concentrated in vacuo and purified by flash chromatography with EtOAc.

TLC [EtOAc]: $R_f$ = 0.23

Yield: 3.14g, 11.4mmol (76%)

$^1$HNMR (600 MHz, CDCl$_3$) $\delta$ = 7.28-7.42(m, 5H), 5.05-5.2(m, 2H), 4.63-4.77(m, 1H), 4.43-4.57(m, 1H), 3.63-3.77(m, 1H), 3.15-3.24(m, 1H), 1.89-1.99(m, 1H), 1.66-1.89(m, 5H)

$^{13}$C NMR (150 MHz, CDCl$_3$) $\delta$ = 171.41, 154.19, 136.31, 128.77, 128.42, 128.15, 67.79, 54.18, 53.47), (45.94, 45.59), (44.98, 44.13), (30.59, 30.20), (27.84, 27.43), 18.12

HRMS : m/z: found 275.1390 [M + H]$^+$, calculated 275.1396 [M + H]$^+$

7.2.11 Synthesis of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27
7. Experimental Section

Step 1: 1-Benzyl 2-methyl 6-(2-(tert-butoxycarbonylamino)ethyl)piperidine-1,2-dicarboxylate 25 (3.6g, 8.6mmol) in 360 ml 50% TFA in DCM was stirring at room temperature for 1 hour and then concentrated in vacuo. DCM was added and evaporated for three times to remove the TFA. The produced 26 was used for the next step without further purification.
TLC [10 %MeOH in CHCl3]: Rf = 0.31

Step 2: The crude product from step 1 was dissolved in 150 ml pyridine and heated under reflux for overnight. The reaction mixture was concentrated in vacuo followed by purification by flash chromatography with EtOAc.
TLC [EtOAc]: Rf = 0.26
Yield: 840mg, 2.9mmol (33 %)

1H-NMR (300 MHz, CDCl3): δ = 7.28-7.38(m, 5H), 6.52-6.74 (m, 1H), 5.12-5.24(m, 2H), 4.96-5.18 (m, 1H), 4.6-4.74(m, 1H), 3.14-3.22(m,1H), 2.88-2.96(m, 1H), 2.24-2.36 (m, 1H), 2.12-2.24(m, 1H), 1.88-1.96(m, 1H), 1.56-1.76(m, 4H), 1.48-1.56(m, 1H).

13C-NMR (150 MHz, CDCl3): δ = 175.24, (156.0, 155.92), (136.37, 136.30), (128.58, 128.52), 128.23, 128.12, 127.00, 127.80, 67.63, (55.51, 55.28), (46.89, 46.44), (39.28, 39.26), (33.02, 32.88), (29.24, 28.91), (28.10, 27.92), (15.32, 15.26)
MS (ESI) m/z: found 289.15 [M + H]+, calculated 289.12
HRMS : m/z: found 289.1546 [M + H]+, calculated 289.1552 [M + H]+

7.2.12 Synthesis of 4-(2-bromoethoxy)-1, 2-dimethoxybenzene 28a

28a was prepared as described. 196

7.2.13 Synthesis of benzyl 3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 29a

To a solution of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 (100mg, 0.4mmol) in 2 ml dry THF under argon at 0°C was added NaH (26mg, 0.9mmol). After stirring for 15 min, 28a (238mg, 0.9mmol) was added and stirred at
7. Experimental Section

Room temperature for 5 days. The reaction mixture was concentrated in vacuo, acidified with 10% HCl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic phases were dried over MgSO₄, concentrated in vacuo and purified by flash chromatography with hexane : EtOAc 2:1

TLC [Hexane : EtOAc 1:2]: Rf = 0.31  
Yield: 104mg, 0.2mmol (63%)

¹HNMR (300 MHz, CDCl₃) δ= 7.3-7.42(m, 5H), 6.74-6.8(m, 1H), 4.45-4.50(m, 1H), 4.34-4.42(m, 1H), 5.07-5.2(m, 2H), 4.42-4.82(m, 2H), 4.05-4.25(m, 2H), 3.9-4.05(m, 1H), 3.77-3.9(m, 7H), 3.38-3.62(m, 2H), 1.92-2.04 (m, 1H), 1.78-1.92 (m, 1H), 1.6-1.78 (m, 4H)

¹³C NMR (75 MHz, CDCl₃) δ=168.6, 154.2, 153.21, 150.14, 144.01, 136.3, 128.77, 128.41, 128.18, 112.21, 104.20, 100.73, 67.71, 66.95, 56.68, 56.11, 54.5, 53.10, 46.79, 45.4, 30.4, 28.2, 18.50

HRMS : m/z: found 455.2176[M + H]⁺, calculated 455.2182 [M + H]⁺

7.2.14 Synthesis of benzyl 3-ethyl-2-oxo-3,9-diazabicyclo [3.3.1]nonane-9-carboxylate 29b

To a solution of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 (500mg, 1.8mmol) in 15 ml dry THF under argon at 0°C was added NaH (109mg, 2.7mmol). After stirring for 15 min, ethyl iodide (421mg, 2.7mmol) was added and stirred at room temperature. The reaction was checked by TLC until 17 was fully converted. The mixture was purified by flash chromatography with 4% MeOH in CHCl₃.

TLC [5% MeOH in CHCl₃]: Rf = 0.56  
Yield: 538mg, 1.8mmol (95%)

¹HNMR (300 MHz, CDCl₃) δ= 7.25-7.45(m, 5H), 5.03-5.23(m, 2H), 4.65-4.77(m, 1H), 4.45-4.65(m, 1H), 3.55-3.78(m, 2H), 3.05-3.33(m, 2H), 1.95-2.07(m, 1H), 1.55-1.90(m, 5H), 1.13-1.23(t, 3H,J=7.18, 7.18Hz)

HRMS : m/z: found 303.1703[M + H]⁺, calculated 303.1709 [M + H]⁺
7. Experimental Section

7.2.15 Synthesis of 3-ethyl-3,9-diazabicyclo[3.3.1]nonan-2-one 31b

To a solution of benzyl 3-ethyl-2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 29b (100mg, 0.3mmol) in 1 ml anhydrous MeOH was added catalytic amounts of Palladium on carbon followed by degassing with H₂. After stirring under 1 atm H₂ at room temperature for 2 h, the reaction mixture was filtered through celite and concentrated in vacuo. A 20% HCl solution (5 ml) was added and extracted with DCM (4 x 10 ml). The aqueous layer was basified with saturated NaHCO₃ solution and extracted with DCM (4 x 10 ml). The organic layer was concentrated and used for the next step without further purification.

TLC [5% MeOH in CHCl₃]: Rᵢ = 0.37
Yield: 45mg, 0.3mmol (81%)

¹HNMR (300 MHz, CDCl₃) δ = 3.6-3.73 (m, 2H), 3.53-3.57 (m, 1H), 3.35-3.43 (m, 1H), 3.22-3.35 (m, 1H), 3.13-3.21 (m, 1H), 1.55-2.03 (m, 6H), 1.15-1.23 (t, 3H, J=7.19, 7.19Hz)

¹³C NMR (75 MHz, CDCl₃) δ = 170.96, 54.63, 51.52, 46.06, 41.34, 32.17, 29.27, 18.51, 12.28

HRMS: m/z: found 169.1333 [M + H]⁺, calculated 169.1314 [M + H]⁺

7.2.16 Synthesis of 1-(3-ethyl-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione 4c

2-Oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a (42mg, 0.2mmol) in 1 ml DMF was treated with oxalyl chloride (47mg, 0.5mmol) and stirred at 0 °C for 3 h. The reaction mixture was first concentrated in vacuo and then dissolved in 1 ml DCM followed by addition of 3-ethyl-3,9-diazabicyclo[3.3.1]nonan-2-one 31b (30mg, 0.2mmol), DIPEA (28mg, 0.2mmol) and stirred at room temperature for 1 h. The reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified by flash chromatography with hexane: EtOAc 2:1.

TLC [Hexane: EtOAc]: Rᵢ = 0.09
HPLC [0-100% Solvent B, 30 min]: Rᵢ = 18.5 min, purity (280 nm) = 99%
Yield: 20mg, 0.05mmol (28%)
7. Experimental Section

$^1$H NMR (300 MHz, CDCl$_3$) δ = 7.23(s, 1H), 7.19(s, 1H), 5.17-5.22(m, 0.5H), 5.05-5.12(m, 0.5H), 4.13-4.18(m, 0.5H), 3.98-4.06(m, 0.5H), 3.94-3.97(m, 3H), 3.88-3.93(m, 6H), 3.62-3.89(m, 1.5H), 3.21-3.42 (m, 2H), 3.13-3.17(m, 0.5H), 2.15-2.25 (m, 1H), 1.72-2.05(m, 5H), 1.16-1.24(m, 3H)

$^{13}$C NMR (75 MHz, CDCl$_3$) δ = (189.91, 189.62), (166.69, 166.19), (164.21, 163.62), (153.70, 153.65), (144.78, 144.72), (128.17, 128.05), (107.40, 107.29), (61.31, 61.28), 56.65, 56.60, 56.31, (51.35, 50.55), (49.75, 48.35), (41.57, 41.47), (31.60, 30.68), (29.09, 28.45), (18.31, 18.21), 12.19

HRMS : m/z: found 391.1863[M + H]$^+$, calculated 391.1869 [M + H]$^+$

7.2.17 Synthesis of benzyl 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 30a

To a solution of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27 (70mg, 0.2mmol) in 2 ml dry THF under argon at 0°C was added NaH (9mg, 0.4mmol) and stirred for 15 min followed by addition of 4-(2-bromoethoxy)-1,2-dimethoxybenzene 28a (158mg, 0.6mmol). The reaction was stirred at room temperature for 3 days and concentrated in vacuo. A 10% HCl solution (5 ml) was added and extracted with DCM (4 x 10 ml). The organic phases were dried over MgSO$_4$, concentrated in vacuo and purified by flash chromatography with hexane: EtOAc 1:3.

TLC [ Hexane: EtOAc 1:3]: R$_f$ = 0.49
Yield: 73mg, 0.2mmol (64%)

$^1$H-NMR (600 MHz, CDCl$_3$): δ = 7.24-7.36 (m, 5H), 6.56 (t, 1H), 6.49 (m, 1H), 6.46-6.48 (m, 1H), 5.12-5.2(m, 1H), 5.0-5.1 (m, 2H), 4.55-4.65(m, 1H), 4.0-4.15(m, 2H), 3.85-3.95 (m,1H), 3.81-3.84 (m, 6H), 3.55.3.65(m, 1H), 3.49-3.54 (m, 1H), 3.21-3.27(m, 1H), 2.3-2.4 (m, 1H), 2.15.2.25(m, 1H), 1.94-2.01 (m, 1H), 1.4-1.7(m, 5H)

$^{13}$C-NMR (150 MHz, CDCl$_3$): δ = 172.23, 155.96, 153.14, 149.87, 143.63, 136.32, 128.55, 128.47, 128.06, 127.90, 127.76, 111.88, 103.79, 100.38, 67.54, 67.22, 56.41, 56.17, 55.85, 51.22, 47.79, 45.85, 32.24, 28.81, 28.79, 15.29

HRMS(EI) : m/z: found 468.2261 [M]$^+$, calculated 468.2260 [M]$^+$
7.2.18 Synthesis of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-
diazabicyclo [4.3.1]decane-10-carboxylate 30b

To a solution of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27 (100mg, 0.3mmol) in 2 ml dry THF under argon at 0°C was added NaH (25mg, 0.9mmol) and stirred for 15 min followed by addition of commercially available 3,4-dimethoxyphenethyl bromide 28b (213mg, 0.9mmol). The mixture was stirred at room temperature for 2 days and concentrated \textit{in vacuo}. A 10% HCl solution (5 ml) was added and extracted with DCM (4 x 10 ml). The organic phases were dried over MgSO₄, concentrated \textit{in vacuo} and purified by flash chromatography with hexane: EtOAc 1:2.

TLC [Hexane: EtOAc 1:2]: \( R_f = 0.44 \)

Yield: 39mg, 0.1mmol (25%)

\( ^1\)H-NMR (600 MHz, CDCl₃): \( \delta = 7.27-7.39 \) (m, 5H), 6.72-6.78 (m, 3H), 5.13-5.17 (m, 2H), 5.09-5.13 (m, 0.5H), 4.99-5.05 (m, 0.5H), 4.45-4.65 (m, 1H), 3.8-3.9 (m, 6H), 3.45-3.77 (m, 4H), 3.27-3.37 (m, 1H), 2.85-2.95 (m, 1H), 2.70-2.85 (m, 2H), 2.30-2.45 (m, 1H), 2.00-2.20 (m, 1H), 1.50-1.80 (m, 3H), 0.86-0.94 (m, 1H)

\( ^{13}\)C-NMR (150 MHz, CDCl₃): \( \delta = 171.81, 171.85, 155.71, 155.90, 148.90, 147.58, 147.52, 136.40, 131.58, 131.23, 128.55, 128.52, 128.17, 128.10, 127.95, 127.80, 120.74, 120.68, 112.05, 111.93, 111.19, 111.14, 67.52, 67.45, 56.17, 55.88, 55.85, 53.65, 53.20, 46.55, 46.27, 46.20, 45.73, 33.79, 33.72, 33.25, 31.90, 28.76, 28.65, 15.33, 15.24)

HRMS: m/z: found 468.2484 [M]+, calculated 453.2389 [M]+

7.2.19 Synthesis of 3- (2- (3, 4- dimethoxyphenoxy) ethyl) -3, 9-
diazabicyclo [3.3.1]nonan-2-one 31a

To a solution of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 30a (104mg, 0.2mmol) in 1 ml anhydrous MeOH, catalytic amounts of palladium on carbon was added. The reaction mixture was degassed with H₂ and stirred at room temperature under 1 atm H₂ for 2 h, filtered through celite, concentrated \textit{in vacuo} and used for the next step without further purification.
TLC [MeOH: CHCl₃ 1:9]: Rᵢ = 0.4
Yield: 73mg, 0.2mmol (100%)
¹H-NMR (600 MHz, CDCl₃) δ= 6.80(d, 1H, J=8.75 Hz), 6.51(s, 1H), 6.39-6.44(m, 1H), 4.15-4.25(m, 2H), 3.9-4(m, 1H), 3.8-3.89(m, 7H), 3.54-3.64(m, 2H), 3.45-3.51(m, 1H), 3.35-3.43(m, 1H), 2.39(s, 1H), 1.55-2(m, 6H)
¹³C NMR (300 MHz, CDCl₃) δ= 171.35, 153.08, 149.89, 143.71, 111.95, 104.02, 100.53, 66.81, 56.45, 55.9, 54.4, 54.3, 46.6, 45.9, 31.8, 28.9, 18.22
HRMS : m/z: found 321.1808[M + H]⁺, calculated 321.1814[M + H]⁺

7.2.20 Synthesis of 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-3, 10-diazabicyclo [4.3.1] decan-2-one 32a

To a solution of benzyl 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 30a (60mg, 0.1mmol) in 1 ml anhydrous MeOH, catalytic amounts of palladium on carbon was added. The reaction mixture was degassed with H₂ and stirred under 1 atm H₂ at room temperature for 1 h, filtered through celite, concentrated in vacuo and used for the next step without further purification.
TLC [10% MeOH in CHCl₃]: Rᵢ = 0.17
Yield: 41mg, 0.1mmol (97%)
¹H-NMR (600 MHz, CDCl₃): δ= 6.76 (d, 1H), 6.50 (d, 1H), 6.40 (m, 1H), 4.08-4.15 (m, 3H), 3.85(s, 3H), 3.83 (s, 3H), 3.75-3.82(m, 3H), 3.33-3.35 (m, 1H), 3.2-3.26 (m, 1H), 2.23-2.24 (m, 1H), 1.98-2.12(m, 2H), 1.5-1.75 (m, 6H)
¹³C-NMR (150 MHz, CDCl₃): δ= 172.23, 153.27, 149.85, 143.56, 111.90, 103.89, 100.48, 67.32, 57.97, 56.43, 55.86, 51.05, 47.99, 45.91, 33.79, 30.28, 29.68, 29.85.
MS (ESI) m/z: found 335.13 [M + H]⁺, calculated 335.19[M + H]⁺

7.2.21 Synthesis of 3-(3,4-dimethoxyphenethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32b

To a solution of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decane-10-carboxylate 30b (10mg, 0.02mmol) in 1 ml anhydrous
7. Experimental Section

MeOH, catalytic amounts of palladium on carbon was added. The reaction mixture was degassed with H\textsubscript{2} and stirred under 1 atm H\textsubscript{2} at room temperature for 1 h, filtered through celite, concentrated \textit{in vacuo} and used for the next step without further purification.

TLC [10\% MeOH in CHCl\textsubscript{3}]: \textit{R}\textsubscript{f} = 0.51

Yield: 5mg, 0.02mmol (71%)

MS (ESI) m/z: found 319.42 [M + H]\textsuperscript{+}, calculated 319.20 [M + H]\textsuperscript{+}

7.2.22 Synthesis of 2-oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a

1-(3,4,5-Trimethoxyphenyl)ethanone (2.93g, 13.9mmol) and selenium dioxide (2.32g, 20.9mmol) in 60 ml pyridine were heated to 100° C for 14 h. The mixture was filtered through celite, concentrated \textit{in vacuo} and purified by flash chromatography with hexane: EtOAc: AcOH 1:15:1.

TLC [Hexane: EtOAc: AcOH 1:15:1]: \textit{R}\textsubscript{f} = 0.14

Yield: 2.19g, 9.1mmol (65%)

\textsuperscript{1}HNMR (600 MHz, CDCl\textsubscript{3}) \textit{δ} = 3.91(s, 6H), 3.95(s, 3H), 7.50 (s, 2H)

\textsuperscript{13}C NMR (150 MHz, CDCl\textsubscript{3}) \textit{δ} = 56.31, 61.03, 108.04, 127.55, 144.19, 153.06, 165.74, 186.94

HRMS(EI): m/z: found 240.0624[M]\textsuperscript{+}, calculated 240.0634[M]\textsuperscript{+}

7.2.23 Synthesis of 3,3-dimethyl-2-oxopentanoic acid 33b

To a solution of NaOH (175mg, 4.4mmol) and KMnO\textsubscript{4} (543mg, 3.4mmol) in 5 ml water at 0° C was added 3,3-dimethyl-2-pentanone (200mg, 1.8mmol). After stirring for 1 h at 0° C and 3 days at room temperature, the reaction was acidified with concentrated HCl and extracted with DCM (4 x 10 ml). The organic phases were dried over MgSO\textsubscript{4}, concentrated \textit{in vacuo} and purified by flash chromatography with hexane: EtOAc 5:1.

TLC [Hexane: EtOAc 5:1]: \textit{R}\textsubscript{f} = 0.45

Yield: 97mg, 0.7mmol (39%)
7. Experimental Section

$^1$HNMR (300 MHz, CDCl$_3$) $\delta=1.61(q, 2H, J=7.49,7.49,7.51Hz), 1.21(s, 6H), 0.91(t,3H, J=7.49,7.49Hz),$

$^{13}$C NMR (150 MHz, CDCl$_3$) $\delta= 9.18, 24.38, 33.13, 42.49, 185.25$

7.2.24  Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)eth.yl)-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione 4a

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (35mg, 0.1mmol) in 6 ml DCM was treated sequentially with 2-oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a (29mg, 0.1mmol), EDC-HCl (20mg, 0.1mmol), HOBt (18mg, 0.1mmol), TEA (13mg, 0.1mmol) at room temperature and stirred overnight. The reaction was quenched with saturated NH$_4$Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO$_4$ and concentrated in vacuo. The mixture was purified by flash chromatography with EtOAc.

TLC [EtOAc]: $R_f = 0.54$

HPLC [0-100% Solvent B, 30 min]: $R_t = 21.5$ min, purity (280 nm) = 99%

Yield: 14mg, 0.03mmol (24%)

$^1$HNMR (600 MHz, CDCl$_3$) $\delta= 7.19(d, 2H, J=22.63), 6.72-6.8(m, 1H), 6.42-6.48(m, 1H), 6.34-6.39(m, 1H), 5.22(s, 0.5H), 5.07(s, 0.5H), 4.17-4.27(m, 1.5H), 4.08-4.16(m, 1.5H), 4.04-4.07(m, 0.5H), 3.97-4.04(m, 1.5H), 3.94(d, 3H, J=7.39), 3.79-3.92(m, 12H), 3.62-3.65(m, 0.5H), 3.47-3.56(m, 1.5H), 2.13-2.18(m, 0.5H), 1.93-2.02(m, 1.5H), 1.79-1.9(m, 2H), 1.7-1.78(m, 2H)

$^{13}$C NMR (300 MHz, CDCl$_3$) $\delta= (189.57, 189.30), (167.24, 166.73), (163.90, 163.38), 153.43, 153.39, (152.77, 152.76), (149.92, 149.90), (144.48, 144.46), (143.88, 143.85), (127.86, 127.74), (111.87, 111.85), (107.09, 107.00), (103.94, 103.85), (100.36, 100.35), (66.81, 66.80), (61.07, 61.04), 60.38, (56.39, 56.36), (56.29,56.14), (55.89, 55.86), (53.39, 52.68), 51.17, 49.36, (46.71, 46.55), 42.84, (31.35, 30.49), (28.95, 28.30), (18.03, 17.92)

HRMS(EI) : m/z: found 542.2264 [M] $^+$, calculated 542.2264 [M] $^+$
7.2.25 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-yl)-3,3-dimethylpentane-1,2-dione 4b

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (20mg, 0.06mmol) in 3 ml DCM was treated sequentially with 3,3-dimethyl-2-oxopentanoic acid 33b (18mg, 0.13mmol), EDC-HCl (23mg, 0.13mmol), HOBT (17mg, 0.13mmol), TEA (8mg, 0.08mmol) at room temperature and stirred overnight. The reaction was quenched with saturated NH\(_4\)Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO\(_4\) and concentrated in vacuo. The mixture was purified by flash chromatography with EtOAc.

TLC [EtOAc]: R\(_f\) = 0.6

HPLC [0-100% Solvent B, 16 min]: R\(_t\) = 14.9 min, purity (280 nm) = 98%

Yield: 21mg, 0.05mmol (76%)

\(^1\)HNMR (600 MHz, CDCl\(_3\)) \(\delta\) = 6.74 (d, 1H, J=8.76 Hz), 6.44(t, 1H, J=2.86, 2.86 Hz), 6.35(dt, 1H, J=2.95, 2.95, 8.74Hz), 5.04 (s, 0.5H), 4.89(s, 0.5H), 4.16(ddd, 2H, J=6.88, 11.94, 14.20Hz), 3.85-4.03(m, 2.5H), 3.83(d, 3H, J=2.67Hz), 3.80(s, 3H), 3.69-3.75(m, 1H), 3.56-3.63(m, 0.5H), 3.46-3.54(m, 1H), 1.95-2.1(m, 1H), 1.75-1.9(m, 3H), 1.65-1.57(m, 4H), 1.16-1.26(m, 3H), 1.11(d, 3H, J=5.56 Hz), 0.78-0.88(m, 3H)

\(^{13}\)C NMR (300 MHz, CDCl\(_3\)) \(\delta\) = (207.03, 206.85), (167.30, 166.9), (164.44, 163.63), (152.85, 152.84), 149.88, 143.81, (111.92, 111.87), (103.99, 103.83), (100.43, 100.42), (67.92, 25.57), (66.82, 66.59), (56.39, 56.09), (55.86, 55.83), (53.36, 52.50), (50.76, 42.32), (48.16, 46.47), (46.71, 46.64), (32.40, 32.32), (31.26, 27.96), (30.19, 28.51), (23.63, 23.37), (23.33, 22.84), (18.00, 17.94), (8.84, 8.71)

HRMS : m/z: found 446.2413[M + H], calculated 446.2417[M + H]

7.2.26 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-diazabicyclo [4.3.1]decan-10-yl)-3,3-dimethylpentane-1,2-dione 5b

To a solution of 3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo [4.3.1]decan-2-one 32a (22mg, 0.06mmol) in 3 ml DCM was added sequentially 3,3-dimethyl-2-oxopentanoic acid 33b (19mg, 0.1mmol), EDC-HCl (25mg, 0.1mmol), HOBT (17mg, 0.1mmol), TEA (8mg, 0.08mmol) at room temperature and stirred overnight. The reaction was quenched with saturated NH\(_4\)Cl solution (5 ml), extracted with DCM (4 x
10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The reaction mixture was purified by flash chromatography with EtOAc.

TLC [EtOAc]: Rᵢ = 0.69

HPLC [0-100% Solvent B, 16 min]: Rᵢ = 10.2 min, purity (280 nm) = 98%

Yield: 18mg, 0.04mmol (60%)

¹H-NMR (600 MHz, CDCl₃): δ = 6.77(d, J=8.75) 1H, 6.47-6.5(m,1H), 6.37-6.4(m, 1H), 5.36-5.38 (m, 0.5H), 4.88-4.94 (m, 0.5H), 4.14-4.17(m, 1H), 4.09-4.14(m, 1H), 4.01-4.07(m, 1.5H), 3.96-4.01 (m, 0.5H), 3.92-3.955 (m, 0.5H), 3.85-3.88 (m, 0.3H), 3.85(s, 3H), 3.832-3.84(m, 0.2H), 3.83(d, J=1.69, 3H), 3.77-3.81(m, 0.5H), 3.66-3.77(m, 1.5H), 3.56-3.62(m, 0.5H), 3.28-3.35(m, 1H), 2.44-2.50(m, 1H), 2.36-2.42(m, 1H), 2.27-2.34(m, 1H), 2.16-2.23(m, 1H), 1.99-2.08(m, 1H), 1.78-1.86(m, 1H), 1.52-1.74(m, 6H), 1.24(s, 1.5H), 1.12-1.19(m, 4.5H), 0.82-0.91(m, 3H)

¹³C-NMR (150 MHz, CDCl₃): δ = (208.39, 207.54), (170.67, 170.39), (167.50, 166.19), (153.11, 153.06), 149.85, (143.68, 143.65), (111.92, 111.85), (103.95, 103.90), (100.53, 100.47), (67.20, 67.17), (58.59, 49.40) (56.41, 56.40), 55.85, (52.74, 43.06), (51.32, 51.13), (47.73, 47.39), (46.71, 46.52), (32.57, 31.90), (32.54, 32.53), (30.02, 28.72), (29.25, 29.11), (24.11, 23.39), (23.05, 22.7), (15.81, 15.67), (8.74,8.73)

HRMS(EI) : m/z: found 460.2571 [M]⁺, calculated 460.2573 [M]⁺

7.2.27 Synthesis of 1-(3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-diazabicyclo [4.3.1]decan-10-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione 5d

To a solution of 3-(3,4-dimethoxyphenethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32b (27mg, 0.09mmol) in 3 ml DCM were added sequentially 2-oxo-2-(3,4,5-trimethoxyphenyl) acetic acid 33a (23mg, 0.1mmol), EDC-HCl (20mg, 0.1mmol), HOBT (14mg, 0.1mmol) and TEA (10mg, 0.1mmol) at room temperature followed by stirring overnight. The reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The reaction mixture was purified by flash chromatography with EtOAc.

TLC [EtOAc]: Rᵢ = 0.42

HPLC [0-100% Solvent B, 16 min]: Rᵢ = 14.4 min, purity (280 nm) = 99%
Yield: 35mg, 0.07mmol (75%)

$^1$H-NMR (600 MHz, CDCl$_3$): $\delta$ = 7.17(d, 2H ,J=2.09), 6.74-6.82 (m, 5H), 4.27-4.30(m, 1H), 3.94(d, 3H, J=4.9), 3.90(d, 6H, J=3.27), 3.87(d, 3H, J=2.64), 3.85(d, 3H, J=2.45), 3.80-3.84(m, 1H), 3.66-3.78 (m, 2H), 3.54-3.66 (m, 1H), 2.96-3.03 (m, 1H), 2.78-2.87 (m, 2H), 2.50-2.58 (m, 1H), 2.32-2.38 (m, 1H), 2.23-2.31 (m, 1H), 2.05-2.12 (m, 1H), 1.77-1.91 (m, 2H), 1.69-1.76 (m, 1H), 1.51-1.59 (m, 1H)

$^{13}$C NMR (150 MHz, CDCl$_3$): $\delta$ = (190.59, 190.23), 171.11, (170.02, 169.72), (166.95, 165.85), (155.48, 153.44), (148.95, 148.91), (147.63, 147.61), (144.44, 144.38), (131.40, 131.30), (127.99, 127.81), (120.78, 120.77), (112.05, 111.97), (111.33, 111.28), (106.94, 106.78), (61.06, 61.05), 58.71, (56.38, 56.35), (55.92, 55.89), (55.86, 55.85), (53.63, 53.35), 53.05, 49.61, (46.38, 46.26), 43.15, (33.89, 33.75), (33.25, 32.06), 30.15, (29.65, 29.45), (29.2, 28.95), 21.03, (15.78, 15.58), 14.18

MS (ESI) m/z: found 541.27 [M + H]$^+$, calculated 541.25
HRMS(El) : m/z: found 540.2479 [M]$^+$, calculated 540.2472 [M]$^+$

**7.2.28 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-diazabicyclo [4.3.1]decan-10-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione 5a**

3-(2-(3,4-Dimethoxyphenoxy) ethyl)-3,10-diazabicyclo [4.3.1] decan-2-one 32a (20mg, 0.06mmol) in 3 ml DCM were treated sequentially with 2-oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a (16mg, 0.07mmol), EDC-HCl (14mg, 0.07mmol), HOBt (10mg, 0.07mmol) and TEA (7mg, 0.07mmol) at room temperature followed by stirring for 6 h. The reaction was quenched with saturated NH$_4$Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO$_4$ and concentrated in vacuo. The reaction mixture was purification by flash chromatography with EtOAc.

TLC [EtOAc]: R$_t$ = 0.23
HPLC [0-100% Solvent B, 30 min]: R$_t$ = 23.2 min, purity (280 nm) = 98%
Yield: 22mg, 0.04mmol (67%)

$^1$H-NMR (600 MHz, CDCl$_3$): $\delta$ = 7.2(d, 2H, J=3.95), 6.78-6.82 (m, 1H), 6.51-6.55 (m, 1H), 6.4-6.46 (m, 1H), 5.59(s, 0.5H), 5.12(s, 0.5H), 4.0-4.36 (m, 5H), 3.97 (d, 3H,
7. Experimental Section

J=2.62), 3.92 (d, 6H, J=2.23), 3.88(d, 3H, J=2.67), 3.86(d, 3H, J=2.02), 3.6-3.7(m, 1H), 3.36-3.46 (m, 1H), 2.4-2.6 (m, 2H), 1.5-1.8 (m, 6H)

$^{13}$C-NMR (150 MHz, CDCl$_3$): δ=(190.62, 190.22), (170.56, 170.30), 167.04, 165.98, (153.54, 153.49), (153.14, 153.13), 149.95, (144.51, 144.48), (143.80, 143.77), (128.04, 127.86), (112.02, 111.99), 107.01, 106.88, (104.15, 104.09), (100.65, 100.55), (67.33, 67.29), (61.09, 61.07), 58.68, 56.46, 56.45, 56.39, 55.91, 53.09, (51.27, 51.23), 49.81, (47.58, 43.38), (29.7, 29.66), 29.47, 29.03

HRMS(EI) : m/z: found 556.2417 [M$^+$], calculated 556.2421 [M$^+$]

7.2.29 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decan-10-yl)-2-((1S)-2-ethyl-1-hydroxycyclohexyl)ethane-1,2-dione 5c

2-((1S,2R)-2-Ethyl-1-hydroxycyclohexyl)-2-oxoacetic acid (25mg, 0.1mmol)$^{196}$ in 3 ml DCM was treated sequentially with HATU (55mg, 0.1mmol), TEA (15mg, 0.1mmol), and 3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32a (40mg, 0.1mmol) at room temperature followed by stirring overnight. The reaction was quenched with saturated NH$_4$Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO$_4$ and extracted with DCM (4 x 10 ml). The mixture was purified by preparative TLC in EtOAc.

TLC [EtOAc]: $R_f$ = 0.63

HPLC [0-100% Solvent B, 30 min]: $R_t$ = 23.2 min, purity (280 nm) = 98%

Yield: 14mg, 0.03mmol (23%)

$^1$HNMR (600 MHz, CDCl$_3$) δ= 6.78-6.84(m, 1H), 6.52-6.56(m, 1H), 6.38-6.44(m, 1H), 5-5.06(m, 1H), 4.68-6.76(m, 0.5H), 4.05-4.13(m, 0.5H), 3.93-4.03(m, 2H), 3.74-3.84(m, 2H), 3.64-3.74(m, 6H), 3.46-3.64(m, 2H), 3.2-3.3(m, 2H), 2.05-2.3(m, 2H), 1.75-1.95(m, 1H), 1.35-1.7(m, 9H), 1.05-1.3(m, 4H), 0.78-0.86(m, 1H), 0.65-0.85(m, 3H)

$^{13}$C NMR (100 MHz, CDCl$_3$) δ= (209.75, 209.20, 208.90, 208.75), (170.27, 170.25, 169.95, 169.75), (168.00, 167.95, 167.70, 167.30), (153.30, 153.27, 153.25), (150.15, 150.13), (143.71,143.67), (113.33, 113.27), (104.80, 104.77, 104.65), (101.28, 101.26, 101.24, 101.16), (81.66, 81.26, 81.19, 81.17), (66.37, 66.30, 66.26, 66.18), 58.13, 56.54, 55.90, (52.80, 52.66), (50.18, 50.12, 50.08, 50.02), (49.15,
7. Experimental Section

49.25), (46.82, 46.65, 46.48, 46.35), (43.90, 43.50, 43.46, 43.37), (32.20, 32.05, 31.95, 31.80), (29.45, 29.40, 29.30, 29.25), (29.23, 29.17, 29.15, 29.13), (28.85, 28.83, 28.73, 28.67), (25.23, 25.15, 25.07, 25.03), (23.23, 23.07, 23.03, 22.52), (20.67, 20.57, 20.50, 20.47), (15.85, 15.75, 15.65), (12.37, 12.27, 12.25, 12.23)

HRMS: m/z: found 517.3024 [M]⁺, calculated 517.2914 [M + H]⁺

7.2.30 Synthesis of 1-tert-butyl 2-(2-(3,4-dimethoxyphenoxy)ethyl) piperidine-1,2-dicarboxylate 38

38 was prepared as described. 196

7.2.31 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39

1-tert-Butyl 2-(2-(3,4-dimethoxyphenoxy)ethyl) piperidine-1,2-dicarboxylate 38 (456mg, 1.1mmol) in 10 ml 20% TFA in DCM was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo and used for next step without further purification.

TLC [Hexane: EtOAc: TEA 7.5:2.3:0.4]: Rf = 0.19

Yield: 344mg, 1.1mmol (100%)

¹H NMR (600 MHz, CDCl₃) δ = 6.76 (d, 1H, J= 9 Hz), 6.50 (d, 1H, J= 3 Hz), 6.35 (dd, 1H, J= 3, 9 Hz), 4.45-4.54(m, 2H), 4.11 (t, 2H, J= 4.2 Hz), 3.92 (dd, 1H, J= 3.6, 11.4 Hz), 3.83 (s, 3H), 3.82 (s, 3H), 3.55 (d, 1H, J= 12.6 Hz), 2.99-3.04 (m, 1H), 2.24-2.28(m, 1H), 1.82-1.97 (m, 4H), 1.54-1.61 (m, 1H),

¹³C NMR (150 MHz, CDCl₃) δ = 168.48, 152.71, 149.91, 143.98, 111.74, 103.94, 100.97, 65.85, 64.71, 56.83, 56.39, 55.81, 44.14, 25.60, 21.74, 21.50,

HRMS(EI): m/z: found 309.1580 [M]⁺, calculated 309.1576 [M]⁺

7.2.32 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate 6a
7. Experimental Section

2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.2mmol) in 10 ml acetonitrile under argon was treated sequentially with DIPEA (63mg, 0.5mmol), 2-oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a (44mg, 0.2mmol) and HATU (58mg, 0.2mmol). After stirring at room temperature for 3 days, it was concentrated in vacuo followed by addition of 5 ml H2O and extraction with DCM (3 x 10 ml). The organic phases were dried over MgSO4, concentrated in vacuo and purified by flash chromatography with hexane: EtOAc 3:1. TLC [Hexane: EtOAc 1:1]: Rf = 0.32

HPLC [0-100% Solvent B, 16 min]: Rf = 15.5 min, purity (280 nm) = 99%

Yield: 36mg, 0.07mmol (42%)

1H NMR (300 MHz, CDCl3) δ = 7.33-7.39(m, 1.5H), 7.21-7.23(m, 0.5H), 6.73-6.8(m, 1H), 6.46-6.54(m, 1H), 6.3-6.43(m, 1H), 5.41-5.46(m, 1H), 4.5-4.65(m, 2H), 4.1-4.2(m, 2H), 3.94(d, 9H, J=1.96Hz), 3.84(d, 6H, J=2.16 Hz), 3.22-3.54(m, 2H), 2.2-2.44(m, 2H), 1.73-1.88(m, 2H), 1.51-1.69(m, 2H)

13C NMR (300 MHz, CDCl3) δ = (190.83, 190.34), (170.44, 170.19), (167.89, 166.87), (153.54, 153.27), (152.92, 152.78), (149.96, 149.92), (144.01, 143.99), (128.11, 128.01), (111.78, 111.76), 107.25, 107.00, (104.05, 104.0), (101.16, 101.08), (66.34, 66.27), (63.80, 63.78), (60.98, 60.35), 56.43, 56.41, 56.31, 55.87, 51.75, 44.26, 26.31, 24.75, (21.16, 21.02)

HRMS(EI) : m/z: found 531.2105 [M]+, calculated 531.2104 [M]+

7.2.33 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(3,5-dichlorophenylsulfonyl)piperidine-2-carboxylate 6e

2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.16mmol) in 1 ml DCM was treated with DIPEA (63mg, 0.49mmol) and stirred for 30min at room temperature followed by addition of 3,5-dichlorobenzene sulfonyl chloride 34a (40mg, 0.16mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH4Cl solution (5 ml), extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 and concentrated in vacuo. The mixture was purified with preparative TLC in cyclohexane:EtOAc 3:1.

TLC [Cyclohexane: EtOAc 3:1]: Rf = 0.57

HPLC [0-100% Solvent B, 30 min]: Rf = 27.2 min, purity (280 nm) = 99%
7. Experimental Section

Yield: 17mg, 0.03mmol (20%)

$^1$H NMR (600 MHz, CDCl$_3$) δ = 7.64(d, 2H, J=1.85Hz), 7.49 (t, 1H, J=1.86, 1.86Hz), 6.76(d, 1H, J=8.76Hz), 6.48(d, 1H, J=2.8Hz), 6.34(dd, 1H, J=2.83, 8.73Hz), 4.75-4.8(m, 1H), 4.35-4.4(m, 1H), 4.25-4.3(m, 1H), 4.03-4.08(m, 1H), 3.97-4.03(m, 1H), 3.83(d, 6H, J=7.88Hz), 3.72-3.77(m, 1H), 3.16-3.24(m, 1H), 2.16-2.21(m, 1H), 1.73-1.85(m, 1H), 1.65-1.71(m, 1H), 1.47-1.63(m, 2H), 1.33-1.36(m, 0.5H)

$^{13}$C NMR (300 MHz, CDCl$_3$) δ = 170.23, 152.82, 149.92, 143.99, 142.67, 135.64, 132.29, 125.55, 111.76, 103.99, 101.06, 66.13, 63.48, 56.41, 55.85, 55.31, 42.88, 27.92, 24.73, 19.88

HRMS: m/z: found 518.1343 [M + H]$^+$, calculated 518.0807 [M + H]$^+$

7.2.34 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(benzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate 6f

2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.16mmol) in 1 ml DCM under argon was treated sequentially with DIPEA (42mg, 0.32mmol) and 1,3-benzothiazole-6-sulfonyl chloride 34b (76mg, 0.32mmol). After stirring at room temperature overnight, the reaction was quenched with saturated NH$_4$Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO$_4$ and concentrated in vacuo. The mixture was purified by flash chromatography with cyclohexane: EtOAc 1:1.

TLC [Cyclohexane: EtOAc 1:1]: R$_f$ = 0.3

HPLC [0-100% Solvent B, 30min]: R$_t$ = 23.7 min, purity (280 nm) = 98%

Yield: 39mg, 0.077mmol (48%)

$^1$H NMR (300 MHz, CDCl$_3$) δ = 9.18-9.22(m, 1H), 8.47-8.51(m, 1H), 8.19-8.24(m, 1H), 7.90-7.96 (m, 1H), 6.75-6.81(m, 1H), 6.47-6.51(m, 1H), 6.31-6.37(m, 1H), 4.85-4.91 (m, 1H), 4.09-4.38 (m, 2H), 3.89-4.05(m, 2H), 3.83-3.89 (d, 6H, J=2.01Hz), 3.74-3.83(m, 1H), 3.21-3.34(m, 1H), 2.15-2.25(m, 1H), 1.74-1.88(m, 1H), 1.62-1.74(m, 2H), 1.3-1.62(m, 2H)

$^{13}$C NMR (75 MHz, CDCl$_3$) δ = 170.56, 157.63, 155.2, 152.84, 149.94, 144.01, 137.34, 133.95, 124.98, 123.98, 122.00, 111.80, 104.07, 101.09, 66.16, 63.37, 56.44, 55.89, 55.21, 42.80, 27.94, 24.75, 19.98

HRMS: m/z: found 507.1779 [M + H]$^+$, calculated 507.1260 [M + H]$^+$
7.2.35 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(2-oxo-2,3-dihydrobenzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate 6g

2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.16mmol) in 1 ml DCM under argon was treated sequentially with DIPEA (42mg, 0.32mmol) and 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (81mg, 0.32mmol). After stirring at room temperature overnight, the reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified with preparative HPLC using a gradient of 40-50% buffer B in 16 minutes.

TLC [Cyclohexane: EtOAc 1:1]: Rᵢ = 0.74
HPLC [0-100% Solvent B, 30 min]: Rᵢ = 22.0 min, purity (280 nm) = 99%
Yield: 28mg, 0.05mmol (33%)

¹H NMR (400 MHz, DMSO-D₆) δ = 12.30(s, 1H), 8.05(d, 1H, J=1.86Hz), 7.62(dd, 1H, J=1.96, 8.44Hz), 7.19(d, 1H, J=8.45Hz), 6.79(d, 1H, J=8.81Hz), 6.49(d, 1H, J=2.83Hz), 6.35(dd, 1H, J=2.85, 8.75Hz), 4.57-4.68(m, 1H), 4.10-4.28(m, 2H), 3.91-4.07(m, 2H), 3.68(s, 3H), 3.64(s, 3H), 3.54-3.62(m, 1H), 3.01-3.14(m, 1H), 1.87-1.98(m, 1H), 1.44-1.62(m, 3H), 1.04-1.29(m, 2H)

¹³C NMR (100 MHz, DMSO-D₆) δ = 170.75, 170.61, 152.97, 150.09, 143.80, 140.23, 133.95, 126.03, 124.64, 122.46, 113.10, 111.91, 104.79, 101.36, 66.31, 63.65, 56.48, 55.89, 55.13, 42.72, 27.64, 24.39, 19.82

HRMS : m/z: found 523.1185 [M + H]⁺, calculated 523.1209 [M + H]⁺

7.2.36 Synthesis of 9-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,9-diazabicyclo [3.3.1]nonan-2-one 4e

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (24mg, 0.08mmol) in 3 ml DCM was treated with DIPEA (12mg, 0.09mmol) and stirred for 30min at room temperature followed by addition of 3,5-dichlorobenzene sulfonyl chloride 34a (22mg, 0.09mmol). After stirring for 6 h at room temperature, the reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified by flash chromatography with hexane:EtOAc 1:1.
7. Experimental Section

TLC [EtOAc]: R\textsubscript{f} = 0.48
HPLC [0-100% Solvent B, 30 min]: R\textsubscript{t} = 23.8 min, purity (280 nm) = 99%
Yield: 21mg, 0.04mmol (53%)

\begin{align*}
^1\text{HNMR (600 MHz, CDCl}_3\text{)} \delta &= 7.66-7.73(m, 2H), 7.33-7.39(m, 1H), 6.74-6.79(m, 1H), 6.36-6.41(m, 1H), 6.28-6.33(m, 1H), 4.43(s, 1H), 4.28-4.33(m, 1H), 4.04-4.10(m, 1H), 3.88-3.94(m, 1H), 3.73(d, 6H, J= 6.56 Hz ), 3.65-3.72(m, 1.5H), 3.55-3.62(m, 1H), 3.3-3.37(m, 1.5H), 1.88-2.02(m, 2H), 1.72-1.84(m, 2H), 1.54-1.72(m, 2H) \\
^{13}\text{C NMR (300 MHz, CDCl}_3\text{)} \delta &= 166.85, 152.74, 149.83, 143.85, 142.76, 136.14, 132.87, 125.29, 111.92, 103.94, 100.36, 66.89, 56.45, 55.85, 55.12, 52.12, 47.40, 46.57, 31.46, 28.13, 17.27 \\
\text{HRMS(EI) : m/z: found 528.0893 [M]^+ , calculated 528.0889[M]^+}
\end{align*}

7.2.3 Synthesis of 9-(benzo[d]thiazol-6-ylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 4f

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (32mg, 0.1mmol) in 3 ml DCM was treated with DIPEA (15mg, 0.12mmol) and stirred for 30min at room temperature followed by addition of 1,3-benzothiazole-6-sulfonyl chloride 34b (28mg, 0.12mmol). The reaction was stirred overnight at room temperature. The reaction was quenched with saturated NH\textsubscript{4}Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO\textsubscript{4} and concentrated \textit{in vacuo}. The mixture was purified with preparative TLC in 10% MeOH in CHCl\textsubscript{3}.

TLC [EtOAc]: R\textsubscript{f} = 0.47
HPLC [0-100% Solvent B, 16 min]: R\textsubscript{t} = 19.5 min, purity (280 nm) = 99%
Yield: 8mg, 0.02mmol (15%)

\begin{align*}
^1\text{HNMR (600 MHz, CDCl}_3\text{)} \delta &= 9.13(s, 1H), 8.51(d, 1H, J= 1.33Hz), 8.18(d, 1H, J= 8.62Hz), 7.93 (dd, 1H, J= 1.87, 8.63Hz), 6.72(d, 1H, J=8.79Hz), 6.31(d, 1H, J= 2.82Hz), 6.18-6.23(m, 1H), 4.43-4.46(m, 1H),4.35-4.39(m, 1H), 3.92-3.98(m, 1H), 3.78-3.83(m, 6H), 3.7-3.74(m, 1H), 3.5-3.59(m, 2H), 3.29-3.33(m, 1H), 2.97-3.05(m, 1H), 1.96-2.01(m, 1H), 1.9-1.96(m, 1H), 1.76-1.84(m, 1H), 1.7-1.75(m, 1H), 1.6-1.68(m, 2H) \\
\end{align*}
7. Experimental Section

$^{13}$C NMR (300 MHz, CDCl$_3$) δ = 167.25, 158.13, 155.6, 152.66, 149.80, 143.76, 136.86, 134.3, 124.55, 124.38, 122.18, 111.83, 103.86, 100.29, 66.60, 56.39, 55.84, 55.03, 51.90, 47.21, 46.23, 31.53, 28.04, 17.30

HRMS(EI) : m/z: found 517.1340 [M]+, calculated 517.1341 [M]+

7.2.38 Synthesis of 10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5e

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32a (22mg, 0.07mmol) in 3 ml DCM was treated with DIPEA (10mg, 0.08mmol) and stirred for 30min at room temperature followed by addition of 3,5-dichlorobenzenesulfonyl chloride 34a (19mg, 0.08mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH$_4$Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO$_4$ and concentrated in vacuo. The mixture was purified by flash chromatography with cyclohexane:EtOAc 2:1.

TLC [Cyclohexane/EtOAc 1:1]: R$_f$ = 0.40

HPLC [0-100% Solvent B, 30 min]: R$_t$ = 25.5 min, purity (280 nm) = 99%

Yield: 16mg, 0.03mmol (45%)

$^1$HNMR (600 MHz, CDCl$_3$) δ = 7.69(s, 1H), 7.68(s, 1H), 7.48-7.53(m, 1H), 6.74-6.8(m, 1H), 6.47-6.5(m, 1H), 6.36-6.41(m, 1H), 4.68-4.72(m, 1H), 4.34-4.42(m, 1H), 4.07-4.17(m, 2H), 3.98-4.07(m, 1H), 3.93-3.98(m, 1H), 3.86(s, 3H), 3.82(s, 3H), 3.64-3.68(m, 2H), 3.43-3.48(m, 0.5H), 3.31-3.4(m, 1.5H), 2.2-2.3(m, 2H), 1.95-2.05(m, 2H), 1.55-1.75(m, 2H)

$^{13}$C NMR (300 MHz, CDCl$_3$) δ = 170.50, 153.15, 149.9, 144.15, 143.75, 136.30, 132.63, 124.92, 111.98, 104.06, 100.56, 67.25, 57.05, 56.45, 55.90, 51.42, 51.36, 49.1, 48.2, 32.7, (28.35, 27.9), (14.8, 14.1)

HRMS(EI) : m/z: found 542.1045 [M]^+, calculated 542.1045 [M]^+

7.2.39 Synthesis of 10-(benzo[d]thiazol-6-ylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5f

98
7. Experimental Section

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one **32a** (24mg, 0.07mmol) in 3 ml DCM was treated with DIPEA (11mg, 0.09mmol) and stirred for 30min at room temperature followed by addition of 1,3-benzothiazole-6-sulfonyl chloride **34b** (20mg, 0.09mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH₄Cl solution (5 ml), extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified with preparative TLC in 10% MeOH in CHCl₃.

TLC [EtOAc]: Rᵣ = 0.54
HPLC [0-100% Solvent B, 30 min]: Rᵣ = 20.7 min, purity (280 nm) = 99%
Yield: 5mg, 0.01mmol (13%)

1H NMR (600 MHz, CDCl₃) δ = 9.18(s, 1H), 8.48-8.52(m, 1H), 8.23 (d, 1H, J= 8.63Hz), 7.93(dd, 1H, J=1.86, 8.64Hz), 6.77(d, 1H, J= 8.78Hz), 6.47(d, 1H, J= 2.84Hz), 6.36-6.39(m, 1H), 4.74-4.78(m, 1H), 4.42-4.48(m, 1H), 4.09-4.15(m, 2H), 4.02-4.08(m, 1H), 3.95-3.99(m, 1H), 3.84(s, 3H), .815-3.825(m, 3H), 3.6-3.65(m, 2H), 3.3-3.35(m, 1H), 3.05-3.1(m, 1H), 2.25-2.33(m, 1H), 2.15-2.2(m, 1H), 1.97-2.03(m, 1H), 1.7-1.85(m, 1H), 1.55-1.63(m, 1H), 1.1-1.2(m, 1H)

13C NMR (300 MHz, CDCl₃) δ = 166.1, 153.15, 150.70, 148.4, 145.1, 138.93, 133.75, 129.62, 119.86, 119.35, 116.84, 107.10, 99.21, 95.75, 62.45, 52.15, 51.65, 51.12, 44.03, 43.52, 37.15, 24.93, 27.95, 23.02, 17.85

HRMS : m/z: found 532.1560 [M]⁺, calculated 532.1576[M + H]⁺,

7.2.40 Synthesis of 6-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-ylsulfonyl)benzo[d]thiazol-2(3H)-one **4g**

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one **31a** (40mg, 0.13mmol) in 3 ml DCM was treated with DIPEA (32mg, 0.25mmol) and stirred for 30min at room temperature followed by addition of 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride **34c** (62mg, 0.25mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified by preparative HPLC using a gradient of 50-57% buffer B in 16 minutes.

TLC [EtOAc]: Rᵣ = 0.38
7. Experimental Section

HPLC [0-100% Solvent B, 16 min]: R<sub>t</sub> = 13.0 min, purity (280 nm) = 99%
Yield: 35mg, 0.07mmol (53%)

<sup>1</sup>H NMR (300 MHz, DMSO) δ = 12.33-12.40(m, 1H), 8.11-8.15(m, 1H), 7.64-7.71(m, 1H), 7.20-7.26(m, 1H), 6.75-6.85(m, 1H), 6.44-6.48(m, 1H), 6.23-6.32(m, 1H), 4.19-4.28(m, 1H), 4.12-4.18(m, 1H), 3.71-3.83(m, 2H), 3.69(s, 3H), 3.66(s, 3H), 3.36-3.50(m, 2H), 3.20-3.29(m, 1H), 2.97-3.10(m, 1H), 1.35-1.82(m, 6H)

<sup>13</sup>C NMR (75 MHz, DMSO) δ = 170.69, 166.56, 152.95, 150.12, 143.74, 140.65, 133.40, 126.15, 124.90, 122.45, 113.20, 112.11, 104.48, 101.25, 65.55, 56.51, 55.92, 54.85, 50.70, 47.20, 45.41, 31.27, 28.09, 17.25

HRMS (EI) m/z: found 533.1299[M]<sup>+</sup>, calculated 533.1290[M]<sup>+</sup>

7.2.41 Synthesis of 6-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-diazabicyclo [4.3.1]decan-10-ylsulfonyl)benzo[d]thiazol-2(3H)-one 5g

3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,10-diazabicyclo [4.3.1]decan-2-one 32a (15mg, 0.05mmol) in 3 ml DCM was treated with DIPEA (12mg, 0.09mmol) and stirred for 30min at room temperature followed by addition of 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (22mg, 0.09mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified by preparative HPLC using a gradient of 55-65% buffer B in 16mins.

TLC [EtOAc]: R<sub>f</sub> = 0.54

HPLC [0-100% Solvent B, 16 min]: R<sub>t</sub> = 13.6 min, purity (280 nm) = 99%
Yield: 5mg, 0.01mmol (20%)

<sup>1</sup>H NMR (300 MHz, DMSO) δ = 12.07-12.13(s, 1H), 7.85-7.88(m, 1H), 7.56-7.61(m, 1H), 7.12-7.18(m, 1H), 6.68-6.73(m, 1H), 6.67-6.73(m, 1H), 6.41-6.46(m, 1H), 6.29-6.34(m, 1H), 4.54-4.60(m, 1H), 4.20-4.29(m, 1H), 3.93-4.02(m, 2H), 3.75-3.93(m, 2H), 3.65-3.75(m, 8H), 3.20-3.27(m, 1H), 2.15-2.25(m, 1H), 1.95-2.05(m, 1H), 1.87-1.93(m, 1H), 1.05-1.45(m, 3H)

<sup>13</sup>C NMR (75 MHz, DMSO) δ = 175.49, 175.30, 157.94, 154.62, 148.30, 144.97, 139.84, 129.90, 126.01, 125.95, 117.40, 113.70, 109.12, 105.60, 71.41, 61.47, 61.20, 60.57, 55.53, 53.13, 52.60, 37.32, 32.66, 32.36, 19.54
7. Experimental Section

HRMS (EI) m/z: found 547.1446[M] \(^+\), calculated 547.1447[M] \(^+\)

7.2.42 Synthesis of 3,9-diazabicyclo[3.3.1]nonan-2-one 35

To a solution of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 (84mg, 0.3mmol) in 1 ml anhydrous MeOH were added catalytic amounts of palladium on carbon followed by degassing with H\(_2\). After stirring under 1 atm H\(_2\) at room temperature for 2 h, the reaction mixture was filtered through celite, concentrated \textit{in vacuo} and used for the next step without further purification.

TLC [20% MeOH in CHCl\(_3\)]: \(R_f = 0.17\)

Yield: 35mg, 0.25mmol (82%)

7.2.43 Synthesis of 3,10-diazabicyclo[4.3.1]decan-2-one 36

To a solution of benzyl 2-oxo-3,10-diazabicyclo [4.3.1] decane-10-carboxylate 27 (33mg, 0.1mmol) in 1 ml anhydrous MeOH were added catalytic amounts of palladium on carbon followed by degassing with H\(_2\). After stirring under 1 atm H\(_2\) at room temperature for 3 h, the reaction mixture was filtered through celite, concentrated \textit{in vacuo} and used for the next step without further purification.

TLC [20% MeOH in CHCl\(_3\)]: \(R_f = 0.26\)

Yield: 17mg, 0.1mmol (100%)

7.2.44 Synthesis of 6-(2-oxo-3,9-diazabicyclo [3.3.1]nonan-9-ylsulfonyl)benzo[d]thiazol-2(3H)-one 4h

3,9-Diazabicyclo[3.3.1]nonan-2-one 35 (25mg, 0.2mmol) in 1 ml DCM under argon was treated with DIPEA (69mg, 0.5mmol) and stirred for 30min at room temperature followed by addition of 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (53mg, 0.2mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH\(_4\)Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO\(_4\) and concentrated \textit{in vacuo}. The mixture was purified by preparative HPLC using a gradient of 45% buffer B in 16mins.
7. Experimental Section

TLC [10% MeOH in DCM]: \( R_f = 0.71 \)

HPLC [0-100% Solvent B, 16 min]: \( R_t = 10.2 \) min, purity (280 nm) = 99%

Yield: 27mg, 0.08mmol (43%)

\(^1\)HNMR (600 MHz, DMSO-\( D_6 \)) \( \delta = 8.13(\text{d}, 1\text{H}, J=1.88\text{Hz}), \ 7.68 \ (\text{dd}, \ 1\text{H}, J=1.98, 8.44\text{Hz}), \ 7.60(\text{s}, 1\text{H}), \ 7.21(\text{d}, 1\text{H}, J=8.39\text{Hz}), \ 4.12-4.15(\text{m}, 1\text{H}), \ 4.01-4.04(\text{m}, 1\text{H}), \ 3.17-3.25(\text{m}, 1\text{H}), \ 2.93-2.97(\text{m}, 1\text{H}), \ 1.57-1.73(\text{m}, 5\text{H}), \ 1.40-1.50(\text{m}, 1\text{H}) \)

\(^{13}\)C NMR (300 MHz, DMSO) \( \delta = 170.80, \ 167.59, \ 140.59, \ 133.66, \ 126.07, \ 124.82, \ 122.52, \ 112.14, \ 54.62, \ 46.17, \ 44.07, \ 31.11, \ 27.63, \ 17.59 \)

HRMS(El+) : m/z: found 353.0458 [M], calculated 353.0504 [M]

7.2.45 Synthesis of 6-(2-oxo-3,10-diazabicyclo[4.3.1]decan-10-ylsulfonyl)benzo[d]thiazol-2(3H)-one 5h

3,10-Diazabicyclo[4.3.1]decan-2-one 36 (17mg, 0.1mmol) in 1 ml DCM under argon was treated with DIPEA (43mg, 0.3mmol) and stirred for 30min at room temperature followed by addition of 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (33mg, 0.1mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH\(_4\)Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO\(_4\) and concentrated in vacuo. The mixture was purified by preparative HPLC using a gradient of 45% buffer B in 16mins.

TLC [10% MeOH in DCM]: \( R_f = 0.72 \)

HPLC [0-100% Solvent B, 16 min]: \( R_t = 10.6 \) min, purity (280 nm) = 98%

Yield: 5mg, 0.01mmol (12%)

\(^1\)HNMR (600 MHz, DMSO) \( \delta = 8.19(\text{d}, 1\text{H}, J=1.93\text{Hz}), \ 7.90-7.95 \ (\text{m}, 1\text{H}), \ 7.73(\text{dd}, 1\text{H}, J=1.98\text{Hz}, 8.43\text{Hz}), \ 7.25(\text{d}, 1\text{H}, J=8.44\text{Hz}), \ 4.39-4.43(\text{m}, 1\text{H}), \ 4.25-4.31(\text{m}, 1\text{H}), \ 3.25-3.30(\text{m}, 1\text{H}), \ 2.84-2.9(\text{m}, 1\text{H}), \ 2.03-2.17(\text{m}, 1\text{H}), \ 1.85-1.93(\text{m}, 1\text{H}), \ 1.67-1.77(\text{m}, 1\text{H}), \ 1.42-1.50(\text{m}, 1\text{H}), \ 1.17-1.33(\text{m}, 2\text{H}), \ 1.05-1.15(\text{m}, 2\text{H}) \)

\(^{13}\)C NMR (300 MHz, DMSO) \( \delta = 172.4, \ 170.8, \ 140.4, \ 135.3, \ 125.5, \ 124.9, \ 122.1, \ 112.3, \ 56.3, \ 49.1, \ 38.9, \ 33.25, \ 28.0, \ 26.9, \ 14.8 \)

HRMS : m/z: found 368.0736 [M + H], calculated 368.0739 [M + H]
7.2.46 Synthesis of 10-(3,5-dichloro-4-hydroxyphenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5i

3-(2-(3, 4-dimethoxyphenoxy) ethyl)-3, 10-diazabicyclo [4.3.1] decan-2-one 32a (24mg, 0.07mmol) in 3 ml DCM was treated with DIPEA (23mg, 0.09mmol) and stirred for 30min at room temperature followed by addition of 3,5-dichloro-4-hydroxy benzenesulfonyl chloride 34d (23mg, 0.09mmol). After stirring overnight at room temperature, the reaction was quenched with saturated NH₄Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO₄ and concentrated in vacuo. The mixture was purified by flash chromatography with EtOAc followed by 10% MeOH in CHCl₃.

TLC [EtOAc]: Rᵣ = 0.6
HPLC [0-100% Solvent B, 30 min]: Rᵣ = 21.5 min, purity (280 nm) = 98%
Yield: 10mg, 0.02mmol (25 %)

¹H NMR (300 MHz, CDCl₃) δ= 7.78(s, 2H), 6.76-6.82(m, 1H), 6.5-6.54(m, 1H), 6.38-6.44(m, 1H), 4.68-4.74(m, 1H), 4.3-4.45(m, 1H), 4.38.24(m, 3H), 3.85-3.9(m, 7H), 3.6-3.73(m, 3H), 3.3-3-45(m, 1H), 2.2-2.4(m, 2H), 1.95-2.1(m, 2H), 1.6-1.7(m, 1H), 1.35-1.45(m, 1H)

¹³C NMR (75 MHz, CDCl₃) δ=170.4, 153.14, 151.5, 149.9, 143.7, 134.4, 126.83, 122.09, 111.99, 104.07, 100.59, 67.25, 56.93, 56.46, 55.91, 51.43, 51.35, 48.91, 48.27, 31.92, 22.69, 14.11

HRMS(EI) : m/z: found 558.0993 [M]⁺, calculated 558.0994 [M]⁺

7.2.47 Synthesis of tert-butyl allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamate 48

To a solution of tert-butyl N-allylcarbamate (144mg, 0.92mmol) in 1ml DMF was added NaH (22mg, 0.92mmol) under argon and the reaction mixture was stirred for 30min at 0°C followed by addition of 4-(2-bromoethoxy)-1,2-dimethoxybenzene 28a (200mg, 0.77mmol) and stirring at 0°C for 2 h. To the mixture a saturated NH₄Cl solution (10ml) was added and extracted with DCM (5 x 10 ml). The organic layers were dried over MgSO₄, filtered and concentrated in vacuo. The pure product was obtained by flash chromatography with cyclohexane: EtOAc 5:1.
TLC [cyclohexane: EtOAc 5:1]: R\textsubscript{i} = 0.26
Yield: 178mg, 0.53mmol (69%)

\textsuperscript{1}HNMR (400 MHz, CDCl\textsubscript{3}) \(\delta\) = 6.76(d,1H, \(J=8.75\)Hz), 6.49(s,1H), 6.31-6.43(m,1H), 5.70-5.90(m,1H), 5.02-5.23(m,2H), 3.98-4.08(m,2H), 3.88-3.98(m,2H), 3.84(s,3H), 3.81(s,3H), 3.55 (s,2H), 1.45(s,9H)

MS(ESI) : m/z: found 337.93 \([\text{M+Na}]^{+}\), calculated 338.19 \([\text{M+H}]^{+}\)

### 7.2.48 Synthesis of tert-butyl 2-(3,4-dimethoxyphenoxy)ethyl(4-(trimethylsilyl)but-2-enyl)carbamate 50

To a solution of tert-butyl allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamate 48 (100mg, 0.30mmol) and allyltrimethylsilane (135mg, 1.18mmol) in 3ml DCM was added Grubbs catalyst generation I (24mg, 0.03mmol, Sigma-Aldrich) and heated under reflux overnight. The mixture was filtered through celite and concentrated in vacuo. The pure product was obtained by flash chromatography with cyclohexane: EtOAc 6:1.

TLC [cyclohexane: EtOAc 6:1]: R\textsubscript{i} = 0.38
Yield: 85mg, 0.20mmol (67%)

\textsuperscript{1}HNMR (400 MHz, CDCl\textsubscript{3}) \(\delta\) = 6.73-6.82(m,1H), 6.46-6.56(m,1H), 6.35-6.45(m,1H), 5.45-5.67(m,1H), 5.18-5.45(m,1H), 3.87-4.15(m,4H), 3.86(s,3H), 3.84(s,3H), 3.43-3.63(m,2H), 1.50-1.75(m,2H), 1.47(s,9H), -0.09-0.03(m,9H)

\textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}) \(\delta\)=155.50, 153.33, 149.89, 143.55, 129.55, 123.57, 111.91, 103.80, 100.82, 79.54, 67.02, 56.45, 55.82, 50.01, 45.50, 28.45, 22.69, -1.81

MS(ESI) : m/z: found 446.93 \([\text{M+Na}]^{+}\), calculated 446.60 \([\text{M+Na}]^{+}\)

### 7.2.49 Synthesis of N-(2-(3,4-dimethoxyphenoxy)ethyl)-4-(trimethylsilyl)but-2-en-1-amine 51

Excess amount of SiO\textsubscript{2} was added to tert-butyl 2-(3,4-dimethoxyphenoxy)ethyl(4-(trimethylsilyl)but-2-enyl)carbamate 50 (220mg, 0.52mmol) and stirred at 150°C \textit{in vacuo} for 2 h. The SiO\textsubscript{2} was washed with EtOAc for 3 times and the organic layers were collected and concentrated \textit{in vacuo}. The compound was used for the next step without further purification.
7. Experimental Section

TLC [5% TEA in EtOAc]: Rf = 0.6
Yield: 143mg, 0.44mmol (85%)
MS(ESI): m/z: found 323.93 [M+H]⁺, calculated 324.20 [M+H]⁺

7.2.50 Synthesis of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-(trimethylsilyl)but-2-enyl)piperidine-2-carboxamide 53

To a solution of (S)-6-oxo-2-piperidinecarboxylic acid 52 (109mg, 0.76mmol) in 5ml DCM was added sequentially DIPEA (205mg, 1.58mmol), HOAt(104mg, 0.76mmol) and EDC-HCl(118mg, 0.76mmol) followed by stirring for 30 min at room temperature and addition of N-(2-(3,4-dimethoxyphenoxy)ethyl)-4-(trimethylsilyl)but-2-en-1-amine 51 (205mg, 0.63mmol). After 24 h, brine (10ml) was added and extracted with DCM (5 x 10 ml). The organic layers were dried over MgSO₄, filtered and concentrated in vacuo. The pure product was obtained by flash chromatography with 5% TEA in EtOAc.

TLC [5% TEA in EtOAc]: Rf = 0.27
Yield: 260mg, 0.58mmol (90%)
MS(ESI) : m/z: found 449.57 [M+H]⁺, calculated 449.24[M+H]⁺

7.2.51 Synthesis of (S)-tert-butyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-(trimethylsilyl)but-2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 54

To a solution of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-(trimethylsilyl)but-2-enyl)piperidine-2-carboxamide 53 (1070mg, 2.39mmol) in 15ml THF was added 1M BuLi solution in hexanes (184mg, 2.87mmol) dropwise under argon at -78°C and stirred for 1 h followed by addition of di-tert-butyl dicarbonate (1040mg, 4.78mmol). After stirring at -78°C overnight, a saturated NH₄Cl solution (20ml) was added at room temperature and extracted with DCM (6 x 20ml). The organic layers were dried over MgSO₄, filtered and concentrated in vacuo. The pure product was obtained by flash chromatography with cyclohexane: EtOAc 1:1.

TLC [cyclohexane: EtOAc 1:1]: Rf = 0.4
Yield: 947mg, 1.73mmol (72%)
7. Experimental Section

$^1$H NMR (400 MHz, CDCl$_3$) $\delta$ = 6.72-6.79(m,1H), 6.44-6.53(m,1H), 6.31-6.42(m,1H), 5.55-5.75(m,1H), 5.15-5.45(m,1H), 4.95-5.05(m,1H), 3.95-4.25(m,4H), 3.77-3.90(m,6H), 3.55-3.77(m,2H), 2.54-2.65(m,1H), 2.35-2.50(m,1H), 1.50-1.65(m,4H), 1.38-1.49(m,9H), 0(t,9H,J=12.30,12.30Hz)

$^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ = 171.37, 171.13, 153.13, 153.09, 149.76, 143.51, 131.93, 122.53, 111.80, 103.95, 100.51, 83.04, 66.64, 55.82, 55.57, 51.36, 45.29, 34.40, 27.96, 25.84, 22.91, 19.13, -1.92

MS(ESI) : m/z: found 571.34 [M+H]$^+$, calculated 571.28[M+H]$^+$

7.2.52 Synthesis of (1S,5S,6R)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 57

To a solution of (S)-tert-butyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-(trimethylsilyl)but-2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 54 (100mg, 0.18mmol) in 1ml THF under argon was added dropwise DIBAL-H (78mg, 0.55mmol) and stirred at -78°C for 1 h followed by removal of the solvent in vacuo. The oily residue in 1ml DCM was treated dropwise with 1ml 10% TFA in DCM at -78°C followed by stirring at 0°C for 2 h, addition of 1mL TFA and stirring for another 2 h. A saturated NaHCO$_3$ solution (10ml) was added and extracted with DCM (6 x 10ml). The organic layers were dried over MgSO$_4$, filtered and concentrated in vacuo. The pure product was obtained by preparative TLC with 5% MeOH and 5% TEA in EtOAc.

TLC [5% MeOH, 5% TEA in EtOAc]: $R_I$ = 0.38

Yield: 50mg, 0.14mmol (76%)

$^1$H NMR (400 MHz, CDCl$_3$) $\delta$ = 6.77(d, 1H, J=8.76Hz), 6.49(d, 1H, J=2.81Hz), 6.38(dd, 1H, J=2.84,8.73Hz), 5.65-5.76(m, 1H), 5.07(s, 1H), 5.01-5.05(m, 1H), 4.22-4.30(m, 1H), 4.13-4.20(m,1H), 3.99-4.10(m,2H), 3.84-3.90(m,1H), 3.83(s,3H), 3.82(s,3H), 3.55-3.78(m,1H), 3.26-3.35(m,1H), 2.97-3.04(m,1H), 2.73-2.83(m,1H), 2.23-2.32(m,1H), 1.69-1.82(m,2H), 1.48-1.68(m,4H)

$^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ = 172.90, 153.11, 149.81, 143.56, 138.58, 115.55, 111.77, 103.46, 100.48, 67.33, 57.00, 56.40, 55.79, 52.73, 52.51, 51.34, 48.88, 28.70, 27.28, 16.24

MS(ESI) : m/z: found 361.09 [M+H]$^+$, calculated 361.21[M+H]$^+$

106
7. Experimental Section

7.2.53 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71

A solution (1S,5S,6R)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 57 (80mg, 0.22mmol) in 1mL DCM under argon was treated with DIPEA (34.4mg, 0.266mmol) and stirred for 30 min at room temperature followed by addition of 3,5-dichlorobenzene sulfonyl chloride 34a (65mg, 0.27mmol). After stirring overnight at room temperature, the pure product was obtained by preparative TLC with cyclohexane: EtOAc 1:1.

TLC [cyclohexane: EtOAc 1:1]: R<sub>f</sub> = 0.68
Yield: 60mg, 0.11mmol (48%)

<sup>1</sup>HNMR (600 MHz, CDCl<sub>3</sub>) \( \delta = 7.68(d, 2H, J=1.85Hz), 7.53(t, 1H, J=1.85, 1.85Hz), 6.76(d, 1H, J=8.77Hz), 6.46(d, 1H, J=2.79Hz), 6.36(dd, 1H, J=2.81, 8.75Hz), 5.77-5.86(m, 1H), 5.05-5.16(m, 2H), 4.65-4.71(m,1H), 4.07-4.21(m,3H), 3.99-4.05(m,3H), 3.94-3.98(m,1H), 3.83(s,3H), 3.82(s,3H), 3.45-3.53(m,1H), 3.22-3.3(m,1H), 2.67-2.76(m,1H), 2.24(d,1H, J=13.52Hz), 1.42-1.53(m,3H), 1.14-1.22(m,2H)

<sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) \( \delta = 170.18, 153.04, 149.83, 144.05, 143.66, 137.52, 136.31, 132.67, 124.84, 116.54, 111.81, 103.52, 100.52, 67.29, 56.80, 56.40, 55.79, 54.92, 53.39, 51.60, 49.25, 27.60, 26.27, 15.41

MS(ESI) : m/z: found 570.62 [M+H]<sup>+</sup>, calculated 570.51[M+H]<sup>+</sup>

7.2.54 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1] decan-2-one 72 diastereomeric mixture

To a solution of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71 (20mg, 0.04mmol) in 2ml t-BuOH and water (1:1) was added AD-mix-alpha (308 mg) at room temperature and stirred two days. The pure product was obtained by preparative TLC with 1% AcOH in cyclohexane: EtOAc 1:4.

TLC [1% AcOH in cyclohexane: EtOAc 1:4]: R<sub>i</sub> = 0.35
HPLC [40-42% Solvent B, 30 min]: R<sub>t</sub> = 17.5 min, purity (280 nm) = 99%
Yield: 12mg, 0.03mmol (57%)
7. Experimental Section

^1^HNMR (300 MHz, CDCl\textsubscript{3}) \(\delta\) = 7.68-7.72(m,2H), 7.52-7.56(m,1H), 6.74-6.81(m,1H), 6.54-6.58(m,1H), 6.38-6.44(m,1H), 4.67-4.74(m,1H), 3.90-4.35(m,6H), 3.85(s,3H), 3.82(s,3H), 3.30-3.80(m,6H), 2.08-2.30(m,3H), 1.35-1.55(m,3H), 0.82-0.85(m,1H)

\(^{13}\)C NMR (75 MHz, CDCl\textsubscript{3}) \(\delta\) = 169.95, 153.09, 149.90, 143.85, 143.82, 136.36, 132.75, 124.86, 111.95, 104.05, 100.76, 72.70, 65.35, 63.90, 56.95, 56.41, 55.89, 52.35, 51.75, 50.55, 49.78, 46.76, 28.25, 22.66, 14.15

MS(ESI) : m/z: found 604.05[M+H]^+, calculated 604.51[M+ H]^+

7.2.55 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1] decan-2-one 73 diastereomeric mixture

To a solution of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71 (20mg, 0.04mmol) in 2ml t-BuOH and water (1:1) was added AD-mix-beta (88mg) at room temperature and stirred overnight. The pure product was obtained by preparative TLC with 1% AcOH in cyclohexane: EtOAc 1:4.

TLC [1% AcOH in cyclohexane: EtOAc 1:4]: R\textsubscript{f} = 0.35

HPLC [0-100% Solvent B, 30 min]: R\textsubscript{t} = 21.6 min, purity (280 nm) = 99%

Yield: 20mg, 0.03mmol (94%)

^1^HNMR (300 MHz, CDCl\textsubscript{3}) \(\delta\) = 7.68-7.72(m,2H), 7.52-7.56(m,1H), 6.74-6.81(m,1H), 6.54-6.58(m,1H), 6.38-6.44(m,1H), 4.67-4.74(m,1H), 3.90-4.35(m,6H), 3.85(s,3H), 3.82(s,3H), 3.30-3.80(m,6H), 2.08-2.30(m,3H), 1.35-1.55(m,3H), 0.82-0.85(m,1H)

\(^{13}\)C NMR (75 MHz, CDCl\textsubscript{3}) \(\delta\) = 169.95, 153.09, 149.90, 143.85, 143.82, 136.36, 132.75, 124.86, 111.95, 104.05, 100.76, 72.70, 65.35, 63.90, 56.95, 56.41, 55.89, 52.35, 51.75, 50.55, 49.78, 46.76, 28.25, 22.66, 14.15

MS(ESI) : m/z: found 604.05[M+H]^+, calculated 604.51[M+ H]^+
7. Experimental Section

7.2.56 Synthesis of (1R,5S,6S)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)-3,10-diazabicyclo[4.3.1]decan-2-one 74 diastereomeric mixture

To a solution of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 73 (20mg, 0.03mmol) in 1ml DCM at 0°C was added 2,6-lutidine (18mg, 0.17mmol) and tert-Butyldimethylsilyl trifluoromethanesulfonate (88mg, 0.33mmol). After stirring for 29 h, no 73 was still existed. The organic layers were concentrated in vacuo. The attempt to purify with preparative HPLC using a gradient of 80-90% buffer B in 16 minutes was failed. As a test reaction, further efforts for purification were not put forth.

MS(ESI) : m/z: found 831.98[M+H]^+, calculated 832.31[M+ H]^+

7.2.57 Synthesis of (2S)-1-benzyl 2-methyl 6-hydroxypiperidine-1,2-dicarboxylate 66 and (S)-methyl 2-(benzyloxycarbonylamino)-6-hydroxyhexanoate 67

To a solution of (S)-1-benzyl 2-methyl 6-oxopiperidine-1,2-dicarboxylate 65 (100 mg, 0.34 mmol) in 2ml MeOH at 0°C was added NaBH₄ (29 mg, 0.76 mmol) and stirred for 6 h. The pure products were obtained by flash chromatography with cyclohexane: EtOAc 4:1

TLC [cyclohexane: EtOAc 1:1]: Rᵣ = 0.64 for 66 and Rᵣ = 0.25 for 67

Yield: 26mg, 0.09mmol (26%) for 66 and 22mg, 0.07mmol (21%) for 67

^1^HNMR (300 MHz, CDCl₃) of 66 δ= 7.3-7.45(m,5H), 5.75-5.85(m,0.5H), 5.1-5.3(m,2H), 4.8-4.9(m,0.5H), 4.70-4.80(m,0.5H), 4.25-4.35(m,0.5H), 3.6-3.9(m,3H), 2.2-2.3(m,0.5H), 1.5-1.8(m,2.5H), 1.2-1.4(m,3H),

^1^HNMR (300 MHz, CDCl₃) of 67 δ= 7.3-7.4(m,5H), 5.3-5.4(m,1H), 5.05-5.15(m,2H), 4.35-4.45(m,1H), 3.7-3.8(s,3H), 3.56-3.7(m,2H), 1.8-1.95(m,1H), 1.65-1.8(m,1H), 1.5-1.65(m,2H), 1.35-1.5(m,2H)

MS(ESI) : m/z: found 316.87[M+Na]^+, calculated 316.32[M+ Na]^+ for 66

m/z: found 318.87[M+Na]^+, calculated 318.33[M+ Na]^+ for 67

109
7.2.58 Synthesis of N-(2-(3,4-dimethoxyphenoxy)ethyl)prop-2-en-1-amine 58

To a solution of tert-butyl allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamate 48 (285mg, 0.85mmol) in 5ml DCM at room temperature were added 2.5 ml TFA. The reaction mixture was stirred for 1 h, concentrated in vacuo, dissolved in H₂O (5 ml) and extracted with EtOAc (3 x 5 ml). The aqueous layers were basified with saturated Na₂CO₃ solution and extracted with EtOAc (6 x 6 ml). The collected organic layers were dried over MgSO₄ and concentrated in vacuo. This crude product was used for next reaction without further purification.

TLC [10% MeOH in CHCl₃]: Rᵢ = 0.46
Yield: 200mg, 0.85mmol (100%)

¹H NMR (300 MHz, CDCl₃) δ = 6.78 (d, 1H, J=8.75 Hz), 6.54 (d, 1H, J=2.8 Hz), 6.41 (d, 1H, J=8.73 Hz), 5.85-6.0 (m, 1H), 5.1-5.3(m,2H), 4.0-4.1(m,2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.3-3.4(m,2H), 3.0-3.05(m,2H), 2.6-2.8(m,1H)

¹³C NMR (75 MHz, CDCl₃) δ = 153.37, 149.87, 143.66, 135.93, 116.70, 111.82, 103.85, 100.97, 67.58, 56.43, 55.82, 52.06, 48.06

7.2.59 Synthesis of (S)-N-allyl-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxopiperidine-2-carboxamide 59

To a solution of (S)-6-oxo-2-piperidinecarboxylic acid 52 (50mg, 0.35mmol) in 5ml DCM was added sequentially with TEA (42mg, 0.42mmol), HATU(160mg, 0.42mmol) and stirred for 30 min at room temperature followed by addition of N-(2-(3,4-dimethoxyphenoxy)ethyl)prop-2-en-1-amine 58 (83mg, 0.35mmol). After 6 h, brine (10ml) was added and extracted with DCM (5 x 10 ml), dried over MgSO₄, filtered and concentrated in vacuo. The pure product was obtained by flash chromatography with 1% TEA in EtOAc.

TLC [1% TEA in EtOAc]: Rᵢ = 0.1
Yield: 116mg, 0.32mmol (91%)

¹H NMR (300 MHz, CDCl₃) δ = 6.75-6.8 (m, 1H), 6.5-6.55 (m, 1H), 6.35-6.4 (m, 1H), 5.7-5.85 (m, 1H), 5.1-5.3(m,2H), 4.55-4.65(m, 0.4H), 4.35-4.4 (m, 0.6H), 4.25-4.3 (m,
7. Experimental Section

13C NMR (75 MHz, CDCl$_3$) δ = 173.55, 171.82, 153.02, 149.84, 143.61, 132.65, 117.65, 111.93, 103.97, 100.68, 66.26, 56.42, 55.88, 52.70, 51.30, 47.09, 30.57, 25.53, 18.62

MS (ESI): m/z: found 363.47 [M+H]$^+$, calculated 363.42 [M+H]$^+$

7.2.60 Synthesis of (S)-benzyl 2-(allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamoyl)-6-oxopiperidine-1-carboxylate 60

To a solution of (S)-N-allyl-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxopiperidine-2-carboxamide 59 (2.33g, 6.43mmol) in 70ml THF was added BuLi (0.5g, 7.71mmol) dropwise and catalytical amount of 4-Dimethylaminopyridine under argon at -78°C and stirred for 1 h followed by addition of Cbz-Cl (2.2g, 12.86mmol). After 2 h at -78°C, a saturated NH$_4$Cl solution (50ml) was added at room temperature and extracted with DCM (6 x 70ml), dried over MgSO$_4$, filtered and concentrated in vacuo.

The pure product was obtained by flash chromatography with cyclohexane: EtOAc 1:2.

TLC [hexane: EtOAc 1:2]: $R_f$ = 0.3

Yield: 1.92g, 3.87mmol (60%), purity >98%

1H NMR (600 MHz, CDCl$_3$) δ = 7.26-7.44 (m, 5H), 6.73-6.78 (m, 1H), 6.47-6.53 (m, 1H), 6.33-6.40 (m, 1H), 6.05-6.2 (m, 1H), 5.7-5.9 (m, 2H), 5.2-5.3 (m, 2H), 5.1-5.2 (m, 1H), 4.0-4.3 (m, 4H), 3.8-3.88 (m, 6H), 3.52-3.78 (m, 2H), 2.45-2.55 (m, 1H), 2.25-2.45 (m, 1H), 1.8-2.1 (m, 2H), 1.5-1.8 (m, 2H).

13C NMR (150 MHz, CDCl$_3$) δ = 173.20, 171.18, 153.10, 154.50, 149.84, 143.66, 153.23, 132.85, 128.49, 128.45, 128.21, 127.97, 127.88, 118.08, 111.87, 104.00, 100.81, 68.72, 66.75, 56.42, 56.11, 55.87, 51.84, 46.26, 34.42, 25.76, 18.10


7.2.61 Synthesis of (S)-benzyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-(trimethylsilyl) but-2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 62
To a solution of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-(trimethylsilyl)but-2-enyl)piperidine-2-carboxamide 53 (923mg, 2.06mmol) in 10ml THF was added 1M BuLi solution in hexanes (158mg, 2.47mmol) dropwise under argon at -78°C and stirred for 1 h followed by addition of Cbz-Cl (421mg, 2.47mmol). After 7 h at -78°C, a saturated NH₄Cl solution (20ml) was added at room temperature and extracted with DCM (6 x 20ml), dried over MgSO₄, filtered and concentrated in vacuo. The pure product was obtained by flash chromatography with cyclohexane:EtOAc 1:1.

TLC [cyclohexane:EtOAc 1:1]: Rf = 0.4

Yield: 871mg, 1.49mmol (73%)

¹HNMR (400 MHz, CDCl₃) δ = 7.26-7.42(m,5H), 6.74-6.78(m,1H), 6.47-6.52(m,1H), 6.34-6.39(m,1H), 5.55-5.7(m,1H), 5.25-5.33(m,2H), 5.2-5.25(m,2H), 5.05-5.15(m,1H), 4.05-4.2(m,2H), 3.9-4.05(m,2H), 3.8-3.87(m,6H), 3.7-3.75(m,1H), 3.5-3.6(m,1H), 2.6-2.7(m,1H), 2.4-2.5(m,1H), 2.2-2.4(m,1H), 2-2.1 (m,1H), 1.7-2.0(m,2H), 1.4-1.5 (m,2H), 0.01(t,9H,J=13.53,13.53Hz)

¹³CNMR (100 MHz, CDCl₃) δ = 171.24, 170.84, 154.66, 153.14, 149.83, 143.60, 135.33, 132.13, 128.48, 128.16, 128.03, 127.92, 127.84, 122.38, 111.97, 104.03, 100.35, 68.68, 66.64, 56.42, 56.13, 55.85, 51.38, 45.26, 34.43, 25.73, 22.92, 18.14, -1.77

MS(ESI) : m/z: found 607.37 [M+H]+, calculated 607.76[M+H]+
8. Abbrevations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH</td>
<td>Adrenocorticotropic Hormone</td>
</tr>
<tr>
<td>AR</td>
<td>Androgen Receptor</td>
</tr>
<tr>
<td>Brine</td>
<td>Saturated NaCl solution</td>
</tr>
<tr>
<td>BuLi</td>
<td>n-butyllithium</td>
</tr>
<tr>
<td>CN</td>
<td>Calcineurin</td>
</tr>
<tr>
<td>CRH</td>
<td>Corticotropin Releasing Hormone</td>
</tr>
<tr>
<td>DCM</td>
<td>Dichlormethane</td>
</tr>
<tr>
<td>DCC</td>
<td>N,N'-Dicyclohexylcarbodiimide</td>
</tr>
<tr>
<td>DIPEA</td>
<td>N,N-Diisopropylethylamine</td>
</tr>
<tr>
<td>EDC</td>
<td>1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid</td>
</tr>
<tr>
<td>EE</td>
<td>Ethylacetate</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen Receptor</td>
</tr>
<tr>
<td>F</td>
<td>Phenylalanine</td>
</tr>
<tr>
<td>FKBP</td>
<td>FK506 binding protein</td>
</tr>
<tr>
<td>FP</td>
<td>Fluorescence Polarisation</td>
</tr>
<tr>
<td>GR</td>
<td>Glucocorticoid receptor</td>
</tr>
<tr>
<td>HOAt</td>
<td>1-Hydroxy-7-azabenzotriazole</td>
</tr>
<tr>
<td>HATU</td>
<td>2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate Methanaminium</td>
</tr>
<tr>
<td>HPA</td>
<td>Hypothalamus pituitary adrenal</td>
</tr>
<tr>
<td>HPLC</td>
<td>High Pressure Liquid Chromatography</td>
</tr>
<tr>
<td>Hsp90</td>
<td>Heat shock protein 90</td>
</tr>
<tr>
<td>LDC</td>
<td>Lead Discovery Center</td>
</tr>
<tr>
<td>LiHMDS</td>
<td>Lithium hexamethyl disilazid</td>
</tr>
<tr>
<td>LiOH</td>
<td>Lithiumhydroxid</td>
</tr>
<tr>
<td>LMU</td>
<td>Ludwigs-Maximilians-University</td>
</tr>
<tr>
<td>MeOH</td>
<td>Methanol</td>
</tr>
<tr>
<td>MD</td>
<td>Major depression</td>
</tr>
<tr>
<td>MPI</td>
<td>Max-Planck-Institute</td>
</tr>
<tr>
<td>MR</td>
<td>Mineralcorticoid Receptor</td>
</tr>
<tr>
<td>NaHMDS</td>
<td>Natrium hexamethyl disilazid</td>
</tr>
<tr>
<td>n-Hex</td>
<td>n-Hexane</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear magnetic resonance</td>
</tr>
<tr>
<td>PPIase</td>
<td>Peptidyl-prolyl-cis/trans-Isomerase</td>
</tr>
<tr>
<td>PR</td>
<td>Progesterone Receptor</td>
</tr>
<tr>
<td>PTSD</td>
<td>Post-traumatic stress disorder</td>
</tr>
<tr>
<td>Rap</td>
<td>Rapamycin</td>
</tr>
<tr>
<td>RT</td>
<td>Room Temperature</td>
</tr>
<tr>
<td>SAR</td>
<td>Structure Activity Relationship</td>
</tr>
<tr>
<td>SHR</td>
<td>Steroid Hormone Receptor</td>
</tr>
<tr>
<td>TFA</td>
<td>Trifluoroacetic acid</td>
</tr>
<tr>
<td>TEA</td>
<td>Triethylamine</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin layer chromatography</td>
</tr>
<tr>
<td>THF</td>
<td>Tetrahydrofuran</td>
</tr>
<tr>
<td>V</td>
<td>Valine</td>
</tr>
<tr>
<td>WT</td>
<td>Wildtype</td>
</tr>
</tbody>
</table>
9. References

9. References


9. References


64. Belmaker, R. H., Major Depressive Disorder
9. References


9. References

inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta
Armistead, D. M.; Saunders, J. O.; Boger, J.; Harding, M. W., Cellular and biochemical
characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated
Desbarats, J.; Escalante, M.; Singh, K.; Sundarababu, S.; Parris, K.; Childs, G.; August, A.;
Siekierka, J.; Weinstein, D. E., A role for schwann cells in the neuroregenerative effects of a
130. Bocquet, A.; Lorent, G.; Fuks, B.; Grimee, R.; Talaga, P.; Daliers, J.; Klitgaard, H.,
Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur J
Proximity Assay for the Identification of FKBP-12 Ligands. J Biomol Screen 1999, 4, (1), 3-
7.
132. Rabinowitz, M.; Seneci, P.; Rossi, T.; Dal Cin, M.; Deal, M.; Terstappen, G., Solid-
phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands. Bioorg Med
133. Sich, C.; Improta, S.; Cowley, D. J.; Guenet, C.; Merly, J. P.; Teufel, M.; Saudek, V.,
Solution structure of a neurotrophic ligand bound to FKBP12 and its effects on protein
Hausch, F., Evaluation of Synthetic FK506 Analogs as Ligands for the FK506-Binding
135. Gerard, M.; Deleersnijder, A.; Demeulemeester, J.; Debyser, Z.; Baekelandt, V.,
Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration. Mol Neurobiol 2011,
107-112.
137. Hamilton, G. S. N., M. H.; Wu, Y.-Q. Carboxylic acids and carboxylic acid isosters of
N-heterocyclic compounds. 2000.
FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of
Chatterjee, A.; Vanderpool, D.; Bigge, C.; Showalter, R.; Bender, S.; Augelli-Szafran, C. E.;
Lunney, E.; Hou, X., Design, synthesis, and biological activity of novel polycyclic aza-amine
activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. Bioorg Med
Chem 1998, 6, (8), 1309-35.
Hausch, F., Exploration of Pipecolate Sulfonamides as Binders of the FK506-Binding


9. References

10.Curriculum Vitae

YANSONG, WANG

Research Group Chemical Genomics
Max Planck Institute of Psychiatry
Kraepelinstr. 2-10, 80804, Munich, Germany
Email address: yansong@mpipsykl.mpg.de
Phone: +49-(0)17621895586

Education:

2008-2012 Ph.D study, Max Planck Institute of Psychiatry, Munich, Germany.
2006-2008 Master of Sciences (M.Sc), Molecular Biosciences at the University of Heidelberg, Germany.
1999 - 2003 B.S., College of Pharmacy, The Second Military Medical University, Shanghai, China.

Grants and Fellowships:

- Max-Planck doctoral fellowship for doctoral research at the Max Planck Institute of Psychiatry, Munich, Germany. 2008 to present
- MCB scholarship from MCB program Heidelberg University, Heidelberg, Germany 2006-2008

Talks:

1. MPIP Institute PhD seminar series, 2011
2. Ligands for FKBP51 and FKBP52. MPI Psychiatry Ringberg symposium 2011.

Patent filing:

1. Wang Y, Hausch.F. [3.3.1] and [4.3.1] bicyclic piperolate analogs as FKBP51 and FKBP52 ligands.
Publications and Manuscripts:


